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The rapid advances in genotyping technology has increased the power to identify loci associ-
ated with a complex trait through genome-wide association (GWA) studies. Despite the success
of GWA studies that has enabled the identification of associations between common genetic
variants and complex diseases, which generally consider only the most significant SNPs/genes,
such a single-marker-based approach has shown certain limitations. Therefore it might not pos-
sess adequate power to detect important genetic variants, mostly with relatively small effect
sizes in complex diseases. As a consequence, the estimated heritability remains unexplained
by these variants for most complex diseases covered by published GWAS so far. Extending
GWA study findings and exploring related discoveries in a more mechanistic way, taking into
account the genetic architecture of the disease as well as the genetic mechanism involved in
the disease pathogenesis, to uncover biological pathways and biological networks relevant to
phenotypes, should involve combining weak signals from the individual variants from GWA
studies to approximate the true disease process more closely and provide biological insights.
This would facilitate better understanding of the biological basis of disease susceptibility and
using these genetic risk factors to make predictions about who is at risk, in order to develop
new prevention and treatment strategies such as new pharmacologic therapies and personalized
medicine. Recently, several studies have explored the feasibility of pathway or network-based
analysis approaches for GWA studies and they have proposed several methods to summarize
the significance of a set of genes or a biological pathway from a collection of SNPs and to adjust
for multiple testing at both the gene and pathway levels.
In this project, we review some existing pathway-based approaches for GWA study analyses,
by exploring different implemented methods for combining effects of multiple modest genetic
variants at gene and pathway levels. We then propose a graph-based method, ancGWAS,
that incorporates the signal from GWA study, and the locus-specific ancestry into the human
protein-protein interaction (PPI) network to identify significant sub-networks or pathways as-
sociated with the trait of interest. This network-based method applies centrality measures
within linkage disequilibrium (LD) on the network to search for pathways and applies a scoring
summary statistic on the resulting pathways to identify the most enriched pathways associ-
ated with complex diseases. In addition, the proposed method also tests for possible signals of
unusual differences in excess/deficiency of ancestry at gene and pathway levels in admixed pop-
ulations. Through simulations of well-characterized heterogeneous populations, we evaluated
and compared the developed method with some existing methods, and demonstrated that this
approach may enable more efficient and more powerful analysis of GWA studies, compared to
most existing methods, as it incorporates topological properties of networks that provide more
information on the relatedness and interconnectivity of genes. We applied the new approach
to the GWA study dataset from the Cancer Genetic Markers of Susceptibility (CGEMS) for
postmenopausal women of European ancestry with invasive breast cancer. Our analysis on
the CGEMS breast cancer data revealed some previously targeted breast cancer pathways,
and many others believed to be involved in breast carcinogenesis including, the Proteaglycan
syndecan-1-mediated signaling pathway, the ErbB receptor signaling network, the Regulation of
Androgen receptor activity pathway, and the Integrin family cell surface interactions pathway.
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Motivation and outline
The rapid advances in genotyping technology have increased the power to identify loci asso-
ciated with a complex trait through genome-wide association (GWA) studies, which examine,
at the genomic level, the relationship between each Single Nucleotide Polymorphism (SNP)
marker and the trait of interest. GWAS have been successful during the past few years and
through this experimental design, many novel genes have been identified to be significantly and
strongly associated with one or more complex trait, leading to important contributions to the
understanding of the biological underpinnings of disease susceptibility for a broad spectrum of
complex traits (Iles, M. M., 2008; Hindorff, L. A. et al., 2013a). It is now well known that genes
do not operate in isolation, rather they collaborate in groups to carry out specific biological
functions. Therefore, depending on the genetic architecture of a complex disease, it is possible
that many SNPs or genes having low or moderate risk interact to confer a significant combined
effect for the complex disease (Schadt, E. E., 2009). Many recent studies have investigated and
demonstrated the role of complex molecular networks and cellular pathways in the pathogenesis
of complex diseases such as the noninfectious disease cancer (Collins, A. et al., 2011; Filmus,
J., 2001; Leivonen, M. et al., 2004), and the autoimmune disease rheumatoid arthritis (RA)
(Martinez, A. et al., 2006). For instance, a highly significant interaction was detected between
genes associated with the infectious disease tuberculosis (TB) (de Wit, E. et al., 2011). In
other examples, genes of the complement pathway are suspected to be involved in the disease
pathogenesis of age-related macular degeneration (AMD) and the autophagy pathway was sus-
pected to be implicated in the inflammatory Crohn’s disease (CD) pathogenesis (Wang, K. et
al., 2010).
Motivation and purpose of the study
Despite the success of GWA studies, which generally consider only the most significant SNPs,
at the identification of associations between common genetic variants and complex traits, such
a single-marker-based approach has shown certain limitations and might therefore not pos-
sess adequate power to detect important genetic variants, with relatively small effect sizes in
complex diseases. As a consequence, the disease heritability remains unexplained for almost
all the complex diseases covered by published GWAS so far (Iles, M. M., 2008; Wang, K. et
13
al., 2010; Akira, S. et al., 2004; Visscher, P. M., 2008). Extending GWA study findings and
exploring related discoveries in a more mechanistic way, by taking into account the genetic
architecture of the disease, to uncover biological pathways and biological networks relevant
to phenotypes, would involve combining weak signals from the individual variants from GWA
studies to approximate the true disease process more closely. Knowing pathways involved in
disease pathogenesis may help to tackle disease progression more efficiently. This would fa-
cilitate better understanding of the biological basis of disease susceptibility and enable using
these genetic risk factors to make predictions about who is at risk, in order to develop new
prevention and treatment strategies and move towards personalized medicine (Ramanan, V.
K. et al., 2012).
Proposed methodology and study outline
Recently, several studies have explored the feasibility of pathway or network-based analysis
approaches for GWA studies and they have proposed several methods to summarize the signifi-
cance of a set of genes or biological pathway from a collection of SNPs and to adjust for multiple
testing at both the gene and pathway levels (Schadt, E. E., 2009; Jia, P. et al., 2011; Wang, K.
et al., 2010; Ramanan, V. K. et al., 2012). Pathway-based approaches jointly consider multiple
contributing factors in the same pathway and examine whether a group of genes in the same
pathway are jointly associated with the trait of interest. Using prior biological knowledge on
gene functions to facilitate more powerful analysis of GWAS datasets, these approaches have
become increasingly popular and invaluable tools enabling powerful association tests. Thus,
they might complement the most-significant SNPs/genes approach to provide additional in-
sights into the interpretation of GWA studies and help to formulate new hypotheses on disease
susceptibility and disease progression (Wang, K. et al., 2010). Most existing pathway-based
approaches for GWA study data analysis have focused on thoroughly examining a collection
of predefined gene sets or pathways based on certain prior biological knowledge, and summa-
rize the significance of each pathway based on the association with the disease of markers in
or near genes that are components of the pathway. However, accounting for biological net-
work topology and properties, gene-gene interactions may also enable more powerful analysis
of GWA study data sets, compared to analysis of groups of distinct genes, as networks pro-
vide more information on the relatedness and interconnectivity of genes (Wang, K. et al., 2010).
Here we review some existing pathway-based approaches for GWA study analyses, by explor-
ing different implemented methods for combining effects of multiple modest genetic variants at
gene and pathway levels. We then propose a graph-based method that incorporates the signal
from GWA study in the human protein-protein interaction (PPI) network to identify signifi-
cant sub-networks or pathways associated with the trait of interest. This graph-based method
applies centrality measures within linkage disequilibrium (LD) on the network to search for
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significant sub-networks and applies a scoring summary statistic on the resulting sub-networks
to identify the most enriched pathways associated with complex diseases. In addition, the
proposed method also tests for possible signals of unusual differences in excess/deficiency of
ancestry at gene and pathway levels in admixed populations.
This work starts with an introduction to genetic association studies and genome-wide associa-
tion studies, which contains three parts. First, we start with basic concepts on population-based
association studies, focusing on the case-control design of these studies. Linkage disequilib-
rium, a very important concept in population studies that measure dependencies between loci
on the same chromosome, is then introduced. We also discuss two measures of genetic risks
in case-control studies (odds ratio and relative risk), and their inference. One major pitfall
of case-control association studies is hidden population substructures that may not have been
considered. Basic definitions of two common population substructures, and methods for de-
tecting and correcting population stratification and cryptic relatedness are introduced. The
concept of a genome-wide association study is introduced, and their design, current limitations
and future directions are broadly discussed.
Chapter 2 introduces pathway-based approaches for GWA study. This chapter is really im-
portant in the context of this study, as it introduces basic concepts on pathway-based analysis
of GWAS datasets. It first covers resources needed to exploit the pathway-based approach
for GWA studies such as protein-protein interaction (PPI) and pathway annotation databases,
before exploring the motivation and different existing methods for pathway-based analysis of
GWAS datasets.
Chapter 3 presents a new proposed method developed here, ancGWAS, for examining disease
association signals from multiple interacting genes. It uses an algebraic graph-based approach,
by integrating disease association signals from single SNPs, and the locus-specific ancestry in-
formation into the human PPI network to identify enriched sub-networks for the disease, and
testing for any signal of excess or deficiency in ancestry. Different methods for mapping SNPs
to genes, combining individual p-values and ancestral information at the gene level, construct-
ing the LD-weighted PPI network, searching algorithms for network clustering, sub-network
scoring and test for differences in ancestry at gene and sub-network levels, and finally pathway
enrichment of identified modules are presented. Finally, a short note on the implementation of
the new model is described in a detailed work-flow, and some concluding remarks are presented.
A thorough evaluation of the new proposed method is performed in Chapter 4, using 2 sim-
ulated case-control datasets, a pathway-based GWAS dataset for a heterogeneous population,
as well as simulated interactive disease loci in a complex admixed population. We compare
ancGWAS to an existing pathway-based method, dmGWAS, to assess the ability of ancGWAS
to approximate the disease pathway. Finally, we apply ancGWAS to real data from the Cancer
Genetic Markers of Susceptibility (CGEMS) for postmenopausal women of European ancestry
15
with invasive breast cancer with 1, 145 cases and 1, 142 controls genotyped at 528, 169 SNPs.




studies and Pathway-based approaches for
GWAS analysis
The advances in genotyping technologies allowing for large-scale sequencing efforts have in-
creased the power to uncover the genetic underpinnings of complex diseases, driving a multitude
of investigators to embark on population-based genetic association studies. These studies differ
from traditional epidemiological studies by their explicit considerations of genetic factors and
family resemblance, instead of just focusing on the relationship between the environment and
the occurrence of the disease, and its determinants in populations (Burton, P. R. et al., 2005;
Morton, N. E., 1982). Genetic variations occur in populations all the time, some with harmful
effects contributing to an increase or decrease in disease risks in those populations. Some of
these variations can reach substantial frequency in the population due to random drift or just
by natural selection and they can exist as many different types depending on their effect on
protein function, the associated susceptibility to a disease and their physical nature (Burton,
P. R. et al., 2005; Morton, N. E., 1982). In the latter case for instance, when a variation occurs
at a single location within a gene and is present in at least 1% of a population, it is commonly
referred to as a single-nucleotide polymorphism (SNP). Humans share common ancestry, and
with the completion of the HapMap project along with the availability of genotyping technolo-
gies, enabling the genotyping of more than 1million genetic polymorphisms at once, as well as
the genome-wide characterization of the levels and patterns of these human variations, genetic
association studies of complex traits have become more comprehensive and effective.
Here, we discuss how genetic association studies are performed to determine whether these
genetic variants are associated with a disease, focusing on case-control studies, in attempt to
answer the second of two essential questions in genetic association studies including: (1) is there
a genetic component to the disease, and (2) what genes are involved? Special attention will be
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given to genome-wide association (GWA) studies, which involve whole and partial genome-wide
scans in order to identify associations between SNPs and a trait, in order to identify genetic risks
factors that can later be thoroughly analyzed using classical epidemiology methods. Population
substructure is discussed, as well as different existing approaches to control for confounding due
to population substructure for GWA study among population-based samples (Khoury, M. J. et
al., 1993; Lunetta, K. L., 2008). We also introduce PA approaches for analysis of GWA studies.
We embark on discussing the current state of available biological knowledge on genes, which
are generally exploited in these PA approaches. This biological knowledge includes the Gene
Ontology (GO), and known human protein-protein interaction (PPI) data. We only focused on
human PPI data, generally freely available in online databases. We also present some technical
differences among current PA approaches, as well some common challenges observed in these
methods.
1.1 Population-based association studies
In the context of genetic association studies, a phenotype, defined formally as a physical at-
tribute or the manifestation of a trait, refers to a measure of disease progression. A phenotype
can either be quantitative or binary, which refer respectively to continuous and binary vari-
ables. A quantitative trait refers to one that can often be measured and given a quantitative
value whereas a binary trait is one that can take on two values, such as healthy or unhealthy.
In this last case, the phenotype can easily be predicted knowing the genotype (Andrea, S. F.,
2009). Clinical measures such as height and total cholesterol level are examples of quantitative
traits, whereas a heart attack as an indicator for a cardiovascular outcome and the indicator
of whether or not a patient has tuberculosis are examples of binary traits. Genetic associ-
ation studies should only be undertaken if the trait of interest has established evidence for
heritability, and when the question of whether a disease has a genetic component arises, the
detection of higher occurrence rates in siblings or offspring is generally the first step. Other
classical observational designs including studies on twins, adoptees and even migrants may
suggest whether or not there is a genetic component in the etiology of a disease or trait of
interest. Familial aggregation of a trait is a necessary but not sufficient condition to infer the
importance of genetic susceptibility, because environmental and cultural influences can also ag-
gregate in families, leading to family clustering and excess familial risk, as for instance similar
environment may also contribute to familial aggregation (Tevfik, D. M., 2009).
Population-based association studies generally aim to relate genetic information to a clinical
outcome or phenotype at a population level, in contrast with family-based studies. The latter
involves data collected on multiple individuals within the same family unit. One statistical con-
sideration that differs between family-based and population-based studies is that individuals
in the same family are more likely to be similar to one another than individuals from differ-
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ent families. That is, the trait under study is more likely to have a high correlation among
individuals within the same family. In population-based studies instead, the assumption of in-
dependence between individuals is fundamental, and this non relatedness actually means that
the relationship between individuals is unknown and assumed to be distant. Although there
exist several situations where this assumption may be violated, such as in the case of repetition
of measurements of a trait in study on the same individual; and in cases of within-cluster cor-
relation, where for instance study samples may be collected across multiple hospitals, implying
that patients from the same hospital are more likely to be similar than those across hospitals.
In all of these cases, analytical methods for relatedness among the study individuals are es-
sential for correctly estimating variance components (Andrea, S. F., 2009), described briefly
in Section 1.2.2. Though there exist several study designs for genetic association studies, this
review will focus specifically on the design and statistical analysis methods in the case-control
study.
1.1.1 Case-control design
A typical design to test for population-based association is the case-control study, in which the
frequency of SNP alleles in a series of well-defined groups of unrelated individuals are compared.
Cases are those who have been diagnosed with the disease under study, and controls are a series
of individuals who have been screened as negative for the presence of the disease in study or
have been randomly selected from the population and must be at similar risk of developing
the disease (Lewis, C. M., 2002). A clear definition of cases and controls is very crucial in
a case-control study, and the same data must be collected the same way from both groups
otherwise the study may suffer from researcher bias. Though sometimes less valued for being
retrospective, case-control studies are cost-effective and they are actually the only ethical and
efficient way to investigate association between an exposure and an outcome (Andrea, S. F.,
2009). If carried out with care, with the definition and selection of controls, and reducing
potential biases, case-control studies can generate effective results. A higher frequency of a
SNP allele in cases compared with controls can be interpreted as the SNP allele increasing risk
of disease, although several other interpretations can be considered (Section 1.1.3).
1.1.1.1 Statistical analysis methods of case-control studies
Let us consider an analysis on a single SNP with alleles A and B on a set of cases and controls.
The data generated by this design can be summarized in a 2×3 or 2×2 contingency table con-
sisting of six or four counts of the numbers of genotypes (G0 = AA, G1 = AB and G2 = BB)
for each group. Assume that a total of r cases and s controls need to be tested, and n0, n1
and n2 are the total number of AA, AB and BB observed genotypes, respectively. The genetic
model (Lewis, C. M., 2002), which refers to a specific mode of inheritance, has to be deter-
mined in order to decide which is the right statistical test to use for association analysis. This
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will also determine whether a genotype-based approach or an allele-based approach (additive
or multiplicative models) must be undertaken (Zheng, G. et al., 2012). The general genetic
model (case in Table 1.1(a)) requires 2 degrees of freedom (df) for testing an association with
a SNP, whereas the other models require only 1 df . The general genetic model retains the
3 distinct genotypes AA, AB and BB, with no assumptions about how the risk or mean for
heterozygotes compares with the 2 homozygotes (Lunetta, K. L., 2008). Depending on the ge-
netic model, a particular test statistic can be applied to this contingency table (see Table 1.1).
There exist several test statistics to analyze association between the genotype and the disease
under study, generally genotype-based and allele-based approaches. If the Hardy-Weinberg
equilibrium1 holds, both approaches are equivalent, otherwise allele-based tests can generate
invalid results (Freidlin, B. et al., 2002). Here, we will focus on the genotype-based approach
using goodness-of-fit tests, including the Pearson’s chi-squared test and the Cochran-Armitage
Trend Tests (CATT), which are the commonly used test statistics for genetic association using
a case-control design, rather than likelihood-based or regression methods and the allele-based
test. When the Hardy-Weinberg holds, the trend test is based on the assumptions that one
of the alleles is the risk allele, so that the risk of developing the disease is proportional to the
number of risk alleles in the genotype. The trend test may not be powerful when the genetic
model is misstated, as different trend tests are used for the four different genetic models (see
Table 1.1(b-e)).
For example, with the hypotheses that allele B increased disease risk (dominant model), the
case in (b) will be considered with a 2 × 2 table. On the other hand, if a recessive model is
considered, two copies of allele B will be required to increase disease risk with a 2 × 2 table
too. In a multiplicative model, whereby observed genotypes are broken down to compare the
frequency of A and B alleles in cases and controls, the disease risk is increased by a factor r
for genotype AB and of 2r for genotypes BB. This model shows a clear trend of an increased
number of AB and BB genotypes, with disease risk for AB genotypes approximately half that
for BB genotypes, whereas in an additive model, the disease risk is increased by a factor r for
genotype AB and of r2 for genotypes AA and BB. The latter can be tested using Armitage’s
test for trend (Zheng, G. et al., 2012).
1.1.1.2 Pearson’s Chi-Squared Test
The Pearson’s test instead does not rely on any genetic information, thus it remains robust to
any given genetic model. It is generally used for assessing deviation from the null hypothesis
that cases and controls have the same distribution of genotype counts, and follow a chi-squared
1The Hardy-Weinberg principle predicts how gene frequencies will be inherited from generation to generation
given a specific set of assumptions. It states that in a large randomly breeding population, allelic frequencies will
remain the same from generation to generation assuming that there is no mutation, gene migration, selection
or genetic drift (Lewis, C. M. et al., 2012).
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Table 1.1: Case-control study contingency tables for genetic models. Test (a) is the starting point for any
analysis unless prior hypotheses are made. r0, r1, r2, s0, s1 and s2 are observed genotype counts in cases and
controls.
(a) Full genotype table for general genetic model
AA AB BB Total
Cases r0 r1 r2 r
Controls s0 s1 s2 s
Total n0 n1 n2 n
(b) Dominant model: allele B increases disease risk
AA AB +BB
Cases r0 r1 + r2
Controls s0 s1 + s2
(c) Recessive model: two copies of allele B required to increase disease risk
AA+AB BB
Cases r0 + r1 r2
Controls s0 + s1 s2
(d) Multiplicative model: r-fold increased disease risk for AB and r2 for BB. Tested only using allelic
approach.
A B
Cases 2r0 + r1 r1 + 2r2
Controls 2s0 + s1 s1 + 2s2
(e) Additive model: r−fold increased disease risk for AB and 2r for BB. Analyzed only using
genotypic approach.
AA AB BB
Cases r0 r1 r2
Controls s0 s1 s2
distribution even when the Hardy-Weinberg proportion does not hold in the population (Lewis,
C. M. et al., 2012).
We assume the general genetic model described in Table 1.1(a), with (r0, r1, r2) and (s0, s1, s2),
the counts for (AA, AB and BB) genotypes, and the total number is r = r0 + r1 + r2 and
s = s0 + s1 + s2 respectively in cases and controls, with their expected values. Let the total
number of genotype Gj be ni = ri+si, for i in {1, 2}, and n = r+s = n0 +n1 +n2 be the total
number of individuals. Under H0, the null hypothesis that the disease status and genotypes
are independent, the expected counts for cases ri is given by Eri = nir/n and for controls si by














Tχ22 asymptotically follows a chi-squared distribution χ
2
2 with 2 df . H0 is rejected at the level
α if Tχ22 > χ
2
2 (1− α), where χ22 (1− α) is the 100 (1− α)th percentile of χ22.
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Let us consider a single marker (rs1219648 ) in the FGFR2 gene associated with risk of sporadic
postmenopausal breast cancer from the CGEMS Breast Cancer study (Hunter, D. J. et al.,
2007). The contingency Table 1.2 represents genotype counts for different genotypes on this
data, with one missing genotype in controls. This table shows that cases have higher frequency
of both GG and AG genotypes compared with controls.
Table 1.2: rs1219648 genotypes for a breast cancer case-control study with 1, 142 controls and 1145 cases
Genotypes
Cohort No. of individuals AA AG GG Frequency of allele G
Cases 1, 145 352 (30%) 543 (47%) 250 (21%) 40%
Controls 1, 142 433 (37%) 538 (47%) 170 (14%) 45%
Total 2, 287 785 1, 081 420
We can determine whether the risk of developing the disease is proportional with the number of
the alternate allele G by estimating the probabilities of having allele G given disease statuses
by P̂r (G | case) = (r1 + 2r2) / (2r) = (543 + 2 (250)) /2287 = 0.456 and P̂r (G | control) =
(s1 + 2s2) / (2s) = (538 + 2 (170)) /2287 = 0.384. P̂r (G | case) > P̂r (G | control), therefore
the allele G is likely to be the disease risk allele.
Applying Tχ22 on Table 1.2 with the observed genotype counts in cases and in controls respec-
tively (r0, r1, r2) = (352, 543, 250) and (s0, s1, s2) = (433, 538, 170), the expected genotype
counts of AA, AG and GG for cases and controls are respectively 393.19, 541.45 and 210.37.
Under the null hypothesis “H0: There is no association between the marker and the disease”,
and the alternative hypothesis “H1: There is association between the genetic marker and the



















Tχ22 = 23.6123 with p-value = 7.459 × 10
−06 with 2 df . This suggests that the distribution of
this data is due entirely to chance, with a 0.0007% chance of finding a discrepancy between
observed and expected genotype distribution, disproving the null hypothesis of no association
between the marker M and the phenotype. Thus, we can conclude the existence of a moderate
association between the marker rs1219648 and breast cancer through this simple test statistic
using the Pearson’s Chi-Squared Test. More specifically, genetic associations can be measured
using the odds ratio (see Subsection 1.1.2), whereby the null hypothesis of no association
between the marker and the disease can be defined as H0: θ = 0 and the alternative hypothesis
as H1: θ 6= 0. If the direction of the association is specified and the risk allele is known, a
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one-side alternative hypothesis can used and defined as H1: θ > 0 or H1: θ < 0.
1.1.2 Measure of genetic risks in case-control studies
After assessing for departure of the distribution of SNP allele frequencies in cases and in con-
trols, estimating the disease risk conferred by the SNP allele is a decisive routine in genetic
association studies. These measures estimate the effect size of the SNP allele with respect
to the disease, instead of a significance value (John, F. Y. B., 2010). These are also useful if
the time lag between the exposure and the disease is very long or if the disease of interest is rare.
Table 1.3: 2× 2 table of levels of risk factor for n individuals with case and control status.
E+ E−
Case a b a+ b
Control c d c+ d
a+ c b+ d n
In a cohort study design, where a group of individuals exposed to a disease agent and a well
selected group of individuals without the disease and not exposed to the disease agent (Table
1.3) are observed and compared until an event of interest occurs or for a specified period of
time, the association between the exposure and the disease can be expressed as the relative risk






In a case-control study design on the other hand, the Odds Ratio (OR) for a disease is a com-
monly used measure of association in genetic association studies, which compares the odds that
an outcome will occur in the presence a specific exposure to the odds of the outcome occurring
in the absence of that exposure, or simply the ratio of allele porters to the non-porters in cases
compared with the same ratio in controls (Lewis, C. M., 2002).
Technically, even though easy to interpret, as the apparent RR is dependent on the number of
controls chosen and the disease prevalence, RR should not be used to express results in case-
control studies. However, the OR, though less intuitive, can be a reasonable approximation of
the RR when the disease is relatively rare or when less than 1% of people exposed to an agent
develop disease. When the disease rate rises above 1% it produces progressively larger errors,
in this case, when the study design allows for calculation of a RR, OR can be interpreted as if
it were RR, comparing risks rather than just a comparison of odds.
For a retrospective case-control study, we define the odds of being E+ (exposed) versus being
23
E− (not exposed) as
Pr (E+ | d)
Pr (E− | d)
, (1.2)
where d = 1 is for a case and d = 0 is for a control. Thus, the OR with respect to two levels
of R, e.g. with respect to case and control groups is defined as
ORR=E+:R=E− =
Pr (E+ | d = 1)
Pr (E− | d = 1)
/
Pr (E+ | d = 0)
Pr (E− | d = 0)
(1.3)










where the log transformation is used to promote normality as the odds ratios do not follow a
normal distribution, which can be used to produce the confidence interval for the OR. The
















referred tp as the Woolf’s estimate of the standard error (Lewis, C. M. et al., 2012), and the
confidence interval (CI) for the log ÔR can be obtained from
elog ÔR±zSDlog ÔR , (1.6)
where e ≈ 2.71828 is the base of the natural logarithms, and z is a Standard Normal deviate
corresponding to the level of confidence (1.645 for 90% confidence, 1.96 for 95% confidence,
and 2.576 for 99% confidence).
In the case of a diallelic marker with alleles A and B as described in the 2 × 3 contingency
table in Table 1.1, two ORs can be derived to measure the association. Let us denote OR1
the OR between AA and AB and OR2 the OR between AA and BB, using the genotype
with wild-type AA homozygotes as a reference in both cases. These ORi and their asymptotic
standard deviation are given by




















, for i in {1, 2}. (1.7)
If we assume an unbiased and well conducted study: an OR of 1 implies no association between
the exposure and the outcome; an OR of more than 1, and if its 95% CI does not include 1,
is said to be statistically significantly different, that is, a positive association between the ex-
posure and the outcome at the 5% significance level. In other words, the odds of exposure are
greater in cases than in controls, which suggests in the context of genetic association studies
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that the marker or variant increases the risk of the disease. An OR of less than 1, and if its 95%
CI does not include 1, implies a negative association between the exposure and the outcome at
the 5% significance level. In other words, the odds of exposure are greater in controls compared
to cases, suggesting a protective role of the exposure with respect to the outcome. If the 95%
CI contains 1, even though the resulting OR is greater or less than 1, the association between
the exposure and the outcome is not proven at the 5% significance level (Szumilas, M., 2010;
Bigby, M., 2000).
The genotype data for the marker rs1219648 in Table 1.2 was found to have significant associ-
ation with the disease under study from Pearson’s chi-square test with p-value= 7.459×10−06.
Computing the odds ratio for this association as described in Equation 1.7, we have OR1 = 1.24
with 95% CI = (1.03, 1.50) and OR2 = 1.18 with 95% CI = (0.93, 1.50). From these results,
we observe evidence for association between the marker rs1219648 and breast cancer in ho-
mozygote cases, however it does not reach statistical significance in heterozygote cases, as the
95% CI of the OR for this group of individuals spans 1.
1.1.3 Linkage disequilibrium and indirect association
Case-control study design generally requires large numbers of cases with the disease and controls
with thousands to millions of SNPs genotyped using currently available chip-based microarray
technologies, taking into account both sample size and SNP coverage to have sufficient power.
SNPs may be selected across the genome or may be selected specifically for their coverage
using existing data, which can be used as tagging SNPs. Thus some considerations have to be
taken into account to ensure that the majority of required loci and individual sites that must
be examined are captured. First, the specific genetic variation differences in populations must
be determined to enable the proper study design to be undertaken for different populations.
Secondly, the position and density of commonly occurring variations in the population need to
be known in order to avoid or reduce redundancy, taking into consideration the existing cor-
relations among SNPs to be captured (Bush, W. S. et al., 2012). As a result of the association
between these SNPs or linkage disequilibrium, they can be considered as markers, helping to
locate genes that are associated with the disease.
1.1.3.1 Linkage disequilibrium
Linkage disequilibrium (LD) refers to the property of SNPs in the same region of the genome
that describes the degree to which an allele of a SNP M1 is correlated or inherited from an
allele of another SNP M2 within a population. This dependence between loci on the same
chromosome pair and close enough to each other arises because any novel locus occurs on a
background of fixed alleles at other loci (Lewis, C. M. et al., 2012). Suppose the SNP M1 is a
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functional locus for a disease with unobserved alleles, and the SNPM2 is a non functional locus
with observed alleles, M2 is said to be a marker. Let us assume A and B the normal alleles,
and a and b the disease alleles for M1 and M2, respectively, with allele frequencies given by
Pr (a) = p, Pr (b) = q, Pr (A) = 1− p and Pr (B) = 1− q. We define the linkage disequilibrium
coefficient for each haplotype, under independence by
D = Pr (AB)− Pr (A) Pr (B) , (1.8)
as the deviation between the observed and expected numbers of disease alleles and normal
alleles or its equivalent expressions Pr (ab)− Pr (a) Pr (b), Pr (AB)− Pr (A) Pr (b), Pr (BA)−
Pr (a) Pr (B), Pr (AA) Pr (BB) − Pr (Ab) Pr (aB). The joint distribution of the alleles at the
two loci M1 and M2 are given in Table 1.4.
Table 1.4: 2 × 2 joint distribution of marker and functional locus in the same region of the genome
for a sample from a given population.
B b
A (1− p) (1− q) +D (1− p) q −D 1− p
a p (1− q)−D pq −D p
1− q q 1
A D value of 0 indicates the two loci are independent and are said to be in complete linkage
equilibrium, implying frequent recombination and statistical independence under principles of
Hardy-Weinberg equilibrium (Bush, W. S. et al., 2012), whereas when D = 1, the two loci are
in complete LD, implying no recombination between the two loci. When the marker SNP is
also a functional SNP and their allele frequencies are the same, we have the following cases:
• Single-locus model: A = B, a = b implying p = q, Pr (AB) = Pr (A) = 1 − p and
D = p (1− p);
• Two-locus model: A = b, a = B with p = 1 − q, Pr (AB) = 0 and D = −p (1− p).
This model also implies when D 6= 0, the two loci are also said to be in gametic phase
disequilibrium.
Mutations arise in a population initially closely associated with existing polymorphisms, that
is in high LD with neighboring SNPs and they are transmitted as a haplotype (see Figure
1.1). If a mutation is causative with strong disease risk, then SNPs in the region can be
used as markers of its presence. These SNPs usually maintain and appear to be in strong
statistical association with the disease of interest. Two commonly used measures of linkage
disequilibrium are the standarized LD coefficient D′ and the squared Pearson coefficient of
correlation r2, standardized in both case to remove the arbitrary sign introduced by allele
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Figure 1.1: Two SNPs are initially
in strong LD in a population, but as
mutations spread within the population
through recombination events over gen-
erations, LD between these two SNPs
breaks down. During this process, the
sizes of initial haplotype blocks are
shrunk, giving rise to six different hap-
lotypes in the population. Over time,
a pair of SNPs move from linkage dis-
equilibrium to linkage equilibrium. Re-
produced from (Rosset, S. et al., 2011).




D/min{(1− q) p, (1− p) q} ifD > 0.D/min{(1− p) (1− q) , pq} ifD < 0. (1.9)
r2 =
D2
pq (1− p) (1− q)
. (1.10)
Though D′ relies on recombination events, there exist some dependencies between these two
measures, in the sense that r2 is sensitive to the allele frequencies of the two SNPs and can
only be high in regions of high D′ . In these cases, |D′ | = 1 refers to complete LD and |D′ | = 1
together with A = B and a = b with p = q (D > 0), A = b and a = B with p = 1− q (D < 0)
refers to perfect LD (Zheng, G. et al., 2012).
LD varies across human sub-populations and genome regions and between pairs of markers in
close proximity. The degree and pattern of LD is also influenced by many factors on several
levels of comparison. Factors such as genetic drift, population size, admixture and inbreed-
ing are specific to a population, whereas factors such as natural selection, gene conversion
and recombination rate are specific to the genomic region (Shifman, S., 2003). Thus, African
populations have shorter regions of LD as they are the most ancestral and have accumulated
more recombination events (Figure 1.1a). European-descent and Asian-descent populations,
which were created by sampling of chromosomes from the African populations, resulting in
change in the number of founding chromosomes, and size, as well as the generational age of the
population, have, on average, longer regions of LD in contrast to African populations (Figure
1.1b).
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Figure 1.2: The disease polymorphism (p) is shown in white and the adjacent chromosomal markers
are shown in their chromosome colour accordingly. Due to recombination, they have been shuffled.
(a) Mutations that occurred recently have had fewer recombinational events, therefore they are as-
sociated with long LD intervals. (b) Mutations that occurred a long time ago have had many more
recombinational events, therefore they are associated with short LD intervals. Adapted from (Ostrer,
H., 2001).
To further illustrate what the impact of LD differences between populations can be in the
design of case-control genetic association studies, we consider the WT1 gene that was recently
identified to be associated with a protective role in the pathogenesis of tuberculosis (TB) (Thye,
T. et al., 2012; Chimusa, E. R. et al., 2013), located in the p13 region on chromosome 11. Figure
1.3 illustrates how LD structures differ in different populations. Thus, as the patterns of LD
vary in populations, the ability to detect association within the region harboring the disease
allele will depend on the strength of LD between unobserved and observed markers accordingly,
consequently influencing the specific trait-associated markers.
Figure 1.3: LD patterns of the
WT1 gene in different popula-
tions from the HapMap 3 project.
The Utah Residents (CEPH) with
Northern and Western European
ancestry (CEU), and the British in
England and Scotland (GBR) rep-
resent two European populations
with generally large blocks of LD,
whereas the Luhya in Webuye in
Kenya (LWK) and the Yoruba in
Ibadan in Nigeria (YRI) represent-
ing African populations with small
blocks of LD.
28
1.1.3.2 Direct and indirect association
Because the functional locus that has a causal effect for a disease is unknown, a marker is
typed and subsequently tested for association with the disease. Figure 1.4 describes the three
outcomes that are possible from the subsequent genetic association study. In the first outcome,
the polymorphism is a putative causal variant. This case is referred to as a direct association,
in which the variant influencing a biological system, which in the end leads to the disease, is
genotyped and found to be statistically associated with the phenotype in the study (Bush, W.
S. et al., 2012). Exomic polymorphisms, which cause change in an amino acid, are generally
considered as candidate variants for association studies, but it is also possible that mutations
that occur in non-coding regions influence the pathogenesis of complex diseases. This type of
study is easier to carry out and the most powerful, the difficulty resides in the identification
of candidate variants, as we actually do not know which variants might have effects on the
disease, or which part of the genome harbors functional polymorphisms (Cordell, H. J. et al.,
2005).
Figure 1.4: Three forms of associ-
ation between a marker and a dis-
ease and the relationship among the
marker, the functional locus, the con-
founder and the disease.
In the second situation, the functional marker is not genotyped, instead a polymorphism that
is statistically associated with the disease is typed and is in high LD with the influential marker
(Figure 1.5). This polymorphism acts as a proxy to the causal polymorphism and this case
is referred to as an indirect association. Indirect associations are less powerful than direct
associations and they are even more difficult to analyse (Cordell, H. J. et al., 2005). As in most
cases, indirect associations have weaker signals than the causal associations they reflect, so as
many markers as possible surrounding the causal marker need to be genotyped to have a higher
chance of detecting those indirect associations (Figure 1.5).
Considering these first two possibilities, a statistically significant SNP association from a case-
control study should not be considered as the causal polymorphism unless additional studies
are carried out to determine whether the identified SNP has an indirect or direct effect on the
disease, or just has a surrogate role for a causal variant. One then needs to map the precise
location of the casual variant. To this end, most of the time investigators concentrate on candi-
date genes identified either from animal model studies or on the basis of their known biological
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function (Bush, W. S. et al., 2012; Cordell, H. J. et al., 2005).
Statistical association between a marker and the disease can also be an outcome of neither a
direct or indirect association, but rather a result of false findings (positive confounding) or a
result of a negative confounding factor obscuring the true causal association signals (Figure
1.4). In this third situation, the marker association might be due to the effects of chance
(random error) or to confounding by stratification and substructure within the population,
leading us to conclude the existence of a valid statistical association when one does not exist
(false positive or type I error) or alternatively the absence of an association when one is truly
present (false negative or type II error). Section 1.2 discusses different confounding factors
that might disrupt case-control design studies including population stratification and cryptic
relatedness, and some existing methods for detecting and circumventing this difficulty.
Figure 1.5: Typed SNPs can lie in
a region of high linkage disequilibrium
with a disease risk SNP. Markers should
be selected specifically to capture the
variations at nearby sites and serve as
surrogates for functional SNPs through
indirect associations.
Because of these different possible interpretations of an association test outcome, a concise
knowledge of the variability of linkage disequilibrium is essential to appropriately developing
and interpreting association studies. In addition, as the variance of linkage disequilibrium is
also sensitive to population structure, each region included in a genotype-phenotype association
study should be assessed accordingly (Goldstein, D. B. et al., 2001).
1.2 Population structure and impact of population stratification
All mutations result in new alleles, which can persist or be lost in a population and their
frequency can vary over the years due to chance or selection, or due to admixture between
populations or be influenced by population size and bottlenecks. In the latter case, the pop-
ulation genetic variation can be reduced by a lot, resulting in the inability to adapt to new
selection pressures, such as climatic change because the alleles that selection would act on may
have already drifted out of the population (de Wit, E. et al., 2010; Li, H. et al., 2011; Caldwell,
R. et al., 2014). An example of this scenario is the South African Coloured (SAC) population,
which is a result of mainly a few Dutch settlers, and has an unusually high frequency of cer-
tain alleles such as those involved in Huntington’s disease or tuberculosis, just because those
original colonists happened to carry those alleles with unusual high frequency (de Wit, E. et
al., 2010; Caldwell, R. et al., 2014). If we consider a 20 year-generation population, with only
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two or so average offspring per generation, a mutation spreads slowly for a long-time period,
and this process is influenced by stochastic factors such as birth, death, and migration. A
variation that occurs commonly in a population is likely to be relatively old even though it is a
result of natural selection. Thus, it has disseminated over time via demic exchange over larger
geographic areas, proportionally with frequency, age, and geographic distribution. Because of
the recent history among species, common variation is typically global and those variants were
probably present at the time of human expansion out of Africa approximately 100, 000 years
ago.
The accumulation of these processes of mutation in populations for a long time period have
shaped human variation, and because of Gregor Mendel’s laws of inheritance, chromosomally
linked markers and functional variants are co-transmitted to offspring generations, reflecting
the history of shared genetic variation or “ancestry”. As a result, markers are shared among
samples of related individuals with statistically specifiable patterns of disease (Kittles, R. A. et
al., 2003). Investigators typically use this statistical information in trying to infer regions of the
genome that harbor these shared disease markers, which can quickly lead to the gene. Investi-
gators typically use this fact by first searching among closely related individuals. However, as
related individuals share much of their entire genome, it can be advantageous to look among
more distantly related groups of affected individuals who, because of recombination since their
common ancestors, disproportionately share variation at the chromosome region responsible
for the common disease (Kittles, R. A. et al., 2003; Dries, D. L., 2009).
1.2.1 Population structure
Because all genes in a geographic region share the same general population history, there exists a
greater correlation among variants found in one region compared to another geographic region.
However, because of random drift or even selection, some non-linked genes might be subject
to more or less independent changes in allele frequency resulting in genetic variant differences
across a subpopulation (Zheng, G. et al., 2012; Kittles, R. A. et al., 2003).
It has been suggested that seven major clusters exist in the global human populations, de-
termining the genetic structure of these populations, with the largest component lying along
geographic lines. These clusters include the Europeans/West Asians (Whites), sub-Saharan
Africans, North Africa/Middle Est, East Asians, Pacific Islanders, and Native Americans,
where some subpopulations have mixed ancestries from other major geographic regions as
illustrated in Figure 1.6A.
The SAC population of South Africa in Figure 1.6B is an example of a population with a
mixed ancestry, which is generally interpreted as either a recent population admixture or shared
ancestry before the divergence of contributing populations. It has been reported in accordance
with historical data that the SAC population is rather a result of a recent admixture, whose
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Figure 1.6: Proportion of an individual’s ancestry. Each individual is represented by a vertical line.
(A) Worldwide human population structure based on 650, 000 SNPs from 938 unrelated individuals
from 51 different populations using the frappe program. From (Li, J. Z. et al., 2008). (B) South African
Coloured (SAC) population based on 959 individuals with 75, 000 autosomal SNPs genotyped from
the Western Cape area of South Africa with individual ancestry generated using the STRUCTURE
program. From (de Wit, E. et al., 2010).
genomes consist of predominantly Khoisan (32 − 43%), Bantu-speaking Africans (20 − 36%),
European (21 − 28%) and a smaller Asian contribution (9 − 11%), depending on the model
used (de Wit, E. et al., 2010) as in Figure 1.6B.
Therefore, the structure of a population can result in inbreeding because individuals in different
subpopulations or ethnic groups can share common ancestries even in the occurrence of random
mating. These substructures in population can affect case-control design for genetic association
studies, and two types of substructure have been substantially considered in the literature,
including population stratification and cryptic relatedness.
1.2.1.1 Population Stratification
Population stratification (PS) arises in case-control designs when two subpopulation groups in
a population are poorly matched for genetic ancestry, resulting in a change in allele (genotype)
frequency of the marker across the subpopulations (Lewis, C. M. et al., 2012). Several genetic
association studies have been cited as examples illustrating how population stratification can
affect case-control studies (Thomas, D. C. et al., 2002). Two circumstances have been identified
as leading to this phenomena, therefore when testing for disease-marker association, their
existence must be tested to confirm the influence of hidden PS on the study design. The two
conditions which have to be satisfied in PS are whether; (1) the allele frequency of the marker
varies across the subpopulations, and (2) the disease rate varies across the subpopulations.
To control the allele frequency of the marker for PS, one can just avoid large allele frequency
differences between subpopulations or ethnic groups, which can be done using Wright’s F -
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Figure 1.7: Illustration of PS effect in a candidate gene study of the potential association between
Gm3:5,13,14 and type 2 diabetes (T2D) using American Indian samples. An artifact of the haplotype
derived from allotypic markers Gm3:5,13,14-carrying frequency difference of 0.05 is produced by this
unequal proportion of American Indian heritage in case and control groups. From (Li, W., 2008;
Knowler, W. C. et al., 1988).
statistic for the purpose of measuring the effect of admixing subpopulation (Wills, C., 2007).
Let the allele frequency of an allele in n subpopulations be p1 and p2 for n = 1, 2, the allele
frequency of another allele q1 = 1 − p1, q2 = 1 − p2, the frequency of heterozygote in the two
subpopulations will be 2p1q1, p2q2, and the heterozygote frequency in the combined population
will then be
Hwhole = 2pq, (1.11)
where p = wp1 + (1− w) p2, q = wq1 + (1− w) q2 are the averaged allele frequency of the two
alleles, and w and 1− w the mixing proportion of the two population, and the heterozygosity
in each subpopulation is given by
Hsub = 2wp1q1 + 2p2q2 (1− w) . (1.12)
We can observe that the frequency of heterozygotes always increases when the subpopulations
are combined and can be written as Hwhole ≥ Hsub. Therefore, the inflation of the heterozy-
gote frequency in the combined population will vary proportionally with the allele frequency
difference |p1 − p2|. The percentage of increase of the heterozygote frequency by combining
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subpopulations is the Wright’s F=statistic given by
F ≡ Hwhole −Hsub
Hwhole
=
2w (1− w) (p1 − p1)2
Hwhole





(p1q1) / (1− w) + (p2q2) / (w)
While the F value can be marker-specific or dataset-specific, an F = 10−1 appears to describe
normal variation between major ethnic groups and an F = 10−4 ∼ 103 appears to describe
variation between regions of an isolated population (Li, W., 2008).
Figure 1.7 is a typical illustration in a genetic association study of type 2 diabetes (T2D),
where a 10% difference in the composition of the studied population ethnic groups has lead
to Type I error signal. In this study, carried out in 1988 by Knowler (Li, W., 2008), a hap-
lotype Gm3:5,13,14 is examined in American Indians with various degrees of Indian heritage.
Assuming that the Gm3:5,13,14-carrying probability is practically the same between the case
and the control group, indicated by the two straight lines, the Gm3:5,13,14-carrying frequency
as a function of Indian heritage is shown in crosses (0 for European Caucasians, 7/8 for one
non-Indian grand-grandparent, 1 for 100% Indian heritage and so on), we can observe a dra-
matic Gm3:5,13,14-carrying frequency change with the population proportion with an increase
from 0.01 for 100% Indians to 0.66 for 100% Europeans. The solid square indicates the case
group with 99.9% Indian heritage, and the open square indicates the control group with 99%
Indian heritage.
The occurrence of PS is also subject to population heterogeneity in disease rates. The allele
frequency differences must also be correlated with the subpopulation differences in their baseline
disease rates. If there is no variation in the rates not attributable to specific genes under study
in the case of a candidate study for instance, then confounding cannot occur. Epidemiological
studies on infectious diseases have stated that there exists a broad range of susceptibilities
to major infectious diseases, depending on population history for the disease, and whether
the populations have been exposed only relatively recently or the populations have been in
equilibrium with respect to the disease for a long time (Thomas, D. C. et al., 2002).
1.2.1.2 Cryptic Relatedness
While PS typically considers remote common ancestry of large groups of individuals, another
source of confounding in a case-control design that might actually be a more serious source
of error, Cryptic Relatedness (CR), refers to recent common ancestry among smaller groups
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of individuals (Astle, W. et al., 2009). In other words, CR states that some of the individuals
in the case-control data might be close relatives of each other, resulting in their genotype not
being drawn independently from the population frequencies. This could ultimately result in
greater variance in the allele frequency estimates in cases and controls than expected even in the
absence of allele frequency estimate biases, and generate inflated type-1 error when testing for
genetic association using a test statistic this ignores that excess of relatedness among samples
(Voight, B. F. et al., 2005). Voight and Pritchard in (Voight, B. F. et al., 2005) argued that
CR may have negligible effects in well-designed studies of outbred populations, but may cause
serious concerns in founder populations that have grown rapidly and recently from a small size.
To demonstrate this, they analyzed a sample of six phenotypes from the Hutterite population.
They showed that CR decreases an association signal of 10−3 by a factor of approximately 4,
and that the smaller the signal the greater the relative effect. There might also exist a case
where both PS and CR can have an effect on the case-control sample, where, in addition to
relatedness among individuals, the allele frequencies and disease prevalences also change across
subpopulations.
1.2.2 Correcting for population stratification and cryptic relatedness
In an association study, the sample population can be composed of individuals from different
subpopulations or ethnic groups, whose allele frequencies as well as disease history, such as the
levels of exposure, differ, as discussed in sections 1.2.1.1 and 1.2.1.2. This heterogeneity with
respect to environmental factors among subpopulations or the genetic background may cause
spurious correlations, leading to false-positive or false-negative results depending on whether
these differences are in the same or opposite directions (Thomas, D. C. et al., 2002).
Consider a genetic association study, testing for association between a genotype G at a partic-
ular locus and a phenotype Y , where individuals are collected from a continuous geographical
space Z, directly correlated with PS. Let us assume a qualitative trait with disease status 0
and 1 for control and case, respectively. If we assume a conditional independence between the
phenotype Y and genotype G of an individual given that the individual is sampled at a position
z ∈ Z, there is no direct or indirect association between Y and G for a given z. In this case,
the null hypothesis H0 is equivalent to
Pr (G|z, Y = 1) = Pr (G|z, Y = 0) = Pr (G|z) , (1.13)
where Pr (G|z, Y = 1) and Pr (G|z, Y = 0) are the genotype frequencies at z for a case and a
control, respectively, implying no association conditional at the fixed region. If the specific
regions where cases and controls are sampled from are unknown in an association study, the
null hypothesis H0 can be expressed as
Pr (G|Y = 1) = Pr (G|Y = 0) , (1.14)
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If H0 does not hold, based on (1.14) when (1.13) holds, the association is referred to as a
spurious association Note that if cases and controls are collected from the same geographical
region (z ∈ Z is a constant) or from the same genetic background, then (1.13) implies (1.14)
and a spurious association will not occur (Zheng, G. et al., 2012).
PS and CR can act as confounding factors, which can be eliminated through better study
design or detected and controlled in the analysis. When not eliminated through study design,
statistical tests have to be adjusted for confounding factors that are known to have an impact
on the trait such as age, sex, study site, and other clinical covariates. Covariate adjustment
can extensively reduce spurious associations due to population structure and other sampling
artifacts, and various methods can be used to protect association studies from confounding.
Here, we discuss some major existing methods for detecting and adjusting for PS and CR in
genetic association studies.
1.2.2.1 Kinship coefficients based on marker data
The relatedness between two individuals can also be defined as the probabilities that each
subset of their alleles at any given locus is identical by descent (IBD), in other words, that
they have been inherited from a common ancestral allele without an intermediate mutation
(Astle, W. et al., 2009). The correlation coefficient Kij for variables indicating whether alleles
drawn from each of i and j individuals are some given allelic type, let’s say A, denotes the
Kinship coefficient. Let us denote p the frequency of allele A, xi and xj the A allele counts of
i and j respectively, with xi and xj in (0, 1, 2), then Kij can be estimated from genome-wide
covariances of allele counts by
Cov (xi, xj) = 4p (1− p)Kij , (1.15)
where p represents the population fraction of A alleles. Thus, the estimator of the kinship






(xl − 2pl1) (xl − 2pl1)T
4pl (1− pl)
, (1.16)
where x is a column vector over individuals, pl is the frequency of allele A at locus l and L
is the number of loci. Entries in K̂ can also be interpreted in terms of excess allele sharing
beyond that expected for unrelated individuals, given the allele fractions. Although the corre-
lations resulting from shared ancestry are in principle positive, because of bias resulting from
estimation of the pl, off-diagonal entries of (1.16) can be negative. However, for the purpose of
phenotypic correlations, genotypic correlations seem to be intuitively appropriate. In this case,
K̂ij can be interpreted as excess allele-sharing, where negative values represent the sharing of
fewer alleles than expected given the allele frequencies (Astle, W. et al., 2009).
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On the other hand, if we consider the probability that alleles chosen at random from each
of two individuals match at a genotyped dialelic locus, that is, identical by state (IBS), the









IBS arises as a result of IBD, usually when the mutation rate is low. The excess allele-sharing
or genotypic correlation estimator of kinship coefficients (1.16) is typically more precise than
(1.17) because it includes weighting by allele frequency. In addition, because the rare allele is
likely to have arisen from a more recent mutation event, sharing a rare allele suggests closer
kinship than sharing a common allele (Astle, W. et al., 2009; Slatkin, M., 2002).
The kinship estimate practically tells us how similar the genomes of people involved are, and is
used in many methods in genetic association studies for protecting from confounding factors.
Those methods are generally formulated within standard regression models in which, for the
phenotype of the ith individual, the expected value yi is expressed as a function of its genotype
xi at the SNP of interest as well as optional covariates such as gender or age as
g (E [yi]) = α+ xiβ, (1.18)
where g is a link function and β is a scalar or column vector of genetic effect parameters at
the SNP, and α is a normally distributed noise term that accounts for unexplained variation
in y. In a case-control design, g is the logit function and β a matrix of log odds ratios. Here,
case-control status is treated as the outcome, this refers to a prospective model. However, if
considering a retrospective case-control model, where some ascertainment effects can not be
correctly modeled prospectively, the standard linear model (1.18) can be expressed as
g (E [xi]) = α+ yiβ, (1.19)
where g here is typically the identity function g (yi) = yi.
1.2.2.2 Using better measures of populations through study design
As mentioned earlier, confounding factors can be controlled and eliminated during study design,
by matching, stratification, or multivariate adjustment models. In the case of population
stratification for instance, the need for more detailed information on ethnicity than just broad
conventional categories such as African, Caucasians, Asians and others, can be substantial.
Thomas and Witte in (Thomas, D. C. et al., 2002) underlined two main challenges with respect
to this perspective:
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1. Individuals must be of well-defined and subtle ethnic origin groups. Data collection must
be done with a high degree of specificity, along with a suitable definition of ethnicity
groups with respect to the trade-off between specificity and reliability.
2. Individuals from mixed-ethnic groups pose greater challenges, thus they must be consid-
ered appropriately. The investigator has to rely on multivariate models for adjustment
when it is difficult, but not impossible to find matching controls from individuals with
multiple ethnic origins.
1.2.2.3 Family-Based Test of Linkage and Association
When matching controls by ethnicity is very difficult or even impossible, the use of family-
members as controls can help to overcome this (Thomas, D. C. et al., 2002). The most commonly
used familial-based case-control method involves the use of siblings or parents as controls
(Schaid, D. J. et al., 1998). One of the major practical difficulties of this is that not all cases
will have an available sibling, and yet the sibling control must have already survived free of
the disease to the age when the case has been diagnosed. Alternatively, cousins can be used as
controls, but again are less readily available for closer matching on age and year of birth. An
increasingly used family-member case-control study design uses parents as controls (Thomas,
D. C. et al., 2002). A special case of this design is the transmission disequilibrium test (TDT),
which tests for systematic differences between the genotypes of diseased children and those
expected under Mendelian randomization of alleles of their unaffected parents. TDT allows
both linkage and association tests, respectively robust to population structure (causal allele)
or subject to fine-scale mapping (non-causal allele in LD in causal allele). While homozygous
parents are uninformative, alleles from heterozygous parents are assumed to be independent,
implying a multiplicative disease model (Astle, W. et al., 2009).
Let nA and na be the number of A and a alleles transmitted to affected children by Aa
heterozygous parents, respectively. Linkage infers that each parental allele is equally likely to
be transmitted, thus the null hypothesis for the TDT can be formulated as
H0 : E [na] = E [nA] .
Conditional on the number of heterozygote parents na + nA, the test statistic na has a
Binomial(na + nA, 1/2) null distribution. However, the McNemar’s test that can approximate




The TDT can also be derived from logistic regression models where transmission is the outcome
variable, and the parental genotypes are predictors (Schaid, D. J. et al., 1998; Visscher, P.
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M., 2010). Though TDT has several advantages, the main disadvantages of the TDT and
other above-mentioned family-based case-control methods are the difficulty of obtaining enough
families for a well powered study and the additional high costs of this 1 : 3 matched case-control
study, where three individuals have to be genotyped to obtain the equivalent of one case-control
pair (Astle, W. et al., 2009; Visscher, P. M., 2010).
1.2.2.4 Genomic Control
Recently, investigators have proposed the use of genomic information to help address the prob-
lem of bias attributable to PS and over-dispersion attributable to CR. If a test statistic T has
an asymptotic χ21 distribution under the null hypothesis of no association, it has been demon-
strated that in the presence of confounding factors, the test statistic is distributed as χ21 up
to some scaling constant (Astle, W. et al., 2009; Devlin, B. et al., 1999). Using a simulation
under an island model with admixture and ascertainment bias, Astle and Balding in (Astle,
W. et al., 2009) demonstrated an approximately linear inflation of the Armitage test statistic
due to a combination of PS and CR, and Devlin and Roeder in (Devlin, B. et al., 1999) argued
that this inflation holds more generally. They therefore proposed to correct for type I error
from the test statistic T by adjusting all the test statistics by a constant factor λ, keeping the
ranking of markers in terms of significance unchanged, that is, GC appears as an adjustment
of the significance threshold (Astle, W. et al., 2009). The main idea here is to multiply all the
test statistics with λ in order to make the T distribution to fit a χ21 distribution. A number





the median estimator “median(T 2)/0.455” and the regression estimator “slope of regression of
observed T 2 on the expected” (Astle, W. et al., 2009; Devlin, B. et al., 1999).
The mean estimator is more effective than median estimator under the null hypothesis. How-
ever, given that, for most diseases, only a few markers are expected to have strong causal
associations with test statistics in the upper tail of the empirical distribution, the portion of
empirical distribution that is away from the upper tail can not be used to estimate λ because
it should normally reflect the null distribution of association. Astle and Balding in (Astle, W.
et al., 2009) proposed to remove the highest test statistics from consideration and then use the
mean estimator.









where dk is the distribution function of a χ21 random variable.
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Proof. Let X χ21, then
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Ultimately, Estimate(λ) = mean(lower 95% of T 2)/0.759. A deviation of λ from 1 suggests
that the analysis model failed to account for the population structure, and another model
should be used. GC assumes an additive disease model while it can be adapted for tests of
other disease models. In addition, GC assumes that PS and CR act in the same direction across
all loci which is not true. In other words, it does not distinguish markers at which the pattern
of association is correlated with the underlying pedigree from those at which the pedigree does
not contribute to the association, for which no adjustment should be performed. Finally, it is
also important to consider that the inflation factor λ is dependent on sample size, so special
methods should be used when the number of people typed for different markers differs (Astle,
W. et al., 2009).
1.2.2.5 Structured Association
With the high availability of several thousand genome-wide markers, the ethnic group or sub-
population of an individual in a population can be more confidently inferred. After determining
for each individual the ethnic group membership, which is assumed to possess no population
structure, any test statistics can be applied within each subpopulation to estimate a correct
type I error rate. This process is referred to as the Structural Association (SA) method, based
on the island model of population structure, and the ancestry of each individual is assumed to
be drawn from one or more islands (Zheng, G. et al., 2012; Astle, W. et al., 2009). The null hy-
pothesis H0 of no association is tested between a marker and the disease at the subpopulation
level, assuming that the subpopulation is in Hardy-Weinberg equilibrium, as in (1.13), rather
than the overall null hypothesis H0 as in (1.14). Some popular software packages, including
STRUCTURE (Pritchard, J. K. et al., 2000) and ADMIXMAP (Hoggart, C. J. et al., 2003),
which are available free of charge, can be used to infer the subpopulation memberships of in-
dividuals. These methods model variation in ancestral subpopulations along a chromosome as
a Markov process. Stratified test statistics for association can then be performed to combine
association signals across all subpopulations, where in general, logistic regression models of
the form (1.19) are used with the admixture proportions of each subpopulation as covariates,
making these approaches computationally intensive. The number of subpopulations can be es-
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timated from the population data using an optimized measure of model goodness of fit, which
significantly increases the computational burden, although, there is usually no satisfactory es-
timate of the number of subpopulations, as the population model on which these approaches
rely (island model) is not well suited for most human populations. Similar to GC, SA methods
are only effective using ∼ 102 SNPs (Astle, W. et al., 2009).
1.2.2.6 Principal Component Adjustment
Price in (Price, A. L. et al., 2010) demonstrated that population structure can be controlled
using a logistic regression model of the form (1.18) with the use of ∼ 100 widely spaced, pu-
tatively neutral SNPs as regression covariates. These covariates are informative about the
underlying pedigree and are supposed to eliminate its effect in regression-based tests with the
locus of interest (Astle, W. et al., 2009; Price, A. L. et al., 2010), and these approaches are
computationally faster than SA and more robust to ascertainment bias than GC, allowing one
to take advantage of the flexibility of regression methods.
Principal Components (PCs) are often used to summarize high dimensional data without los-
ing much information. PCs can be used to produce maps closely reflecting the environmental
and cultural variations in worldwide populations, as well as population migration. They are
ideal for summarizing the genetic markers across the genome and proposed for characterizing
population differences and controlling for population structure in genetic association studies
by integrating PCs of genome-wide SNP genotypes as regression covariates (Yu, J. et al., 2006;
Price, A. L. et al., 2006). The idea here is that the genetic background of an individual can
be represented using his/her genetic markers, therefore, individuals with similar variations or
similar PC values are likely to come from the same subpopulation (Zheng, G. et al., 2012).
Let X be a n × L matrix of genotypes initially coded as allele counts (0, 1 or 2), where
n and L represent the number of individuals in rows and the number of SNPs in columns,
respectively. After standardization of genotypes to zero mean and unit variance, the n × n





Given that K̂ is symmetric and positive semi-definite, it can be written as an eigenvalue
decomposition
K̂ = vΛvT , (1.23)
where v and Λ is a matrix whose columns are the eigenvectors, or PCs of K̂ and their corre-
sponding diagonal matrix (nonnegative) eigenvalues in decreasing order, respectively.
As for SA and regression control, the main idea motivating PC adjustment is that if measures
of ancestry, PCs in this case, can partly explain a correlation between the phenotype and a
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given SNP, then including these PCs as regression covariates prevents that part of the signal
association from contributing to the test statistic. This allows protecting against spurious as-
sociations, provided that sufficient PCs are incorporated in the model to consistently explain
confounding structure. Generally, in a population, the first two PCs v1 and v2, jointly, can
accurately predict the proportion of an individual’s ancestry arising from each of the subpopu-
lations, and because of case-control ratio variations across the subpopulations, they can also to
some extent predict the case-control status (Astle, W. et al., 2009). A popular implementation
of PC adjustment, the EIGENSTRAT software, for computational reasons, does not include
PCs as logistic regression covariates, but instead performs a linear regression of both pheno-
types and genotypes, including the first ten PCs (Price, A. L. et al., 2006). Though it is still
unclear how many PCs have to be appropriately included to protect the association test from
any eventual inflation, experience has suggested that 2 to 15 PCs are typically sufficient. PC
adjustment may fail to protect from population structure effects under more complicated and
realistic models of population structure; inflation due to family structure and CR for instance
is not guaranteed to be ameliorated by PC adjustment (Astle, W. et al., 2009; Price, A. L. et
al., 2010).
1.2.2.7 Mixed Regression Models
Yu et al. in (Yu, J. et al., 2006), as well as many other investigators, have proposed the use of
mixed models to model population structure, family structure and CR. The main idea here is to
model phenotypes using a mixture of fixed effects, the candidate SNP and optional covariates
including age or sex, and random effects, a phenotypic covariance matrix as a sum of heritable
and non-heritable random variation (Price, A. L. et al., 2010), Let us consider the standard
linear model described in Section 1.2.2.1, extending (1.18) by integrating for each individual
i ∈ {1 . . . n} a latent variable δi such as
E [yi|δi] = α+ xiβ + δi, (1.24)
where δi denotes the random effects, which in the context of a case-control study can be
interpreted as a polygenic contribution to the phenotype, resulting in many small additive
genetic effects distributed across the genome (Price, A. L. et al., 2006), Assuming an additive
polygenic, the δ variance-covariance structure that is proportional to the correlation structure





 =: δ ∼ N (0, 2σ2h2K) , (1.25)
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and the residuals are assumed to satisfy









where the parameter σ2 relates K to the phenotype y. By capturing the extent to which ge-
netically similar individuals are phenotypically similar, this enables removing of confounding
effects, whereas h2 ∈ [0, 1] is the narrow sense heritability of the trait, which represents the
proportion of variation due to additive polygenetic effects.
Mixed models have proven useful theoretically but are very computationally extensive. Typi-
cally, ∼ 105 SNPs are required for adequate estimation of K in human populations, which is
much more than what is required in PC adjustment. However very recent computational ad-
vances have now made their application in population-based genetic association possible. The
software package EMMAX, developed by Kang et al. in (Kang, H. M. et al., 2010), enables fast
inference in linear mixed models using a likelihood ratio test. Another fast method for inference
of mixed linear models, TASSEL, proposed by Zhang et al. in (Zhang, Z. et al., 2010), uses
a compression approach, called ‘compressed MLM’, that decreases the effective sample size of
large datasets by clustering individuals into groups, markedly reducing computing time while
maintaining or improving statistical power.
1.3 Genome-wide association studies: progress and limitations
The ultimate goal of genetic association studies is to identify genetic risk factors, and elucidate
the mechanisms through which these factors exert their effects on rare Mendelian diseases such
as sickle cell anemia and cystic fibrosis (Bush, W. S. et al., 2012; Wright, F A. et al., 2011),
and on common complex diseases such as heart disease (HD), type 2 diabetes (T2D) and
tuberculosis (TB). This goal, is not only limited to identifying the genetic factors, it extends
also to providing an overall genetic architecture including estimating the genetic heritability,
the number of loci underlying phenotypic variation, and the distribution of effect sizes, as well
as suggesting whether or not the effect of epistasis or pleiotropy exist (Stranger, B. E. et al.,
2011; Hardy, J. et al., 2009).
1.3.1 Overview of GWA studies
Candidate gene association studies interrogate human genetic variations for association with
complex diseases, prioritizing certain genes or genomic regions for further investigation. Re-
cently, genetic association studies have utilized LD-based (1.1.3) genome-wide association
(GWA) studies, which permit interrogation of allele frequencies at each of several hundred
thousand markers spaced throughout the entire human genome at levels of resolution previ-
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ously unachievable, in thousands of unrelated case and control individuals. GWA studies are
unbiased with respect to genomic structure and prior hypotheses regarding genetic association
with the disease, in contrast to candidate gene studies, where the knowledge of the trait is used
to identify candidate loci involved in the etiology of the disease of interest (Pearson, T. A. et
al., 2008). GWA studies have also been valuable over family-based linkage studies (see 1.2.2.3),
which, though successful in identifying genes of large effects in Mendelian disease, have had
less success in common diseases that are in most cases the results of multiple genes generally
of small effects (McCarthy, M. I. et al., 2008; Bush, W. S. et al., 2012).
Figure 1.8: The spectrum of disease association can be conceptualized in a 2-dimension representation
as function of allele frequency and penetrance or effect size. The bulk of identified genetic associations
lie on the diagonal denoted by the dashed lines. Highly penetrant variants with large effect sizes usually
for Mendelian diseases are extremely rare, while common variants that are mostly identified through
GWA studies are of small effect sizes and have very low homozygote risk penetrance.
Though unbiased with respect to previous biological knowledge, and with respect to the genome
location, GWA studies are not unbiased with respect to what is detectable (Visscher, P. M.
et al., 2012). In fact, GWA studies rely on the common disease, common variant (CDCV)
hypothesis, suggesting that genetic factors influencing many common diseases will be at least
to some extent attributable to a limited number of allelic variants present in more than 1%
to 5% of the population. Therefore, as illustrated in Figure 1.8, GWA studies are by design
underpowered to detect association with variants that are relatively common with modest effect
sizes (OR of 1.1 to 1.5), even when combined, their overall impact on the population variance
and predictive power still remains limited, and many important complex disease-causal variants
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may be rare, and are therefore unlikely to be identified through this approach (Stranger, B. E.
et al., 2011; Visscher, P. M. et al., 2012; Pearson, T. A. et al., 2008).
1.3.1.1 Progress of GWA studies
The first successful GWA study was reported in 2005 with ∼ 100, 000 SNPs from 96 age-related
macular degeneration patients and 50 healthy controls (Klein, R. J. et al., 2005), and since then
several hundred impressive GWA studies have been published covering a range of complex
human traits. A landmark study by the Wellcome Trust Case Control Consortium (WTCCC)
in 2007 was carried out on seven different common diseases including bipolar disorder (BP),
coronary artery disease (CAD), Crohn’s disease (CD), hypertension (HT), rheumatoid arthrisis
(RA), type I diabetes (T1D), and type 2 diabetes (T2D), covering ∼ 500, 000 SNPs from
1500− 2000 cases and 3000 shared controls (Wellcome Trust Case Control Consortium, 2007).
As of December 2013, 1, 779 GWA studies and 12, 126 genetic variants have been published
according to The Catalogue of published Genome-Wide Association Studies. These cover a
broad of spectrum of complex traits and diseases conducted in an unprecedented global research
effort in only 8 years, including hundreds or even thousands of case and control participants.
Through the experimental design of GWA studies, previously implicated loci, and also a number
of novel associated loci for complex diseases, have been discovered to be significantly associated
with one or more complex traits (Hindorff, L. A. et al., 2013b), including autoimmune diseases
such as type 1 diabetes (T1D), ulcerative colitis (UC) (Anderson, C. A. et al., 2011) and
Crohn’s disease (CD) (Rioux, J. D. et al., 2007; Mathew, C. G., 2008; Franke, A. et al., 2010);
metabolic diseases such as type 2 diabetes (T2D) (Saxena, R. et al., 2007), fasting glucose and
insulin levels, body-mass index (BMI) and obesity (McCarthy, M. I., 2010).
1.3.1.2 Study designs used in GWA studies
The most frequently and substantially used design for GWA studies to date has been the case-
control design (see 1.1.1). These studies are often easier to conduct and cost effective compared
to other designs, particularly in cases of sufficient numbers of case-control individuals or sample
size. Additional assumptions are made in this design, which, if not met, can lead to substantial
biases and spurious associations (see 1.2.2). That said, the statistical power of GWA studies
depends on certain factors including phenotype definition, sample size, effect size, causal allele
frequency, and marker allele frequency as well as its relationship with the causal variant (Platt,
A. et al., 2010; Pearson, T. A. et al., 2008; Spencer, C. C. et al., 2009). Therefore, it is required
for instance, to have large population samples to be able to detect variants of even moderate
effect sizes (OR of 1.5 to 2.0). Statistical power and sample size can be substantially increased
through meta-analyses of independent GWA studies for the trait of interest. Several software
packages are available for carrying out meta-analysis such as METAL (Willer, C. J. et al.,
2010). When different array technologies and different marker coverage are used, only a few
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SNPs may be common, therefore, genome-wide imputation methods, recently developed and
implemented in software packages such as IMPUTE and MaCH, can be of great benefit to infer
genotypes of untyped SNPs using a reference panel of more densely genotyped samples (e.g.
The International Hapmap Project - http://hapmap.ncbi.nlm.nih.gov/, and the 1000 Genomes
project - http://www.1000genomes.org/) (Stranger, B. E. et al., 2011; Howie, B. N. et al., 2009;
Hancock, D. B. et al., 2012).
Because the hundreds of thousands to millions of single-locus statistical tests conducted in
GWA studies, expressed as p−values, each having a false positive probability relative to its
test statistics, the cumulative likelihood of detecting one or more false positives among the
whole GWA analysis is much higher. Simple ways to correct for multiple testing approaches
include the Bonferroni correction, and the false discovery rate (FDR). Another approach for
establishing significance in GWA studies is using permutation testing, although a bit more
computationally expensive, this approach is a straightforward way to generate empirical distri-
bution of test statistics of a data set assuming the null hypothesis is true (Bush, W. S. et al.,
2012). In addition to single-locus testing, contemporary association studies consider multi-locus
analysis, whereby interactions among genetic variants across the entire genome are examined.
While presenting enormous opportunity to examine multiple, often correlated phenotypes or
multiple genetic models, this approach still presents various statistical and computational chal-
lenges, and thus it is not as straightforward as a single-locus analysis (Lunetta, K. L., 2008).
1.3.1.3 Quality control in GWA studies
The selection of study participants remains of key importance in a GWA study, as no genetic
association study will have meaningful outcomes without a precise and consistent character-
ization of the phenotype of interest. Misclassification of participants, cases or controls, can
remarkably reduce study power, and introduce systematic biases leading to an increased num-
ber of false-positive and false-negative association signals. Genotyping errors, especially when
occurring differentially between case and control individuals, can also lead to spurious associa-
tions. Although such errors can be avoided through study design (see also 1.2.2.2), a thorough
data quality assessment should be applied both on a per-sample and a per-marker level to
remove individuals or markers with particularly high error rates (Pearson, T. A. et al., 2008;
Anderson, C. A. et al., 2010).
Checks on samples consist of at least 4 steps including (1) identification of samples with in-
consistent sex information; (2) identification of samples with outlying missing genotype or
heterozygosity rate; (3) identification of related or duplicated samples and (4) identification
of samples of divergent ancestries. For example, as DNA sample quality or concentration can
have large effects on genotype call rate and genotype accuracy, samples with low DNA quality
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must be discarded. The genotype failure rate and heterozygosity rate can be used to measure
DNA quality and only samples with less than 3− 7% missing genotypes are typically reported
and considered for the further analyses. In this case, the most appropriate threshold, which
depends on the sample, can be determined by carefully scrutinizing the genotype missing rates
across the entire data set. Duplicated and related individuals can be identified using the IBS
and IBD metrics. After calculations of IBS and IBD between all pairs of individuals, duplicated
individuals have an IBS = 1 or IBD = 1, however, due to genotyping error, PD and population
structure, which can often cause some variations to these theoretical values, an IBD > 0.98
denotes duplicates, and one of each pair of individuals with IBD > 0.1875 must typically be
removed.
Once samples failing per-individual quality control (QC) are removed, individual SNPs across
the remaining samples undergo further assessments for probable genotyping errors (per-SNP
QC), including (1) SNPs with an excessive missing genotype; (2) SNPs with severe deviations
from the Hardy-Weinberg equilibrium; (3) SNPs with excessive differences in missing genotype
rates between cases and controls and (4) SNPs with very low minor allele frequency, as rarer
SNPs are difficult to measure reliably in case-control design (see Figure 1.8). There exist several
software packages for QC of GWA data including GenABEL (Aulchenko, Y. S. et al., 2007),
snpMatrix (an R package part of the bioconductor project - http://www.bioconductor.org)
and Plink (Purcell, S. et al., 2007), which have advantages over standard statistical software.
Currently, Plink is the most widely used software package for GWA data QC, using the QC
protocol presented by Carl et al. in (Anderson, C. A. et al., 2010), with fully automated
analyses.
1.3.2 Limitations and future directions of GWA studies
GWA studies promise to provide an understanding of the mechanisms underlining the etiol-
ogy and pathogenesis of complex diseases. A fact sheet published by the National Human
Genome Research Institute (NHGR) in 2007, states that the impact of GWA studies on clini-
cal medicine could potentially be substantial and that this could ultimately lead to the era of
personalized medicine, enabling more customized clinical strategies, including individual risk
prediction, disease prevention, and patient-specific treatment (Hindorff, L. A. et al., 2013a).
From a medical genetics perspective, the ultimate goal of GWA studies can simply be viewed
as the identification of genetic risk factors from the validated disease-SNP associations, in or-
der to characterize their functional effects on the disease. When many genes are believed or
suspected to be involved in the pathogenesis of a disease, and when the understanding of the
etiology of the disease, a systems biology perspective should be taken into consideration, in
which perturbations of complex networks are considered to be the basis for the outcome of a
complex trait phenotype (Stranger, B. E. et al., 2011). GWA studies have provided important
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scientific discoveries as discussed in Section 1.3.1.1 and have had an enormous impact on the
field of human genetics, but at the same time, many people have highlighted several problems
and limitations of this single-marker-based experimental design. Those limitations include not
only, but importantly, methodology issues such as insensitivity to rare and structural variants,
requirement of large sample sizes, eventual biases due to selection of study participants, and
genotyping errors. Other limitations include research outcome issues such as the potential for
spurious results, utility of the research findings such as lack of information on gene function,
heritability remaining unexplained in the population, limited information about non-genetic
risk factors, and lack of biological and clinically relevant or meaningful results (Visscher, P.
M. et al., 2012; Pearson, T. A. et al., 2008). These limitations mean, the single-marker-based
approach of GWA studies might not possess adequate power to detect important risk factors
for complex disease because:
1. The majority published GWA studies enumerate only the 20− 50 most significant SNPs
and their neighboring genes (the “most-significant” SNPs/genes approach), while paying
little or even no attention to the rest, thus neglecting most genetic variants with small
effects on the disease. This approach might even miss genetic variants with higher disease
risks, as those variants might not rank among the top 20 − 50 most-significant out of
hundreds of thousands of markers tested, especially in cases where the size of the sample
is not large enough (Wang, K. et al., 2007).
2. This strategy has limited power to unveil the majority of genetic disease risk factors.
For instance, these have been estimated to account for about 80% of the heritability for
the human height trait (Visscher, P. M., 2008), however the total of phenotypic variance
explained by more than 40 variants discovered so far in human height GWA studies, only
sums to about ∼ 14%. Most of the complex disease associated variants identified to date
together account for much less of the phenotypic variance (Stranger, B. E. et al., 2011).
With the exception of age-related macular degeneration (AMD) (Klein, R. J. et al., 2005)
and type 1 diabetes (T1D) (Barrett, J. C. et al., 2009), for which collectively the proportion
of heritability explained to date is approximately 50% and 80%, respectively, most complex
disease variants identified to date, using GWA study design, together account for much less of
the trait variance. Several proposed explanations for this “missing heritability” (Stranger, B.
E. et al., 2011; Manolio, T. A. et al., 2009) include:
1. Effect sizes of associated variants may be underestimated due to incomplete linkage dis-
equilibrium between causal variants and marker SNPs;
2. low-frequency polymorphisms (MAF 0.005−0.05) or rare variants (MAF< 0.005) that are
not captured by current genotyping platforms, including Copy Number Variants (CNVs),
may contribute a portion of the unexplained heritability;
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3. heritability may be overestimated, with epistasis, epigenetics, and genotype–environment
interactions contributing to trait heritability; and
4. many additional, currently undetected small effects may together comprise a significant
contribution to heritability.
Structural variants such as insertions/deletions (indels), inversions and CNVs, as well as rare
variant have been made available from various human genome projects. Along with the launch
of the 1, 000 Genomes Project in 2008, sequencing the genomes of over 2, 000 individuals and
providing low-frequency variants in the human genome, a next wave of GWA studies has been
facilitated to investigate the role of genetic variants not yet explored. This may enable the
discovery of genetic risk variants of moderate and high effect sizes, to cover the substantial
heritability that remains unexplained. In addition, whole-exome sequencing, candidate locus
resequencing, and even whole-genome sequencing will also play a key role in the next generation
of GWA studies. Integrating this with data from the environment, and other high-throughput
technologies such as the proteome and the transciptome, has potential to facilitate further
understanding of biological processes, gene-gene and gene-environment interactions, as well as
epigenetic effects influencing complex human diseases (Klein, C. et al., 2012).
1.4 Overview on biological networks and pathway databases
The remarkable success of genome-wide association studies has been demonstrated in the un-
covering of multiple genetic variants associated with complex diseases, and have clarified our
understanding of the genetic architecture of several traits. In a typical GWA study, the single-
marker-based approach, hundreds of thousands of markers are simultaneously tested, and the
allelic frequencies of each marker between cases and controls compared and evaluated at a
genome-wide significance cutoff p-value of 5 × 10−8, under the assumption of no-association
among markers. Because of the very large number of SNP markers used in such studies, only a
few markers exceed the genome-wide significance threshold, and in almost all published GWA
studies, only the 20−50 most significant markers are listed (the “most-significant SNPs/genes”
approach), while the rest that do not pass this stringent cutoff are generally neglected (see Sec-
tion 1.3.2). However, many of the markers showing modest associations (0.05 >= p > 10−08),
though with small but measurable genetic effects, may represent false negatives, in which case,
accepting the null hypothesis of no-association represents a type II error (Baranzini, S. E. et
al., 2009). In addition, the very small fraction of heritability explained by identified genetic
variants in most GWA studies so far (see Section 1.3.2), suggests that there is a substantial
proportion of risk alleles or genetic variants that are still missing, and can not be detected
through this most-significant strategy (International Multiple Sclerosis Genetics Consortium,
2013).
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Realizing the limitations of conventional single-marker association analyses, alternative or com-
plementary approaches for GWA study analysis have been developed in recent years. These
include association tests that use multiple SNP markers, association tests using imputed geno-
types, those incorporating linkage information and, more recently, pathway-based analysis (PA)
approaches. One of the first studies to propose a PA approach for GWA study analysis was
conducted by Wang et al. in (Wang, K. et al., 2010) where, borrowing ideas from the gene
expression microarray field, they proposed an adapted GSEA (Gene Set Enrichment Analy-
sis) approach (Subramanian, A. et al., 2005) to use pathway information in GWA studies, and
demonstrated that this approach might complement the most-significant SNPs/genes approach
for interpreting GWA results on complex diseases. The main idea behind PA in GWA studies
is that, although association signals of several variants involved in disease etiology may be too
small to detect using the conventional single-marker-based approach, they may be collectively
detected from the combined effect of multiple variants in interacting or grouped genes accord-
ing to their shared functions. Therefore, integrating prior biological knowledge on genes and
pathways into association studies, may increase the power to identify not only genes, but also
mechanisms that influence the susceptibility and development of complex diseases (Wang, K.
et al., 2010; Wang, K. et al., 2007; Fehringer, G. et al., 2012; Baranzini, S. E. et al., 2009;
International Multiple Sclerosis Genetics Consortium, 2013).
Identification of biological functions of disease-related genes that are as yet unknown, will
substantially increase our understanding of biological mechanisms involved in disease patho-
genesis. As it is more likely that proteins that are closely connected collaborate in similar
processes, understanding functional roles of interacting partners may facilitate the understand-
ing of potential functional roles of as yet unannotated disease-related genes, and will increase
our understanding of biological processes underlining complex diseases. These biological pro-
cesses are generally represented as networks interconnecting a very large number of nodes and
are characterized by very complex topologies (Ma’ayan, A., 2011). Several biological networks
have been characterized to date including transcriptional regulation networks (Wei, C. L. et
al., 2006), protein-protein interaction networks (Keshava Prasad, T. S. et al., 2009), metabolic
networks (Karp, P. D. et al., 1998), cell signaling networks (Ma’ayan, A. et al., 2005), epistasis
interaction networks, in which genes are connected only if they exhibit a genetic interaction
when knocked out or down-regulated (Segre, D. et al., 2005), disease gene interaction networks
in which diseases are connected to genes that, when mutated, contribute to the disease (Goh,
K. I. et al., 2007), and drug interaction networks, in which drugs are connected to their targets
(Yildirim, M. A. et al., 2007).
Mathematical objects such as graphs, consisting of nodes and edges interconnecting these
nodes, can offer a convenient and effective level of abstraction for representing the aforemen-
tioned complex networks. Widely used to represent mathematical networks, different compu-
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tational approaches, such as data mining, machine learning, search or optimization problems
and statistical approaches, can be designed based on this graphic representation to reveal the
organization of these complex networks at different levels. Biological scientists too can benefit
from graph-based formalism since they are able to visualize the overall topology of the network,
modify nodes and links and annotate them with additional information. The robustness and
evolution mechanism of a biological network, for instance a cell signaling pathway, is believed
to be dependent on its topological structure (Strangio, M. A., 2009).
1.4.1 Analysis of biological networks
Complex systems such as social organizations and biological systems can be represented as
networks wherein components of the systems are represented as nodes and are linked by edges
representing their interactions or simply their relationships. In the case of biological networks,
components such as proteins, genes, diseases and drugs are typically considered as nodes and
their direct or indirect interactions as edges (A.L., B. et al., 1999). The directionality of such
networks depends on the biological characteristic components, for example, protein-protein and
genetic interactions are usually represented with undirected networks, and transcription fac-
tor binding and metabolic networks are represented as directed networks as their components
have certain directions in their interactions (A.L., B. et al., 1999). The complexity of biological
networks is not only driven by their large number of nodes and their interactions, but also
by other complex dynamic behaviors difficult to observe in the dynamic cellular 3D-space. In
protein-protein interaction networks for instance, interactions are often subject to time and
location, and proteins may vary their partners accordingly. In this case, quantitative mathe-
matical methods may be computationally extremely expensive or even unfeasible. Therefore,
representing the complexity of biological systems as networks may have several advantages such
as for structural analysis of these biological systems, as well as in hypothesis formulation. This
could substantially increase insights into the organizational principles of biological components
and reveal information on the underlying biological functions (Strangio, M. A., 2009; Zhu, X.
et al., 2007). Once represented by a network, a biological process or system can be studied
using tools of complex network theory, to systematically characterize its functional properties.
Network topology is of crucial importance in the architecture and robustness of a network, this
includes information about the global topological properties of the entire network, general and
specific properties of nodes or edges, and modules within the network (Ma’ayan, A., 2011).
Let G be the mathematical representation of a biological network, defined as a couple (V,E)
and composed of a set of nodes or vertices V and edges E, where E = {(i, j) |i, j ∈ V }. We
define by G′ = (V ′, E′) a subgraph, where V ′ ⊆ V and E′ ⊆ E and each edge in E′ is incident
with nodes in V ′. A clique in an undirected graph G is a subgraph G′, in which every pair
of nodes is adjacent. The degree of a node is the number of edges incident to the node. In
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an undirected graph, the degree of a node i is defined as deg (i) = k (i) = |N (i) | with N ,
the number of neighbors of node i. The degree distribution P (k), describes the probability of
a node to be of degree k. The distance δ (i, j) is the smallest number of links that have to
be traversed to get from node i to node j, and the path through the network that achieves
that distance is the shortest path between nodes i and j. In an interaction network, the graph
diameter and the average of shortest path lengths l refer to the maximum and average value
of δ between any two nodes i, j ∈ V , with δ ≥ 1. The clustering coefficient of a node i in a
network, Ci, is the probability that two given nodes i and j which are connected to the node
t are themselves connected. In an undirected graph G is given by Ci = 2Eiki(ki−1) , where k is
the degree of node i, and E is the number of edges between the k neighbours of i in G, with
0 ≤ Ci ≤ 1. The tendency of the whole network to form clusters can be measured using the
average clustering coefficient, and is defined as C = 1N
∑N
i=1Ci, where N = |V | is the number
of nodes.
It is generally assumed that there are small values of l and C, and small l implies that a given
node i can reach any other node j in a few steps. Thus this acts as a measure of the infor-
mation efficiency flow across the network, whereas a small C implies that the network is likely
to not contain clusters (Albert, R. et al., 2002). Several recent studies, including (Albert et
al., 2002), have revealed that many complex systems present small-world and scale-free global
network topological properties. Small-world networks are characterized by significantly larger
C and relatively small l. On the other hand, scale-free networks exhibit P (k) that follows the
power-law distribution P (k) ∼ k−γ , indicating that the fraction P (k) of nodes in the network
with degree k is proportional to k−γ where γ denotes the degree exponent, typically in the range
]2, 3[. In contrast to random networks, where the process of adding nodes is purely probabilistic
with all the nodes having equal importance, in scale-free networks, the process of node addi-
tion follows a preferential rule, meaning that when a new node is added to the network, it is
attached preferentially to the nodes with the highest degrees, leading to the power-law degree
distribution (Strangio, M. A., 2009; Albert, R. et al., 2002). The latter topology is likely to
be the most reasonable and desirable for several biological networks (including protein-protein
interactions, transcription factor binding, metabolic, and genetic networks) given that it con-
verges toward a structure that enables efficiency of its functions (Strangio, M. A., 2009). This
can be explained by the evolutionary character of biological networks, where nodes with high
degrees, important for the survival of the organism, have resisted selective pressure. Moreover,
this topology makes such networks tolerant to random failures and errors such as missense
point mutations, but more vulnerable to targeted attacks, as the removal of nodes with the
highest degrees is highly disruptive for the networks (Albert, R. et al., 2002).
Properties of nodes in a network are important, for instance in detecting central or intermediate
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nodes that affect the topology of the network. Depending on the question asked, these proper-
ties can be crucial in biological networks, for instance, in finding nodes that are not necessarily
central or possessing a high number of links (“hubs”), but that have a critical biological role in
PPI networks. These properties include most basically, connectivity degree (k), or a centrality
measure that characterizes each node or edge according to their contextual location within
the network such as the closeness centrality, the eigenvector centrality, betweenness centrality,
eccentricity centrality and subgraph centrality. Properties of edges include edge betweenness
centrality, the types of relationship that represent inhibiting or activating relationships between
a pair of nodes, and edge directionality, which indicates that the upstream and downstream
nodes are connected by a specific link (Ma’ayan, A., 2011; Pavlopoulos, G. A. et al., 2011).
Centrality measures are discussed in more detail in Chapter 2.
Although the global network topological and node-edge-specific properties have been exten-
sively used to analyse the topological structure of biological networks, recently much attention
has been paid to the local units of the networks, called network modules or network clus-
ters, which represent dense parts of connectivity demarcated by regions of low connectivity
(Ma’ayan, A., 2011; Zhu, X. et al., 2007). Several methods have been developed to find pos-
sible modules in networks, including the traditional method for hierarchical clustering, un-
supervised clustering algorithms, such as nearest neighbor clustering, Markov clustering, and
betweenness centrality-based clustering, which uses nodes with high betweenness centrality and
low connectivity to separate clusters (Newman, M. E., 2001).
Despite the fact that network modules are still ubiquitous structures in most biological net-
works, understanding the topological structure of such networks, using topology analysis mea-
sures mentioned above and others, such as network motifs, may help to better characterize and
understand the interplay between network structure and function (Ma’ayan, A., 2011).
1.4.2 Protein-protein interaction databases
The majority of biological processes in a living cell are driven and mediated by proteins, which
transport or store other molecules, act as catalysts, confer immunity, transmit signals, and
control growth and development. Most proteins function by interacting with other molecules
including lipids, nucleic acids, or other proteins. Proteins do not operate independently, rather
in close collaboration with partner proteins or in complex protein networks, to carry out com-
plex biological activities. PPI networks exhibit scale-free network properties, and one advantage
of scale-free networks is that the robustness-loss of individual components generally maintains
overall network topology, making the system relatively immune to defects in individually tar-
geted components (Zhu, X. et al., 2007). Many forms of cancer for example, require the loss of
multiple components for network breakdown, which may explain, in part, the observation that
processes leading to the onset of cancer are often the results of multiple mutations (Knudson,
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A. G., Jr., 1971). Nevertheless, some regions of networks should be more vulnerable to network
breakdown than others, that is, mutations that exert an influence on hubs and other important
network components are more likely to cause system defects than those affecting the periphery
(Zhu, X. et al., 2007).
Protein-protein interactions (PPI) are generally generated by experimental methods, such as
coimmunoprecipitation, the yeast two-hybrid system or affinity purification, genomic context
or phylogenetic profiling approaches, protein microarrays or synthetic lethality (Bjorn, H. J. et
al., 2008; Lehne, B. et al., 2009; Hart, G. T. et al., 2006). PPI networks represent some of the
largest and most diverse datasets available to date, and, to be effectively exploited, they need to
be stored in a consistent and reliable way (Zhu, X. et al., 2007). Recently, several PPI databases
have been developed, collecting published PPI data, and providing curated datasets for public
access (Lehne, B. et al., 2009). However, due to different methods used for data collection, as
well as different data formats in which these datasets are represented, these PPI databases
differ considerably in their coverage and content. The difference in methods mentioned above
also cause some confusion with respect to the meaning of the term “protein-protein interaction”,
which could be direct physical binding, membership of the same multi-protein complex, or a
functional interaction (Hart, G. T. et al., 2006).
Table 1.5: Protein-protein interaction (PPI) databases.
Database URL Proteins Interactions Publications Organisms
HPRD http://www.hprd.org 30,047 41,327 453,521 1
BioGRID http://www.thebiogrid.org 54,549 500,239 42,172 49
MINT http://mint.bio.uniroma2.it/mint 35,553 241,458 5,554 144
IntAct http://www.ebi.ac.uk/intact 81,209 439,013 12,397 131
DIP http://dip.doe-mbi.ucla.edu 26,453 76,8441 6,678 649
More comprehensive descriptions of PPI databases have been reported in excellent recent re-
views (Lehne, B. et al., 2009; Rohl, C. et al., 2006) and the complete listing is available
at http://www.pathguide.org (Bader, G. D. et al., 2006). Table 1.5 lists some major public
databases, on which we focus in this work, which combine protein interaction data from both
experimental methods mentioned above and data mining of the literature. These databases
include the Human Protein Reference Database (HPRD) (Peri, S. et al., 2004), the Biological
General Repository for Interaction Datasets (BioGRID) (Stark, C. et al., 2006), the Molecu-
lar INTeraction database (MINT) (Chatr-aryamontri, A. et al., 2007), the IntAct molecular
interaction database (IntAct) (Chatr-aryamontri, A. et al., 2007), and the Database of Inter-
acting Proteins (DIP) (Xenarios, I., 2002). The information in Table 1.5 is based on datasets
downloaded from the individual databases in January 2014, containing complete sets of binary
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interactions. Only IntAct and MINT provide information about the model applied to derive the
interactions, “the spokes model”, while no other database provides this information. Though
most databases also provide genetic interactions which refer to the interaction between two
non-essential genes that lead to a non-viable phenotype if they are knocked out simultaneously
(Lehne, B. et al., 2009), only physical interactions are considered in the subsequent analysis.
Currently, BioGRID is the most comprehensive database in terms of unique interactions, with
more than 500, 239 from 49 different organisms, citing up to 42, 172 different publications. We
denote considerable increases in the BioGRID database not only in terms of unique interactions,
as well as in the number of organisms, but also with respect to different publications cited,
expanding from 90, 972 to 500, 239, 10 to 49, and 16, 369 to 42, 172, respectively, from 2008 to
2014 as reported in (Lehne, B. et al., 2009). Surprisingly, although being restricted to human
proteins, HPRD cites over 453, 521 publications for 41, 327 interactions for only one organism.
However, it should be noted that the databases examine publications at different depths, with
different confidence sets or thresholds or differences in the application of the matrix or spokes
model, therefore a higher number of publications should not necessarily be interpreted as a
greater curation effort (Lehne, B. et al., 2009).
The overlap between databases is very small (See Table 1.6), making it difficult to obtain con-
fidence in the interactions. Of the 14, 899 publications shared by two or more databases, 39%
(5, 782) were reported with a different number of interactions for different databases in (Lehne,
B. et al., 2009), although ideally, every database should extract the same interactions from a
given publication. For example, the publication with pubmed ID ‘14605208’ reports 20, 405 in
its abstract (Lehne, B. et al., 2009), whereas the number of interactions reported by all the
five databases citing this publication differ, with the minimum of 20, 043 in BioGRID and a
maximum of 20, 670 interactions in IntAct.
Table 1.6: Overlap of human PPIs between five major databases. The pairwise relative
overlap between databases was calculated for Homo sapiens, and the absolute numbers are normalized
to the total number of PPIs for every row.
PPIs Total DIP MINT IntAct BioGRID HPRD
DIP 3, 299 16% 17% 32% 42%
MINT 22, 847 2% 31% 25% 38%
IntAct 71, 315 1% 10% 12% 7%
BioGRID 138, 709 1% 4% 6% 9%
HPRD 38, 106 4% 23% 13% 33%
PPI relative overlap 0− 14% 15− 29% > 30%
To assess these difference further, we performed a comparison and estimated the relative pair-
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wise overlap only for human PPIs between databases (Table 1.6). HPRD, which focuses on
human interactions and reports the most PPIs, has the highest relative overlaps when com-
pared with all other databases. BioGRID, which currently provides the highest number of
interactions for human, also presents relatively high overlaps with other databases. Thus, sig-
nificant overlaps (> 30%) were observed between BioGRID and HPRD, DIP and BioGRID,
DIP and HPRD, MINT and HPRD, and between MINT and IntAct.
Though databases analyzed here have improved greatly over the past few years, and addressed
some of the important issues, such as data compatibility and exchange. The pairwise overlap
between databases performed here doesn’t even reach 50%, in contrast with previous studies
where up to 75% of pairwise overlaps were reported (Lehne, B. et al., 2009). None of the exist-
ing databases provides a fully comprehensive dataset, and as mentioned above, these databases
differ not only in the different ways to capture and curate information but also in the ways they
represent the data, making the integration of data from the different databases difficult. To
overcome this issue, the International Molecular Exchange (IMEX; www.imexconsortium.org)
consortium was formed. The main aim of this consurtium is to enable the exchange of data and
avoid the duplication of the curation effort, by providing an XML-based proteomics standard,
the proteomics standards initiative, for molecular interaction (PSI-MI), as a standard data
representation format.
1.4.3 Pathway annotation databases
Current pathway-based approaches for analysis of GWAS data sets may receive as input in-
dividual SNP genotypes or a list of p−values relating SNPs or genes to the phenotype under
study, but can broadly be classified according to the strategy discussed in Subsection 1.5.2.
Independently of the overall strategy, these methods utilize functional information on exist-
ing annotated pathways. This is vital for the analysis itself for some approaches (i.e. data
mining and gene set enrichment analysis methods), and for the interpretation of results for
other approaches (i.e. network-based methods). There exist several prominent pathway anno-
tation databases providing diverse features (see Table 1.7), ranging from freeware databases
that provide easily accessible and transparent contents, to commercial databases that provide
user-friendly statistical software along with high-quality visualization interfaces (Fridley, B. L.
et al., 2011). Similar to PPI databases databases (Subsection 1.4.2), most pathway databases
rely on manual curation by experts, or alternatively on electronic curation using text-searching
algorithms to infer relationships (Ramanan, V. K. et al., 2012). In either curation case, inves-
tigators should consider, in accordance with their resources and study goals, criteria used as
evidence for inclusion in pathways, text-searching algorithm accuracy, as well as the biological
coverage of pathway annotations. Although they supply different features such as transcription
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factor networks, gene regulatory networks, signaling pathways, pathway diagrams or metabolic
pathways, across these databases, similarly named pathways can present vast differences in
their constituting components, whereas significant overlaps can be observed among differently
named pathways (Ramanan, V. K. et al., 2012; Fridley, B. L. et al., 2011). This explains some
of the differences in results that can be generated from the same input dataset, so careful
considerations about which pathway annotation data to be used is recommended, and for a
given analysis, multiple databases should preferably be used.
Table 1.7: Some pathway annotation databases.
Name CM Description Cost URL
BioCarta M Driven by user input with expert review of
some pathways
F www.biocarta.com




PharmGKB M Pharmacogenetics and Pharmacogenomics
Knowledge Base with a number of drug
action pathways
F http://www.pharmgkb.org/
Ingenuity M/E Large collection of canonical pathways
from millions of individually; high-quality
pathway maps
C http://www.ingenuity.com/
Reactome M Curated database of human biological
pathways; A suite of data analysis tools to
support pathway-based analysis of
experimental data.
F http://www.reactome.org
Malaria M Database for Malaria biology, biochemistry
and physiology. Contains numerous
metabolic pathways
F www.sites.huji.ac.il/malaria/
MetaCyc M Pathways from over 2391 different
organisms; Describes metabolic pathways,
reactions, and substrate compounds
FA http://metacyc.org/
MetaCore M Integrates data from different levels of
cellular function, including membrane
receptors, signal transduction,
transcription factors, and effector networks.
C thomsonreuters.com/metacore/
Abbreviation: CM, Curation method; M, Manual; E, Electronic; F, Free; C, Commercial; FA, Free for academic only
Because of the broad interest in pathway-based analysis for GWA studies, some refinements of
pathway annotation databases would be of great interest and may expand their use for inves-
tigators from a variety of backgrounds. These enhancements may include user-friendly search
and download mechanisms, consistency in pathway naming and classifications, as well as meth-
ods for describing overlap between pathways. In addition, a universal file annotation format
enabling cross-exchange among analytical tools, might allow investigators more flexibility in
precisely matching their databases and statistical methods (Wang, K. et al., 2010; Ramanan,
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V. K. et al., 2012).
1.5 Pathway-based approaches for GWAS analysis
The limitations of the conventional single-marker-based approach for GWA studies have urged
investigators to explore and develop alternative or complementary approaches for GWA studies
(see Section 1.3.2), including, more recently, pathway-based analysis (PA) approaches. In PA
of GWA studies, predefined sets of interconnected genes are examined based on prior biological
knowledge, and these sets of related genes or pathways are evaluated with respect to their
significance based on the disease association signal of markers in or near genes that are part of
these pathways (Wang, K. et al., 2010).
1.5.1 Linking pathways to complex diseases
It is now well known that genes do not operate in isolation. They collaborate in groups
to carry out specific biological functions, the disruption of which may be related to human
diseases. Therefore, depending on the genetic architecture of a complex disease, it is possible
that many SNPs or genes, randomly distributed with respect to biological function, having low
or moderate risk may interact to confer a significant combined effect for the complex disease
(Jia, P. et al., 2011). Schadt, 2009 has recently looked at how networks act as sensors and
drivers of common human diseases, and demonstrated, as shown in Figure 1.9, that in order to
understand the behaviour of any gene in the context of human disease, individual genes must
be perceived in the context of biological networks that define the disease states (Schadt, E. E.,
2009).
Many other studies have also investigated and demonstrated the role of complex molecular
networks and cellular pathways in the pathogenesis of complex diseases such the autoimmune
disease rheumatoid arthritis (RA)(Martinez, A. et al., 2006). For instance, a highly significant
interaction was detected between genes associated with the infectious disease tuberculosis (TB)
(Hu, P. et al., 2011). In other examples, genes of the complement pathway are suspected to be
involved in the disease pathogenesis of age-related macular degeneration (AMD) (Shahbaba,
B. et al., 2012), the autophagy pathway was suspected to be implicated in the pathogenesis
of inflammatory Crohn’s disease (CD) (Shahbaba, B. et al., 2012), and finally the PGE2 and
calcium signaling pathways were recently implicated in both CD and hypertension, suggesting
a possible relationship between these two complex diseases (Shahbaba, B. et al., 2012).
To illustrate further how biological pathways are involved in disease pathogenesis, Wang et al.
(2010) manually compiled a pathway centred on the interleukins (IL)−12 and IL−23, which is
important pathway for CD (Wang, K. et al., 2010). Figure 1.10 only shows the main proteins
in this pathway, which have been previously identified as being associated with Crohn’s disease
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Figure 1.9: Causal relationship models.
(a) Classical genetic association view that identi-
fied variations in DNA correlate with disease state
or with quantitative traits associated with disease.
(b) DNA variations do not lead to disease on their
own but, instead, lead to changes in molecular traits
that go on to influence disease risk. By layering in
molecular phenotypes as intermediate phenotypes,
causal relationships between genes and disease can
be established directly.
(c) Disease gene networks sense constellations of ge-
netic and environmental perturbations. Therefore,
a more realistic model is one in which constellations
of genetic and environmental perturbations affect
molecular states of networks that in turn affect dis-
ease risk. From (Schadt, E. E., 2009).
in published GWA studies. Only three genes at two loci (IL12B, IL23R and IL12RB2) showed
genome-wide significant associations in the GWA study (Barrett, J. C. et al., 2008), however,
three genes with moderate association signals in this pathway (JAK2, CCR6 and STAT3) were
confirmed as susceptibility genes for CD in replication studies (Barrett, J. C. et al., 2008),
and six other genes with modest association signals (STAT4, IL18, IL18RAP, TYK2, IL27 and
IL10) were confirmed as CD susceptibility genes in other association studies (Wang, K. et al.,
2010).
These examples clearly demonstrate that some genes that may not reach genome-wide signif-
icance in any GWA study due to lack of power, may still work together with multiple related
genes in the same functional pathway to confer disease. Thus, the susceptibility loci for com-
plex traits are not likely to be randomly distributed (Holmans, P. et al., 2009), and because
the underlying genes involved in a disease pathogenesis are likely to be present in the same
functional pathways (Sharma, A. et al., 2013). PA approaches may therefore complement the
single-marker-based approach for GWAS and provide additional knowledge for disease etiology,
by identifying additional susceptibility genes, which could not be detected using conventional
methods, using more mechanistic approaches, without any need to reduce the number of pos-
sibilities of each GWA study locus to a single gene (Wang, K. et al., 2010).
1.5.2 Methods for pathway-based analysis of GWA studies
Over recent years, several different approaches have been proposed to summarize the signifi-
cance of a biological pathway from a collection of SNPs from a GWA study, and to adjust for
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Figure 1.10: Linking biological
pathways to complex diseases. For
many years, the pro-inflammatory cytokine
IL−12, which is mediated by T cells that
produced T helper 1 cytokines (TH1 cells),
was believed to be a major player in
CD etiology. Recently, studies demon-
strated a more important role of the pro-
inflammatory cytokine IL−23, which acti-
vates a subset of T cells responsible for the
production of IL−17 (TH17 cells), required
in the cytokine-mediated gut destruction
process. Each gene is annotated with the
most significant p-value among all its closest
SNPs, and genes with genome-wide signifi-
cant signals are shown in bold font. From
(Wang, K. et al., 2010)
multiple testing at the pathway level (Chen, X. et al., 2010; Guo, Y. F. et al., 2009; Wang, K.
et al., 2007; Jia, P. et al., 2011; Jensen, M. K. et al., 2011; Fehringer, G. et al., 2012; Baranzini,
S. E. et al., 2009; International Multiple Sclerosis Genetics Consortium, 2013; Subramanian, A.
et al., 2005; Tintle, N. L. et al., 2009; Ritchie, M. D. et al., 2001; Yu, K. et al., 2009; Krautham-
mer, M. et al., 2004; Zhang, K. et al., 2010), and some of these algorithms are publicly available
as software packages or web servers (Table 1.8). These PA approaches can be broadly classified
into 3 categories with respect to the overall strategy used, including a data mining approach,
gene set enrichment analysis approach, and network-based approach (Kraft, P. et al., 2009).
In data mining approaches, a group of functionally related genes is identified, and multivariable
analysis techniques are applied to markers in these genes (Ritchie, M. D. et al., 2001; Yu, K.
et al., 2009). More flexible analyses incorporating nonlinear relations between markers and the
trait under study may be applied to uncover additional more plausible evidence of association.
The major challenge of these approaches emerges when searching over data sets with a large
number of markers, which can ultimately lead to substantial downwardly biased p-values and
overestimates of the precision of predicted trait values based on the fit model in a new data set
(Kraft, P. et al., 2009). In Gene set enrichment analysis, a list of markers ranked with respect
to their p-values is tested for enrichment of genes in particular functional pathways (Guo,
Y. F. et al., 2009; Wang, K. et al., 2007; Zhang, K. et al., 2010). The major challenges for
these approaches reside in mapping markers to genes in a many-to-many scenario. Whether
a marker is assigned to a single or several genes, and how it is assigned may greatly affect
the results. In addition, these approaches tend to favor pathways with several large genes to
the detriment of pathways containing only small genes (Kraft, P. et al., 2009). Network-based
approaches generally consider the set of implicated genes from GWA studies, and attempt to
identify nonrandom functional groupings among them (Jia, P. et al., 2011; Raychaudhuri, S. et
al., 2009). Though these approaches present a promising aspect as no prior specification of the
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set of functional pathways to be analyzed is required, they are also subject to several pitfalls;
the biological networks used are not always complete, and sometimes inconsistent, limited by
the scope of human knowledge; and the physical clustering of genes with similar functions can
create spurious observations that several genes in a pathway are associated with the trait under
study (Kraft, P. et al., 2009).
Table 1.8: Publicly available packages for PA on GWAS data sets.
Name Strategy Input data Analysis strategy URL/REF
MDR Data mining Raw genotype Perform multifactor dimensionality
reduction (MDR) to detect





(Ritchie, M. D. et al.,
2001)
ARTP Data mining Raw genotype Compute gene and pathway




(Yu, K. et al., 2009)
GenGen GSEA Raw genotype Assign the best p-value of SNPs to
a gene, then compute
Kolmogorov-Smirnov-like
enrichment score for a pathway.
www.openbioinformatics
.org/gengen/
(Wang, K. et al., 2007)
mSUMSTAT GSEA SNP p-values Similar to GenGen but the pathway
is calculated by averaging χ2 test
statistics within each pathway.
www.jurgott.org/linkage
/sumstat.html
(Fehringer, G. et al.,
2012)
GRAIL Network-based Raw genotype Build networks using published
abstracts, then identify putative
relationships among genes that do
not have a single cocitation
www.broad.mit.edu
/mpg/grail/
(Raychaudhuri, S. et al.,
2009)
dmGWAS Network-based SNP p-values Identify significant PPI modules
and candidate genes using a dense
module searching method on the
GWAS data set and PPI network.
bioinfo.mc.vanderbilt.
edu/dmGWAS.html
(Jia, P. et al., 2011)
In addition to the principal strategy used, these PA approaches can also be classified into two
types with respect to whether the required input data sets are individual SNP genotypes or
simply a list of SNP p-values from a GWA study (Wang, K. et al., 2010). The first type, the
p-value enrichment approach, determines whether a given group of p-values of SNPs or genes
is enriched in association signals (Jia, P. et al., 2011; Fehringer, G. et al., 2012). Many of these
approaches typically use a p-value cutoff of p < 0.05 or p < 0.001, meaning, the results are
partly dependent on the user-specified cutoff (Figure 1.11a). The second approach, the raw
genotype approach, aims to derive test statistics at gene and pathway levels using individual
SNP genotype data (Ritchie, M. D. et al., 2001; Zhang, K. et al., 2010). This approach requires
raw genotypes for phenotype permutation to adjust for the test statistics at both gene and
pathway levels, using for instance a two-step correction procedure (Wang, K. et al., 2007).
61
Though p-value enrichment approaches are straightforward in eliminating many practical chal-
lenges related to data analysis and data sharing, in addition to the fact that raw genotypes
may not always be easily available and permutation procedures computationally expensive, one
advantage of raw genotype approaches is the ability to maintain the correct LD pattern among
neighboring SNPs while permuting (Figure 1.11b).
Figure 1.11: Types of PA approaches. A summary of the two main PA approaches for GWA studies
based on the input data. From (Wang, K. et al., 2010)
1.5.3 Testing the null hypothesis: competitive and self-contained methods
Another criteria for categorizing PA approaches of GWAS data is based on the way the null
hypothesis can be tested, that is, PA approaches can also be divided into competitive (or
enrichment) and self-contained (or association) methods. The differentiation between these
two methods is important, and key differences between these two approaches emanate from
the null hypothesis stated (Fridley, B. L. et al., 2011).
(a) Competitive methods: These methods typically identify first SNPs (or genes) that are
significantly associated with the trait studied, and then evaluate whether the significantly
associated SNPs are likely to cluster in predefined pathways. Thus, they compare the
frequency of significantly associated SNPs in a given pathway P with the frequency of
significantly associated SNPs among all genes outside the pathway P (Figure 1.12b). More
specifically, they aim to verify the null hypothesis:
H0: SNPs/genes in a given pathway are associated with the phenotype as much as
SNPs/genes outside the pathway.
A commonly used competitive method is the GSEA that uses a modified Kolmogorov-
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Smirnov statistic to test the null hypothesis (Wang, K. et al., 2007; Subramanian, A. et
al., 2005). Another commonly used approach for competitive PA uses the Fisher’s exact
test to compare the proportion of associations surpassing some predefined significance level
within the pathway P , to the proportion of such association signals outside the pathway
P (Holmans, P. et al., 2009). Some examples of competitive PA methods include GenGen
(Wang, K. et al., 2007) and i-GSEA4GWAS (Zhang, K. et al., 2010) One major challenge
of the Fisher’s exact test, and similar methods, is the dichotomization of SNP association
signals into significant and non-significant based on a predefined significance level, ignoring
information regarding the strength of the association (Fridley, B. L. et al., 2011). Another
method based on GSEA, with several improvements of the Kolmogorov-Smirnov statistic,
is the Get Set Analysis (GSA) algorithm, which uses a maxmean statistic M for the en-
richment score, potentially leading to greater power compared to the Kolgomorov-Smirnov
test (Hoh, J. et al., 2001; Wu, M. C. et al., 2009), given by:
M = max
{∣∣∣∣∑mi=1 I (ti > 0) tim
∣∣∣∣ , ∣∣∣∣∑mi=1 I (ti < 0) tim
∣∣∣∣} , (1.27)
where m is the number of genes in the pathway P and ti is the test statistic of the i-th gene
in P . The significance of the M statistic is evaluated using the permutation test involving
both genes and class labels.
(b) Self-contained methods: In contrast to competitive methods, self-contained or association
approaches only analyze association of SNPs/genes in the pathway P of interest with the
phenotype, without taking into account the remaining SNPs/genes. These methods test
the null hypothesis versus the alternative hypothesis stated respectively as follows:
H0: No SNPs/genes in the pathway P are associated with the phenotype.
Ha: SNPs/genes in the pathway P are associated with the phenotype.
A commonly used self-contained method is the Global test, which uses generalized linear
models to express the relationship between the expression of genes in P and the pheno-
type, that is, if the pathway P can be used to predict the clinical outcome, its expression
pattern must differ for different outcomes (Wu, M. C. et al., 2009). Let Y be the outcome
(phenotype) of interest, continuous or 1/0 for case/control status, and let X be the n×m
matrix of genes association signals for the pathway (with n the number of samples), with
xij the gene association signal of the j-th gene of the i-th sample, the global test is induced
by a regression model (“Competitive and self-contained gene set analysis methods applied






where g is the logit function for case/control status, and α is an intercept, with sample
class label Yi, and βj is the coefficient for gene j. Then, testing the H0 that no genes in
the pathway P are associated with the phenotype is equivalent to testing:
H0 : β1 = β2 = . . . = βm = 0. (1.29)
Because the sample size is in most cases relatively small compared to the pathway P size,
an additional assumption that the coefficient β1 . . . βm are iid (independent, identically
distributed) with mean 0 and variance τ2 is made, which simplifies the hypothesis and
make the global test feasible (Wu, M. C. et al., 2009).
Figure 1.12: Null hypothesis testing in PA.
Competitive and self-contained methods for testing
the null hypothesis in PA for GWA studies. From
(Wang, K. et al., 2010).
Because of differences between these two approaches, the appropriate approach should be
selected based on thorough considerations of the null and alternative hypotheses being tested, as
well as the constraint imposed by available data. Thus competitive methods can not be applied
in studies that consider only a few candidate pathways, whereas self-contained methods can be
applied to candidate gene association studies, and in a GWA study with accounted genomic
inflation (Fridley, B. L. et al., 2011).
1.5.4 Accounting for gene-level association: one-step and two-step methods
When it comes to whether or not gene-level evidence of association is taken into account when
combining the evidence of association in a pathway, two approaches, the one-step approach and
the two-step approach, can be considered (Fridley, B. L. et al., 2011). In the one-step approach,
all the SNPs in a pathway are used without any consideration of gene-level effects. The two-
step approach first uses SNPs in each gene to assess the association with the gene, and then
combines gene-level tests to evaluate the association of the phenotype with the pathway (Hoh,
J. et al., 2001). Different methods are generally used to combine association signals of SNPs to
assess the association of the gene with the phenotype, these include using the minimum SNP-
specific p-value as the p-value for a gene, using a summary measure of all SNP-specific p-values
within the gene, or modeling the simultaneous effects of all SNPs in the gene on the phenotype
(Fridley, B. L. et al., 2011). Many PA methods for GWA studies have implemented a two-step
approach taking the minimum p-value (or the maximum test statistic) observed for all the SNPs
in a gene (Wang, K. et al., 2007; Yu, K. et al., 2009). However, when several distinct SNPs in
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the gene contribute to the overall association signal, and all have modest effect on the pheno-
type, using the minimum p-value may not be the best or most powerful approach to capture
such information. In addition, larger genes with more SNPs are likely to have smaller minimum
p-values compared to smaller genes with fewer SNPs (Wang, K. et al., 2007; Jia, P. et al., 2012;
Fridley, B. L. et al., 2011). Nevertheless, numerous studies have assessed the performance of
various methods for combining association signals at the gene-level, which may provide guid-
ance for the completion of a two-step correction in PA for GWA studies (Lehne, B. et al., 2011).
Both the one-step and two-step methods have advantages and disadvantages, and their effi-
ciency depends mostly on the underlying disease-causing mechanisms, which are unfortunately
unknown, as well as on the genetic models, for which some study results have indicated that
in general, the two-step approach may be more powerful than the one-step approach when
the self-contained hypothesis is assessed, and the LD between SNPs needs to be accounted for
(Fridley, B. L. et al., 2011).
1.5.5 Impact of LD and adjustment of association significance for pathway
size
Because of LD among SNPs in genes composing a pathway, independence between the SNPs
can not be assumed in the evaluation of the significance of the pathway, though much less non-
negligible correlation may be expected among gene-level p-values. Most PA approaches use
permutation procedures to estimate summary adjusted p-values for given pathways. However,
for p-value enrichment-based approaches, permutation of SNPs typically disrupts LD patterns
between SNPs, thus not generating the correct null distribution. Yet, even in the case of the
raw genotype-based approach, permutation of phenotypes (binary or quantitative traits) still
introduces some biases, because, when performed, the ‘background’ distribution reflects the
case where none of the SNPs or genes is associated with the phenotype, whereas in practice,
for any phenotype, a proportion of SNPs will be genuinely associated with the phenotype in
unpermuted data sets (Wang, K. et al., 2010).
As discussed previously in Subsection 1.5.4, ignoring gene size when assessing gene association
signal, as well as when testing for pathway association, can lead to inflated type 1 error rates.
Permutation procedures can also be used to adjust for size of the pathway and potential bias
introduced by PA methods such as the minimum p-value or maximum test statistic for evaluat-
ing gene association signal from SNPs in the gene, carefully considering the null and alternative
hypothesis and PA methods (competitive or self-contained) being applied. Two-step methods
can involve jointly modeling the effects of SNPs within a gene followed by the combination of
gene-level association signals to evaluate the association of the pathway with the phenotype.
Despite the fact that much less correlation may be expected between the gene-level p-values, a
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much lower but non-negligible correlation between genes in a pathway may exist (Fridley, B.
L. et al., 2011). Therefore, permutation methods are still crucial in pathway-based approaches
for GWA studies, in particular to assess any significant results.
1.6 Challenges and considerations
Pathway-based approaches for GWA studies are becoming an invaluable tool to enable more
powerful association tests, and to help enlighten our understanding of disease susceptibility,
however a number of pitfalls and challenges, some discussed in this review, limit their practical
use. While methods and tools for pathway analysis are dynamically growing in number, several
sources of bias must be carefully considered and addressed, including the capacity for strongly
associated markers to drive pathway association, the possible effects of SNPs being assigned to
multiple genes, the ‘history’ of the accumulation of mutations that can influence the likelihood
of individual genes to show association with the phenotype, and more specifically bias intro-
duced by gene size as well as the bias from pathway size, less commonly addressed in many
current methods (Wang, K. et al., 2010).
Numerous large-scale strategies have been developed to study complex diseases, integrating
large-scale data derived from diverse strategies for identifying structure and function of genes,
including genomics, transcriptomics, proteomics and metabolomics. The integration of such
information into pathway-based analysis would provide a fertile process for exploring more
sensitive and powerful analysis of GWAS data sets (Ramanan, V. K. et al., 2012). Network
approaches, which incorporate biological network structures such as hubs and motifs into the
analysis of GWAS data sets, will be vital for this integration in the years to come.
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CHAPTER 2
ancGWAS: an improved method for gene-
gene interaction analysis of genome-wide
association study data for homogeneous
and admixed populations
Genes can influence each other at the level of enhancement or hindrance. The effect can occur
directly at the genomic level where a gene could code for a protein that prevents transcription
of another gene, alternatively, the effect can be at the phenotypic level, where a pair of genes
can interact to produce a specific phenotype. Thus, interactions can play critical roles in the
cause of disease. In addition, for a given disease, risk genes may differ in different individuals,
but are more likely to lie in the same pathway. Identifying pathways by incorporating prior
biological information on multiple genes associated with a disease may allow us to more easily
unravel the pathogenesis of complex diseases. Therefore, as discussed in previous chapters, the
single-marker-based approach of current GWA studies alone may not be sufficient (see Section
1.3.2). Meta analysis, which aims to pool information from multiple GWA studies to increase
the chances of finding associations with small effect sizes, has been successfully used and has
increasingly helped in identifying additional susceptibility loci (Han, B. et al., 2011; Cantor,
R. M. et al., 2010). A number of additional alternative approaches have been proposed as a
complement to the single-marker-based approaches (See Section 1.5). Examining the combined
effects of genes by detecting genetic signals beyond single gene polymorphisms may increase
our ability to fully characterize the susceptible genes and the genetic structure of complex
diseases (See Section 1.5.1). A suggested new paradigm for GWA studies (Jia, P. et al., 2011;
Cantor, R. M. et al., 2010) involves incorporating both the association signal from a GWA study
and human PPI information to test the combined effects of SNPs and search for significantly
enriched sub-networks for a particular complex disease. This approach is based on combining
p−values from standard GWA studies for correlated SNPs into an overall significance level for
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a gene, and combining p−values for the genes in a pathway into an overall significance level
to investigate the association of a pathway with the disease (Jia, P. et al., 2011). However, in
many cases, SNPs within genes and genes within pathways are correlated, and most methods
do not account for this dependency, but rather assume genes or SNPs to be independent and
uniformly distributed under a null hypothesis. The violation of dependent assumptions in these
methods may generate erroneous results. Here, we present an algebraic graph-based method
(ancGWAS) to identify the most significant sub-networks that may explain ethnic differences
in complex disease risk, both in recently admixed or non-admixed populations by integrating
the association signal from GWA study data, the local ancestry (if an admixed population)
and polymorphism LD into the human PPI network. The ancGWAS method accounts for
the correlation that exists between SNPs within or between genes and between genes within
pathways and tests for signals of unusual difference in excess/deficiency of ancestry in admixed
populations. In addition, this method introduces flexibility in estimating gene and sub-network-
specific ancestry.
2.1 Methods and implementation
2.1.1 Combining p−values at the gene level
One challenge of pathway-based analysis methods for GWA study data sets is how to represent
gene association with the phenotype (Peng, G. et al., 2010; Casci, T., 2007). In the gene expres-
sion field from which the idea of pathway-based analysis of GWA study data sets is borrowed,
gene expression arrays yield a single value of the expression level for each gene, whereas in
GWA studies each gene can be represented by multiple SNPs, some of which are correlated
(Shahbaba, B. et al., 2012). Some PA approaches use the minimum SNP-level signal (maximum
statistic) within a gene to represent the gene (Guo, Y. F. et al., 2009; Wang, K. et al., 2007;
Jensen, M. K. et al., 2011), however, when multiple distinct SNPs within a gene contribute to
the overall association signal, this method can fail to detect additive effects among SNPs with
moderate individual association, therefore may no longer be the best statistic to capture such
information. This approach also introduces biases, as larger genes are more likely to contain
more-significant statistics, and enrichment statistics for pathways containing large genes will
be inflated (Ramanan, V. K. et al., 2012; Wang, K. et al., 2007). Therefore, it is not yet clear
what the best strategy is to combine statistics for multiple SNPs within a gene into a single
value for the gene. In ancGWAS, we implemented three additional methods including Fisher’s
test, Sime’s test, and the Smallest gene-wise FDR, for combining statistics from multiple corre-
lated SNPs, by estimating an overall significance level or summary statistics to represent a gene.
Let us assume multiple SNPs within a gene, all contributing to the overall association of the
gene. We assume an independent and uniform distribution of p−values pi for the corresponding
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test statistic Ti, testing the i−th marker M , under the null hypothesis, although this assump-
tion of independence may be violated because of LD among SNPs within the gene. If we




To combine p−values of all SNPs within a gene, we implemented four methods including the
maximum test statistic (Sidak’s combination test), the Fisher’s combination test, the Sime’s
combination test and the FDR method (Peng, G. et al., 2010).
(a) Sidak’s combination test: Let us consider only the SNP with the maximum test statistic
(the best SNP), we can define the statistic ZB = p(1), which is distributed as P (ZB ≤ w) =
1− (1− w)K , with K the number of independent SNPs.
(b) Fisher’s combination test: The statistic to combine K independent p-values or to





which follows a χ22K distribution.
(c) Sime’s combination test: Let pi be ordered as p(1) ≤ p(2) ≤ . . . ≤ p(k). The combined








(d) False discovery rate method: Let F (α) be the expected proportion of tests yielding
a p−value less than or equal to α. Suppose a set of pd = {p1, . . . pk} with d distinct
p−values, with p̃1 < p̃2 < . . . < p̃d. Let mj be the number of p−values equal to p̃j among






I (p̃j ≤ α)mj ,
where I is an indicator function. For a one-sided test (χ2-test, or trend test) consider









i=1 ai, and ai = 2 min (pi, 1− pi). The estimate v̂ (α) of the expected proportion
v (α) of tests resulting in a false positive when α is used as the p−value threshold to
determine significance is expressed as
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v̂ (α) = π̂α,
where π̂ is the estimate of the proportion π of tests with the true hypothesis. Then, the











q (i) = min
j≥i
{tj} ,





is the false discovery rate for the gene.
2.1.2 Constructing the LD-weighted PPI network
SNPs, their associated local ancestry, ancestral population minor allele frequencies and GWA
study p−values are assigned to a given gene if they are located within the gene’s primary
transcript or 20 kilobases (kb) downstream or upstream. Note that, this distance can still be
decided or adjusted in ancGWAS according to the genetic architecture of the population under
study, given that some genetic variants that may influence the disease might be located much
further than 20 kb downstream or upstream of the gene. If the most significant SNP from
GWAS is located out of this boundary, then all the SNPs within this distance will be included
in the analysis. If a SNP is assigned to multiple genes due to overlapping flanking regions, the
closer gene is chosen according to a specified boundary cut-off. In a similar manner, a given
sub-network (discussed in the next section) can include SNPs associated with each of its genes.
Gene-gene dependency is complex and is crucial for the understanding of different biological
mechanisms (Liang, H. et al., 2007; Wu, J. et al., 2009; Peng, G. et al., 2010). Such dependen-
cies between genes are attributed to physical interactions between encoded proteins or between
a protein and a gene, or as a consequence of coregulation of some transcription factors (Gao, X.
et al., 2009). For instance, in human cancer, the ataxia-telangiectasia mutated (ATM) kinase,
a major regulator of the cellular response to DNA double-strand breaks, is required for p53
tumor suppressor accumulation and phosphorylation in response to increased Myc activity, by
promoting apoptosis (Pusapati, R. V. et al., 2006). Thus if we can identify all gene depen-
dency pairs underlying a specific phenotypic change, we can better understand the biological
mechanism related to the state change of the phenotype. From the genotype data, we weight
the known pairwise protein-protein interactions (PPI) network (Wu, J. et al., 2009; Cowley,
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M. J. et al., 2012) with a weighted correlation. This is accomplished by computing an overall
LD from pairwise LD between SNPs of each given pair of interacting genes. In this manner,
the PPI network is weighted with a correlation estimated from the population genotype data.
This may be useful in efficiently breaking the PPI network into different sub-networks (see the
next section) and helpful in combining p−value approaches that account for dependency of
neighbouring genomic markers within/between genes.
Given two different sets of SNPs Sa = {si}i=1,2,...,m and Sb = {sj}j=1,2,...,n, (si 6= sj , i =
1, 2, . . . ,m and j = 1, 2, . . . , n) associated with genes ga and gb, the pair-wise LD between
SNPs in Sa and Sb are computed using the r2 measure (See Subsection 1.1.3) and a combined
LD can be obtained. Here, we provide three approaches for weighting these interactions (i.e.
estimating the combined LD at the gene level).
(a) Case 1. ClosestLD: Considering each SNP si, (i = 1, 2, . . . , I) along the genome is
assigned to its closest gene gk, k = (1, 2, . . . ,K), thus each pair-wise LD, LDsisj , si 6= sj
(i, j ∈ 1, 2, . . . , I) is considered as a pseudo correlation rglgk of genes ga and gb, for a, b ∈
1, 2, . . . ,K.
rgagb = LDsisj . (2.1)
(b) Case 2. ZscoreLD: We assume sets of SNPs Sa = {si} and Sb = {sj}, si 6= sj ,
(i = 1, 2, . . . ,m; j = 1, 2, . . . , n) are assigned to genes ga and gb; and the pairwise LD of
SNPs between ga and gb are independent. Because the distribution of the LD is not normal,
from si 6= sj , we compute the average z-transforms of LD from all possible combinations of
pairs of SNPs between genes ga and gb. The z-transforms of LD are normally distributed
with mean 0 and variance 1. We compute the combined LD between two genes ga and gb








(c) Case 3. maxLD: Alternatively to the case above, if SNPs between a given pair of genes
are dependent or correlated, we consider the maximum among all possible N pairs of SNPs








The combined LD is used as the weight of the edge between ga and gb genes in the PPI
network.
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2.1.3 Searching for sub-networks using centrality measures
Genes interact in large networks in all living organisms, and some genes in the network are more
important or central than others. Highly connected genes in PPI networks can be functionally
important and the removal of such nodes is related to lethality (Liang, H. et al., 2007). We
consider our weighted PPI network as an undirected network, G = (V,E), where V is the set
of n genes as nodes and E is the set of edges as interactions found between genes weighted
using gene-correlation (See Subsection 1.4.1). To cluster G into sub-networks, we analyse the
general topological properties of G and quantify the usefulness of each gene in G using their
centrality scores; closeness, betweenness, degree or eigenvector. Let us first define the following
centrality measures.
(a) Degree centrality: The degree centrality Cd of a gene g in an undirected graph G is the
number of genes in the network interacting with it. In terms of the adjacency matrix
A = (auv)1≤u,v≤n , which is symmetric for an undirected graph, the degree centrality of
a node u ∈ V (u as a column or a row in the adjacency matrix) is simply the sum of
components in the column or row corresponding to the node u, i.e.
∑
v∈V auv = Cd =∑
v∈V avu (Mazandu, G. K. et al., 2011). The degree centrality provides an indicator of the
influence of a gene in a biological system and indicates whether the gene plays a key role
in the functioning of the system. Cd is also used, for instance, to correlate the degree of a
gene in the network with the lethality of its removal. It could also indicate a central role
in gene expression (transcription factors), diversification and turnover (small GTPases), or
signaling module assembly (docking proteins) (Scardoni, G. et al., 2009).
(b) Closeness centrality measure: The closeness centrality of a node u, Cc (u) in a network
G, is the inverse of the average distance to all other nodes connected to it (Mazandu, G.








where Vu is the set of nodes connected to u, m = |Vu| the number of nodes in Vu and
dist(u, v) is the shortest communication between u and v in the network. The closeness
centrality measure provides an indication on how a gene is functionally relevant for other
genes in terms of accessing information via or propagating information to other genes in
the connected part of the network containing that gene. Thus, a gene with high closeness,
compared to the closeness of the whole network, may be central to the regulation of other
genes (Bjorn, H. J. et al., 2008).
(c) Shortest path betweenness centrality measure: Let us denote σuv, the number of
shortest paths between genes u and v, and σuv (t) the number of shortest paths between
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u and v in the network G using t as an interior node, for t, u, v ∈ V (G). The rate of













δuv (t) . (2.6)
In protein networks, the shortest path betweenness centrality of a protein may determine
its relevance in holding together communicating genes and the capability of a protein to
enable communication between distant genes (Bjorn, H. J. et al., 2008).
(d) Eigenvector centrality measure:
The eigenvector centrality measure assesses the usefulness or the weight of functional con-
nections of genes and can only be considered as a measure of centrality if genes are ranked
based on their participation in different sub-networks. The eigenvector centrality measure
assigns relative weights to all genes in the network based on the fact that connections to
high-weighted genes contribute more to the weight of the gene target. This means the
weight or the contribution xu of the gene u to the functioning of the system is proportional
to the sum of the scores of all genes v connected to u, expressed as∑
(u,v)∈E
xv = λxu, (2.7)
λ is a constant of proportionality and xz denotes the contribution of gene z.
In terms of the adjacency matrix A = (auv)1≤u,v≤n, we have
n∑
v=1
auvxv = λxu, (2.8)
with n the number of genes in the network. It turns out that λ is simply an eigenvalue of
the adjacency matrix and the vector of contributions of genes is the eigenvector associated
with λ (Bjorn, H. J. et al., 2008). In fact, it can only be considered as a measure of cen-
trality if nodes are ranked according to their participation in different network subgraphs;
in a regular graph for instance, all the components of the main eigenvalue are identical
(Rodriguez, J. A. et al., 2007).
Genes that are central in association with complex disease susceptibility are considered to
be centres of biological sub-networks, and are linked to other genes in that sub-network via
few steps (paths in the network) (Jia, P. et al., 2011). These centres are structural hubs with
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centrality scores beyond a certain threshold value. Biological topological property tests of a
biological network can guarantee the aforementioned. Let us denote o (G) the order, s (G) the
size of G and SPmean, the shortest-path mean from every node to every destination within the
network G. Note that the cut-off of different network centrality measures are estimated using
general topological properties of the network (Mazandu, G. K. et al., 2011). For the betweenness
measure, the cut-off is the total number of shortest paths expected in the network, which is
approximately o(G)∗SPmean. For the closeness metric, as defined in equation (2.4), the cut-off
is 1/SPmean and that of the degree centrality measure is the number of expected interacting
genes of a gene in the network, which is s(G)/o(G). In the case of the eigenvector measure,
the cut-off is the mean value of the weight or contribution vector of all genes in the network.
We perform the steps in Algorithm 2.1 to identify sub-networks using centrality scores of each
gene.
Algorithm 2.1 ancGWAS Clustering Strategy
(1) Given network G, find structural hubs and connected components;
(2) For each gene, compute the betweenness, the closeness and the eigenvector scores;
(3) For each centrality score, compute the cut-off for central genes of sub-graphs BetOf,
ClosOf, DegOf and EigOf;
(4) Consider a gene as a hub if its score is greater than or equal to the corresponding cut-off;
(5) Consider a gene as a central gene if it is a hub for all the four scoring measures in step
(3);
(6) For each central gene, search its neighbours given a step n or the mean shortest path.
The central gene and its neighbours constitute a sub-network of G.
2.1.4 Combining p−values at the subnetwork level
Combined p-value approaches are commonly utilized for meta-analysis (Han, B. et al., 2011;
Cantor, R. M. et al., 2010), as are using neighbouring genomic markers in genetic association
studies (Zaykin, D. V. et al., 2002; Jia, P. et al., 2011; Peng, G. et al., 2010), and these have
a long history (Folks, J., 1984; Hedges, L. et al., 1985; Loughin, T. M., 2004). Under the null
hypothesis, the p-values pi, (i = 1, . . . , L) for a test-statistic with a continuous null distribution
are uniformly distributed in the interval [0, 1]. In this framework, a parametric cumulative
distribution function F can be chosen and the p−values can be transformed into quantiles
according to qi = F−1(pi), (i = 1, . . . , L). The combined test statistic CP =
∑L
i=1 qi is a
sum of independent and identically distributed random variables qi, each of which follows the
corresponding probability density function for F . To account for the independent assumption of
p−values and the correlation of p−values among neighboring genomic markers, we implemented
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both the Stouffer-Liptak (Liptak, T., 1958) and Fisher’s Combined probability (Fisher, R.,
1958; Hess, A. et al., 2007) methods accounting for spatial correlations among SNPs within a
gene or SNPs within a given sub-network.
(a) Fisher’s combined probability test: Let F̂ be the cumulative χ2 distribution. Let
pi, (i = 1, 2, . . . , L) be p−values of SNPs associated with a gene or a sub-network. We
obtain the combined p-value test statistic (Fisher, R., 1958; Hess, A. et al., 2007) CP =
−2
∑L
i=1 log(1− pi) which follows a χ2 distribution with 2L degrees of freedom due to the
additivity property of independent χ2. The combined p-value is p∗ = F̂ (CP ), where F̂ is
the cumulative distribution function for the χ2 distribution with 2L degrees of freedom.
Suppose that pi are dependent, we can approximate the distribution of Fisher’s Combined
Probability CP by a scaled χ2 distribution such that CP ≈ c × χ2f , where c is a scaling
factor and f is the degree of freedom. Let,


























i<j Cov[−2 log(pi),−2 log(pj)]
Since CP ≈ χ22L. The combined p-value for Cp is determined by using the approximating




, we apply approximations described
in (Kost, J. T. et al., 2002) by fitting a polynomial regression to the true values using a
grid approach ranging values for the degrees of freedom (9 ≤ ν ≤ 125) and the auto-
correlations σ (−0.98 ≤ ρ ≤ 0.98). We finally compute a q-value score based on the
Benjamini-Hochberg false-discovery correction (Benjamini, Y. et al., 1995).
(b) Stouffer-Liptak test
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Let F be a cumulative standard normal distribution N (0, 1). It follows that F (x) = Φ(x),
where Φ is a cumulative distribution function of the standard normal, and qi = Φ−1(pi).
Each qi, (i = 1, . . . , L) follows the probability density function of a standard normal and
using the additivity property of independent random variables, the Liptak’s combined p-





and the related combined p-value is p∗ = Φ(CP ). To adjust for p−value dependency,
we assume that pi (i = 1, . . . , L) are correlated according to a positive definite and non-
degenerate correlation matrix Σ. It follows that the Cholesky factor C exists such that
Σ = CCT . We transform the correlated quantiles Q = qi into independent quantiles Q̂
as in (Zaykin, D. V. et al., 2002). We then obtain the transformation Q̂ = C−1Q, the qi
(i = 1, . . . , L) are now independent and follow a standard normal distribution (Zaykin, D.
V. et al., 2002). Finally, we apply the Stouffer-Liptak test on Q̂. As for Fisher’s Combined
Probability test, here we compute a q-value on a null-model from shuffled p−values.
2.1.5 Combining local ancestry at the gene and sub-network levels
The aim is to combine the average locus-specific ancestry φmk from kth ancestral populations
(estimated from locus-specific ancestry among I admixed individuals) of SNPm ∈ {1, 2, . . . , L}
associated with a given gene (or to a combined set of SNPs associated with each gene within a
sub-network). Each average locus-specific ancestry φmk can be considered as a single observa-
tion at SNP m, and we make an assumption that each observation φmk can be approximated
to be a normal distribution under neutral drift with mean 0 and empirical variance Vmk de-
rived from the distribution of locus-specific ancestry among the N admixed individuals. Such
an assumption is commonly acceptable in admixture studies because of the large sample size
(Henn, B. M. et al., 2012; Baran, Y. et al., 2012). Here we consider the likelihood of these
observations. For easier presentation, we describe the method at the gene level.
Let {φ1k, φ2k, . . . , φLk} be the average locus-specific ancestry of SNP m ∈ {1, 2, . . . , L} asso-
ciated with gene gj , (j = 1, 2, . . . J). Let Vmk and Wmk be the variance and inverse variance
(precision) of φmk, and µjk be the unknown true gene-specific ancestry of gj from the kth
ancestral population. Assuming φmk, m ∈ {1, 2, ..., L} from the kth ancestral population have
similar magnitude at gj , testing whether µ 6= 0, we can derive µjk from the maximum likelihood



















where µjk is the unknown true gene-specific ancestry at gj from the kth ancestral population.









It is necessary to account for the bias of each observed average locus-specific ancestry (obtained
from current locus-specific ancestry inference methods) and accuracy of the gene-specific ances-
try estimates when combining local ancestry information. To address this, we use an empirical
approach that uses the posterior probability ρjk that the gene-specific ancestry at gene gj is
unbiased. ρjk is estimated from the data as the prior weight for each ancestral population.
Since the posterior probability ρjk is estimated using all possible ancestral populations of the
admixed population, this approach can be thought of as gathering information from all con-
tributing ancestral populations and distributing back in the form of weight at gene-specific
ancestry. Let fmk be minor allele frequency of SNP m ∈ {1, 2, . . . , L} associated with gene gj ,
(j = 1, 2, . . . J) from the kth ancestral population. We can approximate the precision 1ν̂jk such
as 1ν̂jk ≈ ηjk =
∑L
m=1N.fmk (1− fmk), where N is the sample size in the kth ancestral popu-
lation. Now let X̂k and ε̂k be the gene-specific ancestry (see equation 2.9) and the precision

















(1− π)N (φmk|0, ηjl) + π
∫
RN (φmk|θ, ηjl)p(θ)dθ
, l 6= k ∈ 1, 2, . . . ,K. (2.10)
Let θ ≈ N (X̂k, ε̂k) be an empirical prior on θ. Applying the symmetric propriety of the
Gaussian distribution and the fact that the product of Gaussian probability density functions
can yield a single Gaussian density function, equation 2.10 becomes,
ρ̂jk =
πN (µ̂jk|X̂k, ηjl + εk)
(1− π)N (µ̂jk|0, ηjl) + πN (µ̂jk|X̂k, ηjl + εk)
, l 6= k ∈ 1, 2, . . . ,K. (2.11)
Thus, at gene gj for k 6= l ∈ {1, 2, . . . ,K}, we weight the maximum likelihood estimate of µjk









The approach described above is similar to the leave-one-out cross-validation approach usually
used in examining statistical prediction (Han, B. et al., 2011).
2.1.6 Testing case-control ancestry difference for gene or sub-network levels
Let Θ+jk and Θ
−
jk, (j = 1, . . . , N) be the gene-specific ancestries (for N genes within a given
sub-network) estimated from n1 samples of case and from n2 samples of control individuals.
Assuming |Θ+jk−Θ
−
jk| 6= 0, (j = 1, . . . , N), thus let Γj be the rank pairs from smallest absolute
difference to largest absolute difference within the sub-network. We use the Wilcoxon signed-








.Γj | (Wilcoxon, F., 1945), a non-parametric test of
the null hypothesis that the gene-specific ancestries from cases and controls are the same against
an alternative hypothesis. Because N increases, the sampling distribution of W converges to
a normal distribution (Wilcoxon, F., 1945; Siegel, S. et al., 1998), therefore we construct our























jk are the posterior probabilities estimated from case
and control as defined in equation 2.11 in the section above. The sign is an odd mathematical
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function that extracts the sign of a real number (Shirokov, Y. M., 1979). Although the p-value
can be calculated from enumeration of all possible combinations of W given N. However, the
weighted posterior probability in equation 2.13 is not independent of W, the statistic does not
follow a normal distribution. Thus, we compute the p-value using the importance sampling
approach as described in (Wasserman, L., 2004; Penny, P. D. et al., 2000) by allowing the
sampling distribution to be centered at ZW .
2.1.7 Characterization of enriched sub-networks
Here we aim at identifying the association between each sub-network (obtained from our
network-based clustering approach) Si, (i = 1, 2, . . . , T ) within n1, n2, . . . , nT genes and a
set Pj , (j = 1, 2, . . . , J) of human pathways. We obtain 1, 047 annotated pathways from
(Feng, Z. et al., 2012) and collected more than 107 annotated pathways from the KEGG
(http://www.genome.ad.jp/kegg/), BioCarta (http://www.biocarta.com/), and Ambion Gene-
Assist Pathway Atlas (http://www.ambion.com/tools/pathway) pathway databases. We down-
loaded genomic coordinates for all genes from the NCBI ftp-server (www.ncbi.nlm.nih.gov)
and retained only entries for the human reference sequence and protein-coding genes. We
updated genomic coordinates to the latest assembly using the Lift-Over tool in GALAXY
(http://galaxy.psu.edu/). We assign the SNPs located within a gene or less than a particular
distance up/downstream distance (for example < 20kb) of the gene.
Let α be the intersection between genes within Si and genes within pathway Pj . Let β be the
intersection between genes within Si and the total genes in Pj , (j = 1, 2, . . . , J). Let N∗ be the
intersection between genes in the Pj pathway and the total of genes in Pj , (j = 1, 2, . . . , J) and
M∗ be the total of genes in Pj , (j = 1, 2, . . . , J). We compute the statistic of significance of
overlap between sub-network Si of nt genes and a given pathway Pj using Z-score (ZS), which















The approach above does not only score association of overlapping gene sets and a given
pathway, it has the advantage of accounting for the network structure of physical interactions
between the gene sets through sub-networks.
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2.2 Implementation and discussion
2.2.1 Implementation
We implemented the method and algorithm described in Methods (Section 2.1) in ancGWAS.
ancGWAS has the advantage of not only using a LD-weighted network, but also has the flexi-
bility to test for signals of unusual excess/deficiency of ancestry, test genes/sub-networks that
may explain ethnic differences in complex disease risk, and ancestry proportion at the gene
and sub-network levels in admixed populations.
Figure 2.1: ancGWAS workflow. ancGWAS is composed of 5 principal modules (classes), which
implement all the methods presented above. They perform, in a step-wise manner, the whole ancGWAS
algorithm from reading the input to generating the result, either for a homogeneous or heterogeneous
population. Red boxes represent inputs and outputs when the GWA study data set population is
heterogeneous, while the yellow boxes are the standard steps for homogeneous, as well as heterogeneous
populations.
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ancGWAS achieves these through a step-wise strategy, integrating the association signal from
GWA study data, the local ancestry and polymorphism pair-wise LD into the human PPI
network and examining the topological structure of the resulting network. Written in python
using Object Oriented Programming (OOP) abstraction, in a standalone packaging, it also
offers an interactive way to process each step of ancGWAS as described in the workflow 2.1.
The running time is subject to the size of the generated network, which is a factor of the number
of SNPs and mapped genes, and the complexity of the network which, in turn is factor of the
number of interactions and other global network properties such as the degree distribution.
The running time also increases given that ancGWAS computes the gene-gene correlation from
the SNP genotyping data of the GWA study.
2.2.2 Discussion
Pathways are only as good as the annotations on which they are based, therefore, pathway-
based approaches for GWA study analysis will continually improve. Here, we introduced ancG-
WAS, a network-based approach and post GWA study method that integrates the association
signal from GWA study data sets, the local ancestry and gene pair-wise LD into the human
PPI network, for recently admixed or non-admixed populations. Our method accounts for the
correlation that exists between SNPs within a gene and genes within pathways and introduces
flexibility in estimating gene-specific and sub-network specific ancestry. It also tests for sig-
nals of unusual excess/deficiency of ancestry at the gene and sub-network level, which to our
knowledge, is a new contribution in post-GWA study methods. In the next chapter, we assessed
ancGWAS through different simulation scenarios, including a simulation of interactive disease




Evaluation of ancGWAS through simula-
tion of disease in non-admixed and admixed
populations
We thoroughly evaluated the performance of ancGWAS using different simulation scenarios,
including a simulation of interactive disease loci in an admixed population, and a simulation
of pathway-based association study data. We demonstrated through these assessments that
ancGWAS outperformed current approaches especially when compared to dmGWAS (Jia, P.
et al., 2011), and holds promise for comprehensively examining the interactions between genes
underlying the pathogenesis of genetic diseases and also underlying ethnic differences in dis-
ease risk. The choice of dmGWAS as a comparison is motivated by the fact that it uses the
same strategy for the analysis of GWA study data sets, namely the network-based approach
(see Subsection 1.5.2), in integrating GWA study signals into the human PPI network for fur-
ther analysis. This therefore enables a reasonable comparison between these two approaches,
though the final results of ancGWAS could also have been compared to any other existing
pathway-based method for analysis of GWA study data sets. In this chapter, we first briefly
introduce the dmGWAS method that was used to assess the new proposed method, focusing
mostly on the searching strategy implemented in this model, in order to highlight major differ-
ences between the two methods. The first assessment based on case-control simulated data of
a 4-way admixed population allows us to evaluate how well ancGWAS combines locus-specific
ancestries while accounting for the bias of each observed locus-specific ancestry (obtained from
current locus-specific ancestry inference methods), and also assess the accuracy of the gene-
specific ancestry estimates when combining the observed locus-specific ancestry information.
The second assessment allowed us to evaluate the capabilities of ancGWAS to identify impor-
tant disease genes, based on a case-control data set containing a simulated disease-pathway,
and subsequently, compare the performance of ancGWAS with dmGWAS (Jia, P. et al., 2011).
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3.1 Materials and methods
3.1.1 Overview of the dmGWAS method
The dmGWAS method uses the dense module searching (DMS) algorithm for scoring modules
or sub-networks in massive networks. A module M ⊆ V , of a graph G = (V,E), is a set of
nodes that have the same neighbors outside the module. Biologically, they define a module as
a sub-network within the whole network which has a local maximum proportion of higher test
statistics (Jia, P. et al., 2011). The quantitative evaluation of the density of a module with k






where zi is calculated using the p-value of each gene, using the inverse normal distribution
function Φ−1 given in (Ideker, T. et al., 2002)
zi = Φ
−1 (1− Pi) .
Thus, if the p-value is small, the score zi will be large and we seek the module with the higher
Zm score, which would normally be the module with the higher proportion of markers with
more significant p-values (Ideker, T. et al., 2002).
To ensure that the score of a module is not too much higher than expected, a normalization is
computed using random sets of genes. The same number of genes from the network is randomly
chosen 100, 000 times, for a module m of size k. Accordingly, a score Zm (π) will be generated
as an estimated background distribution of Zm, and is given by
ZN =
Zm −mean (Zm (π))
SD (Zm (π))
. (3.1)
Note that in Equation (3.1), ZN does not depend anymore on k, meaning that different mod-
ules, mi, can now be compared, independently of their size ki, therefore the normalized score
ZN of Zm is used to rank modules.
After scoring modules, a strategy is implemented for searching for dense modules. This pro-
cedure is computed depending on two important factors d and r. The parameter d is the
constraint distance for which, any node whose the shortest path to another node is greater
than this cut-off, will not be considered as a neighbor interactor. In accordance with the fact
that the median distance between two interacting proteins in a protein-protein network is not
greater than 5, the parameter d, which has a negligible effect, is set to 2, as used in (Jia, P.
et al., 2011). The parameter r, instead has a considerable effect on the result, it obstructs re-
striction on the score of the module. Thus, during the module expanding process, if r is small,
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a loose restriction is imposed in such way that unrelated nodes with lower zi scores might be
included, but if r is large, a strict restriction is imposed and only those nodes with very high
zi scores, and thus with very low p-values, would be included. In this case, some informative
nodes with moderate p-values may be missed.
The searching strategy is performed using a greedy algorithm for iterative searching, in which
each node in the network is considered as a seed. The follows steps are achieved in order to
find dense modules (Jia, P. et al., 2011):
Algorithm 3.1 Dense module searching (DMS) algorithm
1. A seed module is assigned. In the beginning, the seed module contains only the seed
gene. Zm is computed for the current seed module.
2. Identify neighborhood interactors, nodes with shortest path shorter than or equal to the
predefined distance constraint d.
3. Examine the neighborhood interactors defined in Step (2) and find the genes generating
the maximum increment of Zm. Nodes will be added if the increment is greater than
Zm × r, where r is the rate of proportion increment. That is, the expanded module has
a score Zm + 1 greater than Zm × (1 + r).
4. Repeat Steps 1 - 3 until adding any neighborhood nodes cannot yield an increment that
is greater than Zm × r.
Table 3.1 compares the two approaches, namely the dmGWAS and ancGWAS methods, em-
phasizing the technical improvements made in the new proposed method.
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Table 3.1: Technical differences between dmGWAS and ancGWAS.
dmGWAS ancGWAS
Candidate sub-network searching Yes Yes
Annotation file & human PPI network Yes Yes
Pathway size adjustment Yes Yes
Gene weights p−value p−value, Ancestry proportion
p-value summary method Fisher’s, Simes, Small-
est, FDR
Fisher’s, Simes, Smallest, FDR
Edge weights None gene-LD
Subgraph enrichment p−value p−value, Ancestry proportion
Input data List of SNP p−values List of SNP p−values, SNP geno-
type data
3.1.2 Simulation of non-admixed pathway-based case-control population
To evaluate the performance of ancGWAS in detecting disease genes with weak genetic effects
or strong epistatic effects that a single-marker-based testing approach from a standard GWA
study can not detect, we simulated a pathway-based GWA study using PATHSIMU (Feng, Z.
et al., 2012). To do this, we used real genotype data from the CEU HapMap project to sim-
ulate 500 samples genotyped at 3, 848, 887 markers. We simulated disease-predisposing genes
(DPG) including ATP5O, ATPIF1 and BTG3 with disease-predisposing loci (DPL) rs2834287,
rs507238 and rs2250305, respectively, in the up-regulated aged mouse hypothalamus in NF-κB
pathway. This pathway was randomly selected from a set of 1, 047 annotated pathways from
the KEGG (http://www.genome.ad.jp/kegg/), BioCarta (http://www.biocarta.com/) and Ge-
neAssist Pathway Atlas Databases (http://www.ambion.com/tools/pathway) as disease genes
for a quantitative phenotype. The simulated disease pathway contains 37 additional genes,
including RPS12, MAP4, SNX2, NDUFB5, PRDX1, MAP2K1, AKR1A1, ANP32B, ATP5O,
ATP5L, SEPT4, ATPIF1, ATP5C1, PPP1R7, ITPR1, BTG3, TPD52, CSF1R, C1QBP, PPA1,
PSMA6, PSMA4, CCT6A, HK1, COX7A2, CTSS, PAFAH1B1, CASP6, PSMD14 HEXB,
ADCY9, TBCA, HSPE1, CLK1, ACTB, PREP and M6PR.
The proportions of phenotypic variance explained by additive genetic effects of ATP5O, AT-
PIF1 and BTG3 were assigned 2%, 1% and 1%, respectively. We simulated interactive genetic
effects between ATP5O and ATPIF1, ATP5O and BTG3, and ATPIF1 and BTG3, explaining
0.5%, 0.3% and 0% of phenotypic variances, respectively. From the resulting simulated data,
we then conducted the association analysis by applying EMMAX. The simulated GWA study
data was subsequently analyzed using the ancGWAS and dmGWAS approaches.
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3.1.3 Simulation of admixed case-control population
We used chromosome 1 with 116, 413 autosomal SNPs from the HapMap3 project (Interna-
tional HapMap Consortium, 2010) populations, including CEU (Utah residents with ancestry
from northern and western Europe), YRI (Yoruba in Ibadan, Nigeria), GIH (Gujarati Indi-
ans in Houston, Texas) and CHB (H an Chinese in Beijing, China) data. We independently
expanded CEU, YRI, GIH and CHB to an additional 2, 000 samples. To identify the occur-
rence of the admixture event (Chimusa, E. R. et al., 2014), we sampled the haplotypes from
YRI, CEU, GIH and CHB with a fixed probability (ancestral proportion) 60%, 20%, 12% and
8%, respectively. The choice of ancestral proportion in simulating diploid admixed individ-
uals was arbitrary. Following the sampling process above, the chromosomal segment of the
ancestral population was copied to the genome of the admixed individual, and we recorded the
locus-specific ancestry (the true ancestry) which served to assess ancGWAS. While simulating
admixed individuals (Chimusa, E. R. et al., 2014), we simulated four causal SNPs in which
the risk allele has a higher frequency in YRI than in other ancestral populations. This leads
to the selection of cases with higher than average YRI ancestry at the disease locus. The four
causal SNPS include rs2297977, rs841404, rs790633 and rs6664119 with heterozgyote risks
R = 1.5, 2, 1.5 and 2 and homozygote risks R = 2.25, 4, 2.25 and 2.25 (causal models); and
the null mode risk alleles set to R = 1, 0, 1 and 0 at each SNP, respectively. For the null model,
we chose random subsets of 1, 000 cases and 1, 000 controls. For causal models, we chose a
random subset of 1, 000 controls, and then chose 1, 000 cases from the remaining samples so
that samples with 0 : 1 : 2 reference alleles have relative probabilities 1 : R:R2 of being selected.
Our simulation yielded the genomes of 1000 cases and 1000 controls of mixed ancestry from
YRI, CEU, GIH and CHB, with a total of 116, 413 SNP markers. The simulated causal loci
are on regions 1p31.3 (IL23R gene) for SNPs rs2297977 and rs841404, and 1p34.2 (SLC2A1
gene) for SNPs rs790633 and rs6664119. Of note, IL23R and SLC2A1 are interacting genes.
We conducted standard GWA study analysis on the final simulation data set by applying EM-
MAX (Zhou, X. et al., 2012), which accounts for both population stratification and hidden
relatedness. To account for interacting disease SNPs and moderate risk that may not reach
the intrinsic genome-wide significance cut-off of P < 5.00× 10−08 in the standard GWA study
above, we applied ancGWAS on the simulation GWA study result. We incorporated in ancG-
WAS the true locus-specific ancestry generated from the simulation above and the estimated
locus-specific ancestries from LAMP-LD (Baran, Y. et al., 2012) in assessing our methods for
combining the locus-specific ancestries at both gene and sub-network levels.
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3.2 Results and Discussion
3.2.1 Assessing ancGWAS on a simulated pathway-based association study
We evaluated ancGWAS using a pathway-based case-control simulated data set. The standard
single-marker-based association analysis using EMMAX in Table 3.2, failed to identify (cutoff
p < 5×10−08) our three simulated interactive disease-associated loci rs2834287 (p = 1.1×10−4)
in the ATP5O gene, rs507238 (p = 0.48) in the ATPIF1, and rs2250305 (p = 0.19) IN THE
BTG3 gene. Thus arose the opportunity and need to use a pathway-based approach to analyse
the combined effect of all SNPs within a gene and genes within a pathway. To detect the
simulated interactive disease genes with weak genetic effects in the up-regulated aged mouse
hypothalamus pathway, we applied ancGWAS on the GWA study dataset and compared its
performance to that of dmGWAS. After mapping SNPs to their closest genes, 23, 726 and
23, 498 genes were retained from ancGWAS and dmGWAS, respectively. This slight difference
in number of mapped genes can be explained by slight differences in implementation of SNP-
gene mapping methods in ancGWAS and dmGWAS, such as the cut-off distance upstream or
downstream at which a SNP must be located with respect to a gene to be mapped the gene. In
ancGWAS, the user can decide on the required boundary distance to a gene which a SNP must
be located to be included in the analysis. For this particular analysis, a boundary distance of
20Kb upstream and downstream was considered. ancGWAS performs some additional checks
to ensure that the chosen distance includes the majority of SNPs with significant or moderate
signals, so that significant SNPs are not discarded from subsequent analysis, even though they
are located in flanking regions or just outside the boundary cutoff.
Four possible methods have been implemented in ancGWAS for combining association signal
at the gene level including the Fisher’s combination, Sime’s combination, FDR, and Small-
est methods (See Section 2.1). A summary p-value was computed for each gene from SNPs
within the gene using the smallest method. The results in Table 3.3 displays the top signif-
icant/moderate genes from the ancGWAS analysis where we combined the effect of multiple
SNPs for a gene to refine the association signal, accounting for the difference in number of
SNPs between different genes. To measure the proportion of false positives, we computed the
q-value for each adjusted p-value taking into account the 23, 726 genes in our analysis. These
q-values, expected to have the same magnitude because of their adjusted p-values, indicate a
low level of false positives. Interestingly, our DPGs have substantially increased their signal;
ATPIF1 (p = 9.12× 10−03), ATP5O (p = 9.99× 10−04) and BTG3 (p = 5.15× 10−03).
To construct the LD-weighted PPI network, three methods are available in ancGWAS; closes-
tLD, ZscoreLD and maxLD. These three methods give similar results, therefore for simplicity
of presentation we only report on the simulation result using the closestLD method. Pairwise
correlations between all 23, 726 genes were computed using the closestLD method, and an undi-
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Table 3.2: Top genetic markers with moderate/significant p-values obtained from the single-marker-based
association analysis using simulation of pathway-based GWA study data. Disease susceptibility SNPs are in
bold.
SNP Gene CHR Region A1 A2 P -value
rs16861642 CP 3 q25.1 A G 1.45× 10−06
rs10060036 KIF2A 5 q12.1 C T 2.18× 10−06
rs953121 DCC 18 q21.3 G T 2.65× 10−06
rs4912500 EPHB3 3 q27.1 G TT 3.07× 10−06
rs920822 RDX 11 p15.4 C G 3.15× 10−06
rs2167071 ANGPT2 8 p23.1 A G 3.35× 10−06
rs1882314 FBRSL1 12 q24.33 A G 3.68× 10−06
rs9391129 - - - - - 4.31× 10−06
rs12595323 RFX7 15 q21.3 A G 4.62× 10−06
rs9449387 - - - - - 6.24× 10−06
rs7444781 SLIT3 5 q35.1 A C 6.73× 10−06
rs11724257 - 4 q24 A G 7.72× 10−06
rs4730481 IMMP2L 7 q31.1 A C 7.99× 10−06
rs13006685 - 2 p25.2 A G 9.58× 10−06
rs4709327 RPL21 6 q25.3 A T 1.00× 10−05
rs2343542 AACS 12 q24.31 A T 1.00× 10−05
rs3756187 ACOX3 4 p16.1 C G 1.10× 10−05
rs10140097 RAD51L1 14 q24.1 C T 1.11× 10−05
rs2053108 CADM2 3 p12.1 G T 1.14× 10−05
rs2834287 ATP5O, ITSN1 21 q22.11 C T 1.1× 10−04
rs507238 ATPIF1, SESN2,
DNAJC8, MED18
1 p35.3 T C 0.48
rs2250305 BTG3, CXADR,
CXADRP2
21 q21.1 A G 0.19
Abbreviation: CHR, Chromosome; SNP, Single Nucleotide Polymorphism.
rected LD-weighted PPI network was then constructed composed of 10, 756 genes with 31, 942
interactions. A topological test was performed on the constructed LD-weighted network of
10, 756 pair-wise gene-gene interactions and we assessed whether there is really an opportunity
for using topological properties of the network as a factor for clustering. Figure 3.1a shows
that this network exhibits a small world property, as well as scale-free topology (Figure 3.1b),
that is, the spread of information in this network can be achieved through an average distance
of only 3.9, and the loss of important nodes can lead to the disruption of the network. Inter-
estingly, though the genes ATPIF1, ATP5O and BTG3 are the DPGs, none of them appear
to play a crucial role in this network when looking at their local topological properties. For
instance, looking at the degree centrality of these genes and whether they are central genes or
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Table 3.3: Top genes with moderate/significant p-values after combining single SNP p-values to represent
gene p-values using simulation of pathway-based GWA study data. A correction using permutation was
computed for each p-value as well as the significance of the adjustment. Disease susceptibility genes are in
bold.
Gene P -value Adjusted p-value Q-value
KIF2A 2.17× 10−06 0.0516 0.00010
FLJ37543 2.17× 10−06 0.0516 0.00010
EPHB3 3.07× 10−06 0.0729 0.00010
hCG1651160 3.14× 10−06 0.0746 0.00010
OR52B4 3.14× 10−06 0.0746 0.00010
RDX 3.14× 10−06 0.0746 0.00010
LOC100287015 3.34× 10−06 0.0794 0.00010
MCPH1 3.34× 10−06 0.0794 0.00010
ANGPT2 3.34× 10−06 0.0794 0.00010
GALNT9 3.67× 10−06 0.0872 0.00010
FBRSL1 3.67× 10−06 0.0872 0.00010
MIR585 6.73× 10−06 0.1596 0.00010
SLIT3 6.73× 10−06 0.1596 0.00010
IMMP2L 7.98× 10−06 0.1893 0.00010
LRRN3 7.98× 10−06 0.1893 0.00010
SOD2 1.01× 10−05 0.2372 0.00010
FNDC1 1.01× 10−05 0.2372 0.00010
RPL21 1.01× 10−05 0.2372 0.00010
ACOX3 1.10× 10−05 0.2613 0.00010
CYP51A1 1.13× 10−05 0.2699 0.00010
ATP5O 9.99× 10−04 0.9759 0.00015
BTG3 5.15× 10−03 0.9759 0.00022
ATPIF1 9.12× 10−03 0.9759 0.00028
not, we observe that Dc = 1 for ATPIF1, Dc = 4 for ATP5O and Dc = 1 for BTG3, and none
of these genes is a central gene. Mining or approximating sets of genes they collaborate with
may then be useful to take on these DPGs.
We applied the searching algorithm 2.1 implemented in ancGWAS (Subsection 2.1.3) on the
LD-weighted PPI network of 10, 756 genes. First, we found all the hubs of the networks and
successively, the betweenness centrality, the closeness centrality and the eigenvector centrality
measures for each node were computed. We computed the cut-offs for each centrality measure,
and the intersection of the top genes from each measure were considered to be the set of central
nodes. A central node (central gene) and all its neighbors at distance (path step) d = 1 made up
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Figure 3.1: Topological analysis of LD-weighted PPI network for the pathway-based
case-control simulated data set. (a) Distribution of shortest path lengths between reachable pair-wise
protein functional interactions. This suggests that the transmission of biological information from a given
gene to others is achieved through only a few steps. (b) Connectivity distribution of detected k functional
links per protein, plotted as a function of frequency P (k). This suggests that most of the genes in this
network have few interacting partners but some have many partners.
a module. We assessed the significance of each sub-network using the Stouffer-Liptak method.
A total of 793 sub-networks (modules) were generated from ancGWAS. Table 3.4 lists the 20
top modules ranked by their corresponding p-values. Only hubs of modules are listed here for
ease of presentation. For each module, we performed a pathway enrichment analysis to fully
characterize generated sub-networks based on 1, 047 annotated pathways collected and curated
from several public pathway databases (see Subsection 2.1.7).
Using the collected pathways, we compared each modules genes to those of collected pathways,
and we computed the z-score for each pathway, and reported the number of genes overlapping
between the module and the pathway with the highest z-score. We observed that the first
module (HSPA5, MS = 70 genes, p = 0.545) has also shown the highest similarity score of
ZP = 12.20, overlapping with the ErbB receptor signaling network for MOG = 32 different
genes. ancGWAS incorporates prior knowledge on the disease genes, i.e. previously identified
genes for the disease under study, and uses this information for mining for sub-networks of
genes associated with the disease. For this simulation, a few genes were chosen to represent
genes previously identified for the simulated disease, based on some criteria, including genes
interacting with the simulated genes, in such a way that we can use these known genes to track
unknown genes in some enriched sub-networks. Therefore, genes PLOD2 (p = 3.7 × 10−04),
PLOD3 (p = 4.2 × 10−03), RDH11 (p = 6.7 × 10−03), UBQLN4 (p = 6 × 10−03), PIK3CA
(p = 0.024), CUL2 (p = 4.7× 10−04), and E2F1 (p = 0.036) were set as known disease genes.
Interestingly, all the 20 top modules resulting contained 6 of these known genes (KG) (see Table
3.4), suggesting that integrating prior knowledge on known disease genes may significantly
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Table 3.4: Top 20 sub-networks and related pathway enrichment results from ancGWAS using a simulated
pathway-based GWA study data. For each pathway, the z-score (ZP) is reported representing the level of its
similarity with the related module, which is also a function of the size of the module. Different scores of
overlaps between the module, the pathway and the set of known genes are also reported.
Hub P Q MS Pathway ZP MOG MKG PKG
HSPA5 0.545 0.346 70 ErbB receptor signaling network 12.20 32 7 2
COMMD1 0.546 0.347 81 ErbB receptor signaling network 5.63 18 7 2
COPS6 0.547 0.347 143 Sphingosine 1-phosphate (S1P)
pathway
5.01 26 7 2
KRT14 0.548 0.349 81 ErbB receptor signaling network 7.82 23 7 2
DCUN1D1 0.550 0.352 134 ErbB receptor signaling network 6.09 26 7 2
RPL19 0.566 0.371 76 ErbB receptor signaling network 6.66 18 7 2
CDKN2A 0.572 0.378 107 Sphingosine 1-phosphate (S1P)
pathway
7.96 30 7 2
ELAVL1 0.575 0.382 525 Proteoglycan syndecan-mediated
signaling events
5.58 66 7 2
SQSTM1 0.576 0.383 90 Proteoglycan syndecan-mediated
signaling events
2.09 13 7 2
CSNK2A1 0.576 0.383 280 TRAIL signaling pathway 7.41 56 7 2
GRB2 0.580 0.388 336 TRAIL signaling pathway 11.26 83 7 2
KEAP1 0.585 0.395 90 ErbB receptor signaling network 6.44 20 7 2
HIST1H1C 0.585 0.395 81 Thrombin/protease-activated
receptor (PAR) pathway
6.78 20 7 2
UBXN7 0.586 0.396 82 ErbB receptor signaling network 5.71 17 7 2
HDAC4 0.587 0.397 221 Sphingosine 1-phosphate (S1P)
pathway
7.41 45 7 2
HSPA1A 0.588 0.399 108 IL3-mediated signaling events 9.34 29 7 2
GSK3B 0.594 0.405 246 TRAIL signaling pathway 9.08 57 7 2
RAN 0.595 0.408 199 Proteoglycan syndecan-mediated
signaling events
5.34 37 7 2
TRAF2 0.596 0.408 244 TRAIL signaling pathway 7.97 49 7 2
YWHAB 0.596 0.408 242 TRAIL signaling pathway 7.08 47 7 2
Abbreviation. P : p-value; Q: q-value; MS: Module size; ZP: Pathway z-score; MOG: Gene overlapping between the
module and the pathway; MKG: Number of genes overlapping between the module and the set of arbitrarily chosen
genes as known disease genes; PKG: Number of genes overlapping between the pathway and the set of arbitrarily chosen
genes as known disease genes;
increase the power to identify disease-specific pathways. In addition, ancGWAS was able to
successfully detect one of our simulated disease genes (ATPIF1 ) in all 20 top modules.
We also applied dmGWAS on the PPI network of 10, 756 genes, and 8, 931 sub-networks were
generated from dmGWAS using the default parameter setting of d = 2 and r = 0.1 as recom-
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Figure 3.2: Number of overlapping genes between the top 50 sub-networks obtained from dmGWAS and
ancGWAS, and the simulated disease pathway (AGED MOUSE HYPOTH UP), using the pathway-based
simulated case-control data.
top 50 sub-networks from each approach (ancGWAS and dmGWAS), ranked according to their
enrichment scores, and we subsequently compared the results from the two approaches. The
simulated disease pathway was not found to be significantly enriched, however, we computed
the number of genes overlapping between generated sub-networks with the up-regulated aged
mouse hypothalamus pathway composed of 37 genes, including our DPGs, to assess whether
each method was able to identify the simulated disease loci. We observed in Figure 3.2, that
ancGWAS largely outperformed dmGWAS in approximating the simulated disease pathway in
almost all the top 50 modules from both methods. This demonstrates that using topological
properties of networks may significantly increase our chances of identifying disease associated
sub-networks.
For each sub-network, we also computed the number of genes overlapping with our three sim-
ulated DPGs. Figure 3.3 shows that dmGWAS failed to detect any of the DPGs in any of
its top 50 generated sub-networks. This may be attributable to not only the fact that it does
not use network structural properties, but also that it does not integrate prior information
of previously identified disease genes. As hypothesized earlier, understanding functional roles
of interacting partners may facilitate the understanding of potential functional roles of as yet
unannotated disease-related genes. In other words, known disease genes can be used to track
unknown disease genes segregated in the same biological pathway, and this can be done using
the interactions between these known and unknown genes. In this assessment, ancGWAS was
able to successfully track gene ATPIF1 because of its interaction with genes UBQLN4 and
PIK3CA, which were successfully identified by ancGWAS, and were considered to be known
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Figure 3.3: Number of overlapping genes between the top 50 sub-networks obtained from dmGWAS and
ancGWAS, and the simulated disease-susceptibility genes (ATP5O, ATPIF1 and BTG3 ), using the
pathway-based simulated case-control data.
genes for the disease. The other 2 DPGs were not in the top 20 modules, which may be because
we only used distance path length of one. In Chapter 4, we extend this path length.
Finally, for each pathway mapped to each sub-network from each method, we also computed
the overlap with the simulated pathway, as well as with the three simulated DPGs (Figure 3.4).
Again, the pathways enriched from ancGWAS contained more DPGs than those enriched from
dmGWAS, even though a path length of two (d = 2) were used in dmGWAS.
Results in Figures 3.2, 3.3 and 3.4 show that ancGWAS largely outperformed dmGWAS, and
demonstrated that the sub-networks obtained from ancGWAS better approximate the sim-
ulated disease pathway (AGED MOUSE HYPOTH UP), overlapping with disease-associated
genes and with other genes within the disease pathway. This highlights the importance of char-
acterizing susceptibility genes beyond standard GWA study analysis, which failed to detect the
simulated disease gene signals.
3.2.2 Evaluating ancGWAS on a simulated disease in an admixed popula-
tion
We evaluated ancGWAS using the simulated data of a 4-way admixed population with two
disease loci at the IL23R gene in chromosomal region 1p31.3, and two other disease loci at the
SLC2A1 gene in chromosomal region 1p34.2 (see Section 3.1). We conducted the association
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Figure 3.4: Number of overlapping genes between the top 20 pathways obtained from dmGWAS and
ancGWAS module enrichment, and the simulated disease pathway (AGED MOUSE HYPOTH UP), using the
pathway-based simulated case-control data.
analysis on this simulation data by applying EMMAX (Zhou, X. et al., 2012), which accounts for
both population stratification and hidden relatedness. Table 3.5 lists the top 23 most significant
SNPs obtained from EMMAX, including the four simulated disease loci. Of note, EMMAX
failed to identify as significant the simulated disease loci at SNPs rs6664119 (p = 0.48),
rs2297977 (p = 0.0357), rs841404 (p = 1.51 × 10−06) and rs790633 (p = 1.02 × 10−05) and
other related SNPs in LD with the simulated disease loci, including rs841856 (p = 0.65) and
rs1385129 (p = 0.0043). To cover the moderate risk that did not reach the intrinsic genome-
wide significance cut-off p-value of < 5.00×10−08 in this data (Table 3.5), we combine the effects
of all SNPs in a particular gene, and the effects of genes at the pathway level using ancGWAS.
Here, we first combined the GWA study data set and the true locus-specific ancestry obtained
from the simulation of mixed ancestral populations.
The results in Table 3.6 display the top 20 moderate/significant genes from the ancGWAS
analysis where we combined the effect of several SNPs for a gene to refine the association
signal, accounting for the difference in number of SNPs between different genes (Yang, W. et
al., 2011). Interestingly, the simulated disease gene SLC2A1 (p = 6.60 × 10−21), and other




, SLC2A7 (1.05×10−23), C1orf210
(4.30 × 10−24) and FAM183A (3.3 × 10−62), which were on the boundary of genome-wide
significance from the standard GWA study (Table 3.5), are now significant (Table 3.6) after
combining effects of different SNPs within a gene. Some additional genes, including the simu-
lated disease gene C1orf141 (2.15×10−4), that had weak signals from standard GWA analysis,
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Table 3.5: 23 genetic markers with moderate/significant p-values obtained from the association analysis
with simulated disease loci on the simulation data of the admixed population. Disease susceptibility SNPs are
in bold.
SNP Gene CHR A1 A2 P -value
rs841404 SLC2A1 1 T C 1.51× 1006
rs2027286 PCTK3 1 T C 3.68× 10−06
rs6695238 EBNA1BP2, WDR65 1 G T 8.38× 10−06
rs790633 IL23R, C1orf141 1 T C 1.02× 10−05
rs641350 FAM183A 1 G T 1.10× 10−05
rs475093 FAM183A 1 G C 1.10× 10−05
rs513009 WDR65, EBNA1BP2, RNA5SP46 1 A G 1.32× 10−05
rs1308334 FAM183A 1 C G 1.34× 10−05
rs558404 EBNA1BP2 1 T C 1.72× 10−05
rs2453412 EBNA1BP2, WDR65 1 G A 1.78× 10−05
rs11555249 CDC20, ELOVL1, RP1-92O14 1 G A 1.98× 10−05
rs10890236 FAM183A 1 T C 2.06× 10−05
rs12119303 RP11-135J2 1 G T 2.79× 10−05
rs3120045 BNA1BP2, WDR65 1 G A 2.84× 10−05
rs636969 FAM183A 1 T G 3.56× 10−05
rs7550997 CEP85 1 G A 3.94× 10−05
rs11555248 CDC20, ELOVL1, RP1-92O14 1 A C 4.64× 10−05
rs768665 EBNA1BP2, WDR65 1 C T 4.66× 10−05
rs6664119 IL23R, C1orf141 1 C T 0.48
rs2297977 SLC2A1 1 G T 0.036
are now moderate after combining signals from different SNPs within this gene. This result
demonstrates the power of examining the combined effects of genes by detecting genetic signals
beyond a single SNP.
We also tested for signals of unusual difference in deficiency/excess of ancestry under a null
hypothesis. After combining the average locus-specific ancestry for each gene, we tested for
bias of each observed average locus-specific ancestry and accuracy of the gene-specific ancestry
estimates when combining local ancestry information. The results reported in Table 3.6 indicate
no significant signal of unusual difference in deficiency/excess of ancestry, which is consistent
with our simulation framework, which did not account for a model of differential ancestral allele
frequency. In addition, this result can also be explained by the fact that the simulated time of
the single admixture event was too recent to have an impact on deficiency/excess of ancestry in
the simulated data. The gene level ancestry from mixed ancestral populations reported in Table
3.6 is proportional to the true ancestry proportion used to simulate the admixed population.
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Table 3.6: Association analysis at the gene level on the simulation data of a 4-way admixed population. Top 20 genes with
significant/moderate p-values obtained from the ancGWAS method of combined SNP association analysis with simulated disease on the simulation data of an
admixed population. The table also displays ancestry-specific information from each ancestral population at the gene level, with its permutation p-value and
the corresponding q-value in brackets.
Gene P -value CEU CHB GIH YRI
FAM183A 3.3× 10−62 0.19 (0.66667, 0.00046) 0.187 (0.66667, 0.00046) 0.091 (0.66667, 0.00046) 0.532 (1.0, 0.00019)
WDR65 6.6× 10−43 0.19 (0.66667, 0.00045) 0.187 (0.66667, 0.00046) 0.091 (0.66667, 0.00045) 0.532 (0.94198, 0.00019)
ATP2B4 1.22× 10−37 0.254 (0.66667, 0.00044) 0.096 (0.66667, 0.00044) 0.040 (0.66667, 0.00044) 0.254 (0.67998, 0.00018)
ZC3H11A 6.39× 10−37 0.239 (0.63725, 0.00043) 0.115 (0.63725, 0.00043) 0.046 (0.63725, 0.00043) 0.591 (0.63725, 0.00018)
HHIPL2 1.7× 10−35 0.236 (0.66667, 0.00044) 0.132 (0.66667, 0.00044) 0.072 (0.66667, 0.00044) 0.558 (0.69056, 0.00018)
EBNA1BP2 1.86× 10−35 0.19 (0.66667, 0.00055) 0.187 (0.66667, 0.00055) 0.091 (0.66667, 0.00055) 0.531 (1.0, 0.00023)
LYPLAL1 4.97× 10−35 0.231 (0.66667, 0.00045) 0.130 (0.66667, 0.00045) 0.069 (0.66667, 0.00045) 0.572 (0.92483, 0.00019)
DUSP10 6.87× 10−32 0.236 (0.42349, 0.00037) 0.131 (0.42349, 0.00037) 0.073 (0.42349, 0.00037) 0.559 (0.42349, 0.00015)
CTTNBP2NL 1.03× 10−28 0.140 (0.66667, 0.00044) 0.145 (0.66667, 0.00044) 0.088 (0.66667, 0.00044) 0.624 (0.73621, 0.00018)
TMEM125 5.18× 10−28 0.19 (0.66667, 0.00052) 0.188 (0.66667, 0.00052) 0.090 (0.66667, 0.00052) 0.533 (1.0, 0.00021)
SLC2A5 5.82× 10−25 0.238 (0.66667, 0.00046) 0.137 (0.66667, 0.00046) 0.057 (0.66667, 0.00046) 0.568 (1.0, 0.00019)
C1orf210 4.30× 10−24 0.19 (0.66667, 0.000530) 0.188 (0.66667, 0.000530) 0.088 (0.66667, 0.000530) 0.533 (1.0, 0.00022)
SLC2A7 1.05× 10−23 0.237 (0.66667, 0.00047) 0.138 (0.66667, 0.00047) 0.057 (0.66667, 0.00047) 0.568 (.0, 0.00019)
GYG1 1× 10−35 0.239 (0.66667, 0.00047) 0.146 (0.66667, 0.00048) 0.062 (0.66667, 0.00047) 0.555 (1.0, 0.00019)
TIE1 1.84× 10−23 0.19 (0.66667, 0.00056) 0.188 (0.66667, 0.00056) 0.088 (0.66667, 0.00056) 0.533 (1.0, 0.00023)
ABCB10 4.46× 10−23 0.210 (0.66667, 0.00121) 0.14 (0.66667, 0.00121) 0.093 (0.66667, 0.00121) 0.557 (1.0, 0.0005)
ETV3 3.81× 10−22 0.28 (0.66667, 0.00047) 0.131 (0.66667, 0.00047) 0.038 (0.66667, 0.00047) 0.550 (1.0, 0.00019)
SLC2A1 6.60× 10−21 0.19 (0.38335, 0.00036) 0.187 (0.38335, 0.00036) 0.091 (0.38335, 0.00036) 0.531 (0.38335, 0.00015)
CEP85 3.82× 10−5 0.256 (0.66667, 0.00071) 0.097 (0.66667, 0.00071) 0.071 (0.66667, 0.00071) 0.576 (1.0, 0.00029)
C1orf141 2.15× 10−4 0.271 (0.66667, 0.00056) 0.131 (0.66667, 0.00056) 0.057 (0.66667, 0.00056) 0.541 (1.0, 0.00023)
CEU: Utah residents with ancestry from northern and western Europe; YRI: Yoruba in Ibadan, Nigeria; GIH: Gujarati Indians in Houston, Texas;
CHB: Han Chinese in Beijing, China.
To benefit from fully characterizing susceptibility genes and determining the genetic structure of
the simulated disease, we conducted sub-network association analysis using ancGWAS (see Sec-
tion 2.1), using the closestLD method to construct the LD-weighted network. To this end, we
used the PPI dataset from the PINA (http://cbg.garvan.unsw.edu.au/pina/interactome.stat.do)
database containing 106, 573 human protein-protein interactions, reassembled and curated from
different databases including IntAct, MINT, BioGRID, DIP, HPRD and MIPS/MPact.
A topological test was performed on the constructed LD-weighted network of 1, 742 pair-wise
gene-gene interactions and we assessed whether there is really an opportunity for using topo-
logical properties of the network as a factor for clustering. Figure 3.5 shows that the network
exhibits scale-free topology, meaning that the degree distribution of genes approximates a power
law P (k) = k−γ , where γ ≈ 2.70 is the degree exponent obtained by fitting the model using
the least-square approach. This indicates that most genes have few interacting partners but
some have many and are crucial for the robustness of the network. Figure 3.5 shows that the
network has a small world property, suggesting that the spread of information in the network
is achieved through an average of 7.01 steps, which corresponds to the average shortest paths
in the network. To determine whether we can use topological properties to break down our
network into sub-networks, we ran the searching algorithm (see workflow 2.1). First, we found
all the hubs of the networks and successively, the betweenness centrality, the closeness central-
ity and the eigenvector centrality measures for each node were computed. We computed the
cut-offs for each centrality measure, and the intersection of the top genes from each measure
was considered to be the set of central nodes. We assessed the significance of each of the top
20 sub-networks using the Stouffer-Liptak method, accounting for spatial correlations among
SNPs within a gene or genes within a given sub-network.
Figure 3.5: Topological analysis of the 4-way admixed population LD-weighted PPI network.
(a) Distribution of shortest path lengths between reachable pair-wise protein functional interactions. (b)
Connectivity distribution of detected k functional links per protein, plotted as a function of frequency P (k).
97
Table 3.7: Association analysis at the sub-network level on the simulation data of a 4-way admixed population. Top 20 sub-networks (only
module hubs are displayed) with significant/moderate p-values obtained from the ancGWAS method of combined SNP association analysis with simulated
disease on the simulation data of an admixed population. The table also displays ancestry-specific information from each ancestral population at the gene
level, with its permutation p-value and the corresponding q-value.
Module Hub Liptak Q YRI GIH CHB CEU
TRAF3IP3 8.26e-31 0.00.0 0.553 (0.25, 0.02) 0.076 (0.25, 0.02) 0.132 (0.25, 0.02) 0.231 (0.25, 0.02)
CTTNBP2NL 8.26e-31 0.00.0 0.576 (0.25, 0.02) 0.053 (0.25, 0.02) 0.15 (0.25, 0.02) 0.228 (0.25, 0.02)
RPSA 9.82e-19 0.00.0 0.55 (0.25, 0.034) 0.06 (0.25, 0.034) 0.146 (0.25, 0.034) 0.239 (0.25, 0.034)
SLC2A5 9.82e-19 0.00.0 0.57 (0.25, 0.034) 0.068 (0.25, 0.034) 0.134 (0.25, 0.034) 0.232 (0.25, 0.034)
SRSF10 9.10e-17 4.94e-09 0.571 (0.2, 0.005) 0.056 (0.2, 0.005) 0.141 (0.2, 0.005) 0.235 (0.2, 0.005)
LEPR 3.62e-14 9.17e-08 0.573 (0.25, 0.027) 0.054 (0.25, 0.027) 0.128 (0.25, 0.027) 0.248 (0.25, 0.027)
IPO13 3.08e-12 8.69e-07 0.609 (0.102, 0.003) 0.045 (0.102, 0.003) 0.117 (0.102, 0.003) 0.236 (0.102, 0.003)
SNRPE 8.82e-12 1.48e-06 0.582 (0.2, 0.005) 0.054 (0.2, 0.005) 0.131 (0.2, 0.005) 0.244 (0.2, 0.005)
CTSD 9.03e-12 1.49e-06 0.575 (0.102, 0.003) 0.038 (0.102, 0.003) 0.127 (0.102, 0.003) 0.267 (0.102, 0.003)
PSMA5 9.03e-12 3.11e-06 0.574 (0.102, 0.003) 0.054 (0.102, 0.003) 0.131 (0.102, 0.003) 0.252 (0.102, 0.003)
S100A14 9.03e-12 3.11e-06 0.574 (0.102, 0.003) 0.054 (0.102, 0.003) 0.131 (0.102, 0.003) 0.252 (0.102, 0.003)
PSMB4 9.03e-12 3.11e-06 0.574 (0.102, 0.003) 0.054 (0.102, 0.003) 0.131 (0.102, 0.003) 0.252 (0.102, 0.003)
RPL31 9.33e-11 4.90e-06 0.562 (0.102, 0.003) 0.061 (0.102, 0.003) 0.129 (0.102, 0.003) 0.242 (0.102, 0.003)
CGN 3.58e-10 9.72e-06 0.59 (0.2, 0.005) 0.055 (0.2, 0.005) 0.124 (0.2, 0.005) 0.24 (0.2, 0.005)
STXBP3 4.96e-10 1.14e-05 0.61 (0.2, 0.005) 0.047 (0.2, 0.005) 0.118 (0.2, 0.005) 0.233 (0.2, 0.005)
NID1 1.06e-09 1.68e-05 0.62 (0.102, 0.003) 0.066 (0.102, 0.003) 0.142 (0.102, 0.003) 0.18 (0.102, 0.003)
RPAP2 2.62e-09 2.67e-05 0.609 (0.092, 0.003) 0.045 (0.092, 0.003) 0.117 (0.092, 0.003) 0.237 (0.092, 0.003)
SFN 1.26e-08 5.96e-05 0.609 (0.2, 0.005) 0.046 (0.2, 0.005) 0.117 (0.2, 0.005) 0.239 (0.2, 0.005)
LAMC1 2.07e-08 7.67e-05 0.623 (0.25, 0.008) 0.08 (0.25, 0.008) 0.145 (0.25, 0.008) 0.163 (0.25, 0.008)
APOA2 2.58e-08 8.59e-05 0.556 (0.25, 0.034) 0.056 (0.25, 0.034) 0.139 (0.25, 0.034) 0.25 (0.25, 0.034)
Q: q-value of the Liptak test statistics;
Table 3.7 reports the ancestral proportions of each sub-network for each ancestry component,
which is consistent with ancestral proportions used to simulate this population data. A total
of 382 modules were generated from ancGWAS, and ranked according their Liptak statistics.
For each ancestry, the adjusted Wilcoxon signed-rank statistic p-value and the corresponding
type 1 error level (q-value) are reported. No evidence of difference in deficiency/excess of
ancestry is shown for each those top 20 sub-networks, revealing that gene-specific ancestries
from cases and controls in this population are the same. Importantly, when applying the
enrichment analysis implemented in ancGWAS to the top 20 sub-networks (Table 3.8), the
annotations for pathway/process of the 20 top sub-networks are clustered in signaling pathways,
which include the pathway Proteoglycan syndecan-mediated signaling events, containing many
of our known genes, and more particularly our simulated disease gene SLC2A1. The result in
Table 3.8 highlights the benefit of fully characterizing susceptible genes beyond the standard
GWA study approach. A strong convergence of almost all the pathways associated to modules
generated by ancGWAS was observed, suggesting a possible convergence of all these pathways
into a single network.
Figure 3.6: Central network of 47 genes for the 4-way simulated data from ancGWAS. The size of a node
denotes its significance with size increasing with significance. Each gene is represented with its ancestral
proportions: green for YRI; yellow for GIH; sandy-brown for CHB, white-smoke for CEU.
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Table 3.8: Enrichment analysis of sub-netwokrs using ancGWAS on the simulation data of a 4-way admixed population.
Top 20 sub-networks represented by their hubs generated using ancGWAS, ranked according to their Liptak’s combined p-value test statistic. See Table A.1 in
supplementary materials for a more detailed list of sub-networks and corresponding genes. For each sub-network (module), the most related pathway is
reported with respect to the significance of overlap between the sub-network and the human pathway. ancGWAS was able to identify enriched sub-network
harboring one of our simulated genes (IL23R), and one of the genes (UBE2I ) arbitrarily considered as previously identified to be associated with the
simulated disease in ancGWAS.
Module Hub MS Pathway ZP MOG MKG PKG PDPG
TRAF3IP3 6 Apoptotic execution phase 112.67 1 - - -
CTTNBP2NL 6 Plasma membrane estrogen receptor signaling 2.99 1 - 7 SLC2A1
RPSA 3 Proteoglycan syndecan-mediated signaling events 2.82 1 - 7 SLC2A1
SLC2A5 3 Proteoglycan syndecan-mediated signaling events 2.82 1 - 7 SLC2A1
SRSF10 13 ATR signaling pathway 22.51 1 - - -
LEPR 3 Signaling events mediated by PTP1B 104.92 1 - 2 -
IPO13 26 Proteoglycan syndecan-mediated signaling events 2.39 6 UBE2I 7 SLC2A1
SNRPE 17 Proteoglycan syndecan-mediated signaling events 1.69 3 - 7 SLC2A1
CTSD 32 Immune System 14.48 6 - 3 -
PSMA5 29 Immune System 12.62 5 - 3 -
S100A14 29 Immune System 12.62 5 - 3 -
PSMB4 29 Immune System 12.62 5 - 3 -
RPL31 24 Proteoglycan syndecan-mediated signaling events 4.65 6 UBE2I 7 -
CGN 15 CDC42 signaling events 6.01 3 - 6 SLC2A1, IL23R
STXBP3 15 Proteoglycan syndecan-mediated signaling events 1.69 3 - 7 SLC2A1
NID1 25 Beta1 integrin cell surface interactions 8.44 13 UBE2I 7 SLC2A1
RPAP2 34 Proteoglycan syndecan-mediated signaling events 4.42 11 UBE2I 7 SLC2A1
SFN 15 ATR signaling pathway 28.27 2 - - -
LAMC1 11 Beta1 integrin cell surface interactions 6.32 5 - 7 SLC2A1
APOA2 2 Processing of Capped Intron-Containing Pre-mRNA 0.0 - - 1 -
Abbreviation. MS: Module size; ZP: Pathway z-score; MOG: Gene overlapping between the module and the pathway; MKG: Number of genes overlapping
between the module and the set of arbitrary chosen genes as known disease genes; POG: Number of overlapping genes between the pathway and the
known genes; PDPG: Number of DPGs in the pathway.
Taking advantage of overlapping genes among these sub-networks, we looked for a central
sub-network from the intersection of all the sub-networks. The central sub-network in Figure
3.6 represents the most important sub-network for this simulated data set, and it highlights
important features of why pathway-based or network-based approaches may be crucial as a
complementary approach to the single-marker-based approach in GWA studies. The central
gene STAT3, though it doesn’t show a significant association signal itself, is really important
for the survival of this system, and its removal would result in a complete breakdown of this
network. It can lead to fatal loss of substantial information in this sub-network, such as the
loss of the simulated disease gene IL23R, and other nodes that hold this network together
including genes TIE1, ipo13, UBE21 and YBX1 (Figure 3.6). This gene/protein plays a key
role in many cellular processes such as cell growth and apoptosis. It has been associated with
many diseases including hyper ige syndrome, and autosomal dominant hyper ige syndrome.
In the IL-23 pathway for instance, STAT3 is required for IL-23-mediated IL-17 production in
spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice (Cho, M. et al.,
2006). In another experiment, IL-23 and IL-12 expression in tumor-infiltrating myeloid cells
have been shown to be compartmentalized and oppositely regulated by Stat3, by conditional
knock out of the Stat3 gene in the hematopoietic compartment (Kortylewski, M. et al., 2009).
Taken together, through the simulation of a 4-way admixed population, ancGWAS demon-
strated accuracy and the ability to elucidate the interactions between genes underlying the
pathogenesis of complex diseases that were not detected in a standard GWA study analysis.
It was also able to find ancestry-specific genes or sub-networks, and showed no evidence of no
deficiency/excess differences in ancestry at the SNP, gene and pathway level.
We have shown, through simulation of a pathway-based association study and simulation of
interactive disease loci in an admixed disease population, that ancGWAS holds promise for
comprehensively examining interactions between genes underlying the pathogenesis of genetic
diseases and also underlying ethnic differences. We demonstrated that ancGWAS outperformed
an existing method, dmGWAS, by leveraging the correlation that exists among SNPs within
genes and genes within pathways, and accounting for the topological structure of the network.
Importantly, ancGWAS was able to recover weak and moderate association signals at the gene
and pathway level. It also refined the weak signals of simulated disease SNPs, which failed
in the single-marker-based testing approach commonly used in standard GWAS, to identify
significant and enriched sub-networks associated with complex disease.
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CHAPTER 4
Application of ancGWAS: Identification of
enriched pathways for sporadic postmeno-
pausal breast cancer
Breast cancer is a disease in which certain cells in the breast become abnormal and multiply
without control or order to form a tumor. Like most complex diseases, it is likely to be a
disruption of a mechanism of several interacting genes rather than a result of a single gene,
and as in most cancers, it represents a heterogeneous collection of distinct diseases that arise
as a consequence of carried somatic mutations acquired during tumorigenesis (Hanahan, D. et
al., 2000). The ability to dissect this heterogeneity with respect to the mechanism leading to
the disease, as well as with respect to the nature of the disease itself, is crucial for the under-
standing of the disease etiology. This can critically help understanding the significance of the
genome alterations in breast cancer, and therefore developing more effective therapeutic strate-
gies for personalized medicine, by identifying groups or subpopulations of individual patients
of particular characteristics who are likely to respond positively or negatively to a particular
therapeutic strategy (Chuang, H. Y. et al., 2007). Though most cases of breast cancer are not
inherited, relatively low heritability has been established, estimated to less than 30% of the
genetic component involved in the pathogenesis of breast cancer (Chang, E. et al., 2014). For
instance, mutations in the BRCA1 and BRCA2 genes (major genes related to hereditary breast
cancer), are inherited in an autosomal dominant pattern, so that one copy of each gene in each
cell can sufficiently increase a person’s risk of developing breast cancer (National Institute of
Health, 2014).
Over the years, several different genetic methodologies have been employed to identify multi-
ple loci variations in population frequency that can confer susceptibility, relative risk or play
a potential functional role in breast cancer (Table 4.1). These range from familial linkage and
positional cloning studies, which led to the identification of the BRCA1 and BRCA2 genes
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Table 4.1: Known breast cancer susceptibility genes and regions showing the mapping method used to infer
the association. A more complete list is provided in Table A.2 in supplementary materials. Adapted from
(Collins, A. et al., 2011).
Known gene Location Mapped by All. Freq. Known/possible function
BRCA1 17q21 Linkage Rare DNA repair/genome stability
BRCA2 13q13.1 Linkage Rare Recombinational repair
TP53 17q12.1 Linkage Rare Li–Fraumeni syndrome, apoptosis
ATM 11q22.3 Candidate Rare DNA repair
BRIPI 17q23.2 Candidate Rare DNA repair, associated with BRCA1
CHEK2 22q12.1 Candidate Rare DNA repair/cell cycle
PALB3 16p12.2 Candidate Rare Associated with BRCA2
RAD51C 17q22 Candidate Rare Homologous recombination repair
PTEN 10q23.3 Linkage Rare Cowden disease, cell signaling
STK11 (LKBI) 19p13.3 Linkage Rare Peutz–Jeghers syndrome, cell cycle arrest
CDHI 16q22.1 Linkage Common intercellular adhesion: lobular BC
FGFR2 10q26 GWAS Common Fibroblast growth factor receptor
TOX3 (TNRC9) 16q12 GWAS Common Chromatin structure/cell cycle
MAP3KI 5q11.2 GWAS Common Cellular response to growth factors
LSPI 11p15.5 GWAS Common Neutrophil motility
CASP8 2q33 GWAS Common Apoptosis
SLC4A7/NEK10 3p24.1 GWAS Common Cell cycle control?
NOTCH2/FCGR1B 1p11.2 GWAS Common Signaling/immune response?
RAD5ILI 14q24.1 GWAS Common Homologous recombination repair?
CDKN2A/CDKN2B 9p21 GWAS Common Cyclin-dependent kinase inhibitors?
MYEOV/CCNDL 11q13 GWAS Common Cell cycle control/fibroblast growth factors?
ZNF365 10q21.2 GWAS Common Zinc finger protein gene
ANKRD16/FBX018 10p15.1 GWAS Common Helicase
ZMIZI 10q22.3 GWAS Common Regulates transcription factors?
Abbreviation. All. Freq.: Allele frequency; BC: breast cancer.
Notes. ? refers to ‘possible’/‘uncertain’ gene or function in the breast cancer context. Candidate refers to mapping by
candidate resequencing.
that belong to the DNA repair mechanism in the cells and account for a substantial proportion
of early-onset breast cancer, and the tumor suppressor TP53 and PTEN genes that participate
in processes related to cell cycle control and cell proliferation (Ideker, T. et al., 2002; Collins,
A. et al., 2011), to candidate gene association studies that have led to the identification of
additional rare genetic variants with relatively moderate risks. These include germline muta-
tions in the ataxia-telangiectasia (ATM ) gene (with apparently higher risks below the age of
50 years) and the partner and localizer of the BRCA2 (PALB2 ) gene, which interacts with
BRCA2, and in which mono-allelic mutations are involved in familial breast cancer (Collins,
A. et al., 2011). More recently, GWA studies have led to the discovery of several novel common
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low penetrance risk alleles such as the well-established FGFR2 gene in which common suscep-
tibility variants are located in intron 2 (Hunter, D. J. et al., 2007). Several other studies have
looked at more mechanistic possibilities taking into account interaction effects between genes
(G × G), and between genes and the environment (G × E). For example, Briollais et al in
(Briollais, L. et al., 2007) examined SNP-SNP interactions among 19 SNPs from 18 key genes
involved in major cancer pathways in a sample of 398 breast cancer cases and 372 controls from
Ontario, and identified several simple (two-way) and complex (multi-way) SNP-SNP interac-
tions associated with breast cancer, including an interaction between XPD and IL10 genes as
the most significant two-way interaction. Many other studies of this nature have been carried
out over the years, inspecting the link between groups of genes and breast cancer, resulting in
the identification of many targeted pathways for breast cancer, including the estrogen signaling
pathway, the phosphoinositide-3 kinase (PI3K ) pathway, the HER2 signaling pathway and the
insulin-like growth factor (IGF ) signaling pathway (Chang, J. T. et al., 2009; Baselga, J., 2011;
Ideker, T. et al., 2002), of which many are currently actively used for targeted therapies for
breast cancer treatment (National Cancer Institute, 2014).
Here, we applied the new proposed network-based approach, ancGWAS, to the breast cancer
GWAS dataset of the Cancer Genetic Markers of Susceptibility (http://cgems.cancer.gov/)
project of the National Cancer Institute (NCI, http://www.cancer.gov/). A recent study in
(Hunter, D. J. et al., 2007) has identified significant association in intron 2 in the FGFR2 gene
with breast cancer susceptibility. We first describe the data used in this analysis, and then
present the result obtained through ancGWAS.
4.1 Materials and Methods
We obtained the stage I case-control breast cancer data (Hunter, D. J. et al., 2007), from
the Cancer Genetic Markers of Susceptibility (CGEMS) project. The data set was geno-
typed on an Illumina HumanHap 550 array, and the samples included 1, 145 postmenopausal
women of European ancestry with invasive breast cancer and 1, 142 controls, nested within
the prospective Nurses Health Study cohort. Data quality control was performed, excluding
all unmapped SNPs. 528, 169 SNPs were finally included in this study. After evaluating the
extent of substructure in the data set (separating cases and controls as distinct groups), we
examined whether stratification can be accounted for in the GWAS. Both population stratifica-
tion and hidden relatedness were taken into account by applying the mixed model approach in
EMMAX on the dataset. In addition, we conducted an imputation (Howie, B. N. et al., 2009),
by only incorporating genotypes in the chromosomal region 10q26 that harbours the FGFR2
gene, based on the 1, 000 Genomes project populations, to ensure that the majority of SNPs
in that gene are present in our analysis.
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528, 169 SNPs genotyped from 1, 145 cases and 1, 142 controls were tested for association with
breast cancer, including the additional imputed SNPs. Though the association analysis did not
yield any genome-wide significant signal, the FGFR2 gene was highly associated with breast
cancer susceptibility (Table 4.2). To account for possible interacting breast cancer disease SNPs
and moderate risk that could not reach the genome-wide significance cut-off in the standard
GWAS, and to investigate the joint effect of interacting groups of genes that might be associated
with breast cancer, we applied ancGWAS to the resulting GWAS data set containing 528, 169
SNPs with their corresponding p-values.
4.2 Results and discussion
We applied the method presented in Chapter 2, and implemented in ancGWAS. The results
in this section are reported as a series of distinct stage (stepwise process) as presented in the
work-flow in Figure 2.1, highlighting the approach and results at different stage of the analysis
performed in ancGWAS.
After mapping SNPs to genes at a boundary distance of 20Kb upstream and downstream,
24, 403 genes were retained in ancGWAS, representing 319, 137 of the 528, 169 SNPs (60%)
that were originally genotyped in this GWAS. Summary p-values were computed for genes
from SNPs using the smallest method with a cut-off of 0.05, also accounting for the difference
in number of SNPs between different genes. Table 4.3 displays the top significant/moderate
genes from the first step in the ancGWAS analysis, combining effects of multiple SNPs for
a gene to refine the association signal. Looking at some known breast cancer genes from
previous association studies, we observed that the majority of these genes still did not have
significant association signal in this dataset. Nevertheless some genes such as HAS2-AS1 (p =
3.46× 10−07), MYCL1 (p = 2.73× 10−06), and RAD51C (p = 0.00299) have their association
signal increased after combining p-values from SNPs. However, many of them have still shown
very weak association signals, the FGFR2 gene (p = 0.03702) signal decreased, and at the
extreme, no signal of association was found for BRCA1 (p = 1.0), one of high-penetrance
breast cancer genes. Combining association signals from SNPs for a gene does not necessarily
increase the significance of the signal. For instance, the FGFR2 gene, which has the highest
signal from the single-marker-based association analysis (p = 2.5 × 10−06), now has its signal
decreased (p = 0.03 and adjusted p = 0.14). 138 SNPs are associated with the FGFR2 gene,
90% of which have weak signals greater than or equal to 0.1, which causes the decreasing of
the signal of this gene.
Pairwise correlation between all these 24, 403 genes were computed using the closestLD method,
and an undirected LD-weighted PPI network was then constructed composed of 10, 839 genes
with 34, 665 interactions. The topological analysis of this LD-weighted PPI network reveals in
Figure 4.1a that this network exhibits a small world property, as well as a scale-free topology
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Table 4.2: Top genetic markers with moderate/significant p-values obtained from the association analysis
using 1, 145 postmenopausal women of European ancestry with invasive breast cancer and 1, 142 controls,
genotyped at 528, 169 SNPs.
SNP Gene CHR Region A1 A2 P -value
rs10510126 FGFR2 10 q26.13 C T 2.56e− 06
rs12505080 KIAA1239 4 p14 T C 7.98e− 06
rs17157903 RELN 7 q22.1 C T 1.02e− 05
rs1219648 FGFR2 10 q26.13 A G 1.34e− 05
rs7696175 TLR1, TLR6 4 p14 C T 1.40e− 05
rs2420946 FGFR2 10 q26.13 C T 1.73e− 05
rs6497337 SYT17 16 P12.3 G A 2.12e− 05
rs1250255 FN1 2 q35 A G 3.21e− 05
rs10804287 EPHA4, MIR4268 2 q35 G A 3.63e− 05
rs16943326 PPM1E 17 q22 C T 4.30e− 05
rs2981579 FGFR2 10 q26.13 C T 4.36e− 05
rs1538472 KIF26B 1 q44 T C 4.53e− 05
rs873811 C21orf82, MRPS6 21 q22.11 C T 5.50e− 05
rs4107736 TMEM66, MIR3148 8 p12 A G 5.53e− 05
rs11732323 KIT, KDR 4 q12 G A 5.77e− 05
rs2194225 IL7R 5 p13.2 A G 6.56e− 05
rs12792184 OR8A1 11 q24.2 T C 7.07e− 05
rs12682293 MAP2K1P1 8 p12 C A 7.12e− 05
rs4445554 USP6NL 10 p14 C T 7.16e− 05
rs4866929 HCN1 5 p12 A G 7.17e− 05
rs9953717 CBLN2, SOCS6 18 q22.3 C T 7.65e− 05
(Figure 4.1b), so the spread of information in this network can be achieved through an average
distance of only 3.9. This shows a high connectivity in this network, with a number of important
genes with many partners. The network average degree is 2, which means that every gene in
this network has on average 2 partners.
We applied the searching algorithm from 2.1 implemented in ancGWAS on the LD-weighted
PPI network of 10, 839 genes. After finding all the hubs of this network, we subsequently com-
puted the betweenness, closeness and eigenvector centrality measures for each node. Cut-offs
BetOf, ClosOf, and DegOf for each centrality measure were computed and applied to every
node centrality score, resulting in BetOf = 42033.38, ClosOf = 0.2579, DegOf = 6.288. The
intersection of the set of genes for each centrality measure was considered to be the set of
central nodes. Finally, for each central node (central gene), all its direct neighboring partners
at distance (path step) d = 1 made up a module.
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Table 4.3: Top genes with moderate/significant p-values obtained from the ancGWAS method of combined
SNP association analysis using 1, 145 breast cancer cases and 1, 142 controls, genotyped at 528, 169 SNPs. In
bold are some genes identified in previous association studies as being involved in breast cancer.
Gene P -values AdjP GC Gene P -values AdjP GC
VWA3B 3.08× 10−13 2.84× 10−07 ASCC3 9.31× 10−08 0.00017
MRPS30 7.33× 10−12 1.40× 10−06 SLC4A3 2.53× 10−07 0.00028
RRAGA 7.33× 10−12 1.40× 10−06 ATG10 3.43× 10−07 0.00033
PTCD3 1.35× 10−11 1.92× 10−06 HAS2-AS1 3.46× 10−07 0.00033
IMMT 3.57× 10−10 1.00× 10−05 MYCL1 2.73× 10−06 0.00095
SCARNA8 4.20× 10−09 3.51× 10−05 SOD2 0.00065 0.01644
TADA1L 4.26× 10−09 3.54× 10−05 RAD51C 0.00299 0.03869
CNGA3 4.89× 10−09 3.79× 10−05 SLC4A7 0.02171 0.10990
JRKL 1.01× 10−08 5.51× 10−05 CCND1 0.01044 0.07139
TANK 2.98× 10−08 9.52× 10−05 BARD1 0.02597 0.11694
TSPAN15 3.86× 10−08 0.00010 MPO 0.02732 0.12022
MMRN1 3.93× 10−08 0.00010 FGFR2 0.03702 0.14199
BMPR1B 4.02× 10−08 0.00011 PTGS2 0.04438 0.15690
C6orf10 5.74× 10−08 0.00013 BRCA1 1.0 1.0
KRT18 8.49× 10−08 0.00016
At different stages of any research project, investigators need to choose which genes or proteins
to investigate further experimentally and which to leave out for particular reasons. This is
often done randomly or using a statistical method, and is referred to as “gene prioritization”.
The basic idea behind gene prioritization is that for a given phenotype with genetic hetero-
geneity, different trait-related genes should exhibit some similarities with one another based
on a particular measure. In other words, if we assume a set of genes responsible for a given
disease (“seed genes”), here referred to as “known disease genes” (KDG), then unknown disease
genes can be detected through their similarities (interactions in the case of PPIs) to the seeds
(Bao, S. Y. et al., 2013; Moreau, Y. et al., 2012).
Here, we consider the set of known breast cancer genes (129 genes) in Table A.2 as seed genes,
and subsequently used this set to prioritize certain genes throughout this analysis. We applied
a straightforward gene prioritization strategy, to increase our chance of regaining interactions
between known and probably yet unknown genes for breast cancer from our dataset. Thus,
for each module, if there exists a path of distance equal to the average distance, i.e. the ab-
solute value of 3.9, between a seed gene and the central gene of the module, then the seed
gene from the set of known breast cancer genes is added to the module. We observed that the
modules contained too many genes with too much redundancy among the modules, making
the analysis less manageable. Therefore, to reduce redundancy among our modules during the
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Figure 4.1: Topological analysis of the CGEMS breast cancer LD-weighted PPI network.
(a) Distribution of shortest path lengths between reachable pair-wise protein functional interactions. (b)
Connectivity distribution of detected k functional links per protein, plotted as a function of frequency P (k).
prioritization process, if a seed gene has already been attached to a module, it will not be
attached to another module with the same interactions. This did not affect the results as the
pathway enrichment results were almost the same from these two strategies. Finally, because
over 90% of the pathways from BioCarta in our database had < 30 genes, while other pathways
from databases such as KEGG and PID were generally larger and more variable in size (mean
gene count = 44 and 36, standard deviation gene count = 24 and 16 respectively), we decided
to only retain pathways with size ranges from 10 to 100. This was to avoid bias due to large
pathways, having greater chances of being represented just because of containing a much larger
number of genes.
A total of 596 sub-networks (modules) were generated from ancGWAS, and the significance of
each module was assessed using the Stouffer-Liptak method. From the 20 top sub-networks
obtained from ancGWAS, we performed enrichment analysis on each sub-network using our
pathway database of 1, 047 annotated pathways (see Subsection 2.1.7). Table 4.4 presents the
top 20 module hubs from ancGWAS analysis, ranked by their Stouffer-Liptak p-values, as well
as the pathway with the highest z-score for each module from our enrichment analysis. In-
terestingly, 11 pathways were significantly overlapping with our top 20 modules with higher
amount of overlap, many of them containing at least 1 known breast cancer disease gene. Of
these, Proteoglycan syndecan-1-mediated signaling events from the PID database was the most
frequent, representing almost 35% of pathways mapped to the top 20 modules for breast cancer
in this analysis. This pathway was also identified as the most enriched in a previous pathway-
based analysis study of breast cancer by Menashe in (Menashe, I. et al., 2010) using the same
dataset as this study, but using an enrichment score reflecting the overrepresentation of gene-
based association signals in each pathway using a weighted Kolmogorov-Smirnov procedure.
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Table 4.4: Top 20 sub-networks, and related pathway enrichment results from ancGWAS. For each pathway,
the z-score (ZP) is reported representing the level of its similarity with the related module, which is also a
function of the size of the module. Different scores of overlaps between the module, the pathway and the set of
known genes are also supplied. The list of module genes is provided in Table A.4 in supplementary materials.
Hub P AdjP MS Pathway ZP MOG MKG PKG
MAP3K12 2.69× 10−07 0.19185 17 Beta1 integrin cell surface interactions 1.318 4 2 1
CDKN1A 1.01× 10−05 0.14154 22 Proteoglycan syndecan-mediated
signaling events
2.7858 6 2 1
UNC93B1 3.70× 10−05 0.12664 13 Metabolism of proteins 35.159 2 1 0
EIF2B1 3.97× 10−05 0.17215 19 Beta1 integrin cell surface interactions 2.0834 5 2 1
SMC3 7.61× 10−05 0.11893 26 Cell Cycle, Mitotic 20.865 5 1 1
LNX2 0.00030 0.11164 27 Proteoglycan syndecan-mediated
signaling events
5.3384 11 1 1
ITGA5 0.00064 0.13200 11 Proteoglycan syndecan-mediated
signaling events
1.2439 3 1 1
ATF7IP 0.00085 0.13739 14 Beta1 integrin cell surface interactions 3.7639 3 1 1
GRIN2B 0.00154 0.13751 20 Glypican 6.0553 9 2 2
RTN4 0.00167 0.09724 14 Proteoglycan syndecan-mediated
signaling events
5.3186 6 3 1
PRKCG 0.00210 0.11598 19 ErbB receptor signaling network 2.7864 4 1 1
MAPKAP1 0.00390 0.10279 20 Integrin family cell surface
interactions
5.7685 9 2 1
PACSIN3 0.00513 0.11618 20 Beta1 integrin cell surface interactions 6.5632 8 1 1
LEF1 0.00560 0.07560 21 Proteoglycan syndecan-mediated
signaling events
4.6443 9 4 1
ACVR1 0.00786 0.11361 21 CDC42 signaling events 10.462 5 1 1
PCBD2 0.01319 0.11920 11 Gene Expression 16.282 2 1 0
WAS 0.01377 0.09055 13 Proteoglycan syndecan-mediated
signaling events
4.6116 5 1 1
BSG 0.01920 0.08244 16 Proteoglycan syndecan-mediated
signaling events
1.7079 3 2 1
ARL4D 0.01972 0.11676 12 Regulation of Androgen receptor
activity
21.888 1 1 0
FBXW11 0.02184 0.07183 21 Signaling events mediated by
VEGFR1 and VEGFR2
1.9113 4 2 2
Abbreviation. P : P -value; AdjP : Adjusted p-value; MS: Module size; ZP: Pathway z-score; MOG: Number of genes
overlapping between the module and the pathway; MKG: Number of genes overlapping between the module and the set
of known breast cancer genes; PKG: Number of genes overlapping between the pathway and the set of known breast
cancer genes;
The pathway is believed to be involved in breast cancer development (Menashe, I. et al., 2010).
Other interesting pathways include the ErbB receptor signaling network, also known as the
HER Signaling Pathway, which is one of the most important breast cancer pathways used for
targeted therapies for breast cancer (The HER2 Pathway in Breast Cancer. „ National Cancer
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Institute, 2014); the Glypican pathway, which has also shown significant overlap with one of our
modules, with 2 known breast cancer genes, and has also been shown to be involved in cancer
(Filmus, J., 2001), and the Regulation of Androgen receptor activity pathway. While having
moderate p-values with less overlap with the ancGWAS module and known breast cancer dis-
ease genes, the latter pathway contains genes known to play a role in normal breast physiology,
and is becoming increasingly recognized as an important contributor towards breast carcino-
genesis (Garay, J. P. et al., 2012).
Figure 4.2: Central network of 100 genes for breast cancer dataset. The size of a node denotes its
significance with size increasing with significance. In red are known breast cancer disease genes.
Moreover, we observed that the 20 top sub-networks obtained from ancGWAS also overlap
each other, and most of the hubs are connected directly or indirectly to each other. In light
of this considerable overlap between these modules in our study, we can hypothesize that
common biological modules (pathways) may underlie the enrichment signals in multiple bio-
logical pathways. To explore this hypothesis, we searched for the most important and central
sub-network (Figure 4.2) within the network formed from these 20 sub-networks. For ease of
presentation, we reduced the resulting sub-network by excluding those genes with less than
three edges (neighbours) and applying a recursive approach. Figure 4.2 shows the most im-
portant sub-network related to breast cancer, it contains previously associated breast cancer
genes, particularly the FGFR2 gene (p = 0.037), which was the most significant gene from
the CGEMS study. Though FGFR2 has a moderate association signal, it is interacting with
an important gene (with respect to its connectedness) in this network, the antiapoptotic YW-
HAZ gene, which has 27 partners, and is holding together many other important genes in this
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network, as well as connecting several components of this network. This gene (YWHAZ ) has
not yet been associated with breast cancer, even after combining p-values from multiple single
SNPs (p = 0.00024), however it is a key mediator of different pathways illuminated in this
study and principally in the central sub-network for breast cancer here. A recent study has
demonstrated its involvement in de novo chemoresistance to anthracyclines and its permissi-
bility for metastatic recurrence (Li, Y. et al., 2010). Therefore, it may modulate breast cancer
susceptibility through different biological mechanisms.
Besides FGFR2, two additional known breast cancer disease genes are part of this central
sub-network. The MAP3K1 gene (also known as MEKK1 ), which encodes the MAPK kinase
protein that phosphorylates and activates the MAPK kinase (MAPK2 ), that, in turn, phos-
phorylates the MAPK/ERK to produce downstream signaling effects on a variety of cancer
genes. It is principally a member of the MAPK pathway, strongly associated with HER recep-
tor activity, the mutations of which have been associated with HER2+ breast tumors (Rebbeck,
T. R. et al., 2009). The BARD1 gene forms heterodimers with the breast cancer gene BRCA1,
and it is speculated that BARD1 mutations might affect the function of BRCA1, contributing
to breast carcinogenesis (Ishitobi, M. et al., 2003). Looking at some non breast cancer disease
genes (i.e. genes not yet confirmed to be associated with breast cancer), the RPL7 gene, which
is part of the Metabolism of proteins and Gene expression pathways (A.4 and supplementary
Table A.1), interacts with gene HSPA8, which plays a role in cell growth. It is believed to be
involved in metastasis of breast cancer, yet interacts with gene TLR4, a member of the Toll-like
receptor signaling pathway (TLRs) involved in the production of pro-inflammatory cytokines
with activation of NFκB and MAPK. They are associated with the induction of IFN -beta and
IFN -inducible genes, and maturation of dendritic cells. TLRs are expressed on innate immune
cells, such as macrophages and dendritic cells (Akira, S. et al., 2004). The RPL7 gene, or any
other gene in this sub-network, may have a role in the breast carcinogenesis, but was not de-
tected through the single-marker-based approach of GWAS using this dataset. This illustrates
the benefit of incorporating both the association signal from a standard GWAS and the human
PPI network for testing the combined effects of SNPs and searching for significantly enriched
sub-networks for complex diseases. This had led to new hypothesis of breast cancer-associated
genes, but these would need to be validated.
Finally, we performed a pathway enrichment analysis of this network, and reported the path-
way with the highest score of overlap with our central sub-network. This enrichment resulted
in the Integrin family cell surface interactions pathway, which was also enriched in our top
20 modules in Table 4.4. Integrins are a family of transmembrane glycoprotein receptors that
mediate cell-matrix and cell-cell interactions, consisting of an α and αβ subunits, and they
are known for having a pivotal role in cellular behavior, as well as in many pathological con-
ditions such as inflammation and tumor progression. Several studies have demonstrated the
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association between the regulation of integrin expression and cancer, as well as breast cancer.
Links between the integrins and other important pathways contributing to the development of
breast tumors have also been investigated such as the hepatocyte growth factor/scatter factor
(HGF/SF ) whereby integrins β1, β3, β4 and β5 may be affected by HGF -mediated regulation
of integrin avidity, and insulin-like growth factor I (IGF-I ), which stimulates an increase in
the activity of integrin αV β5. The epidermal growth factor and its receptor (EGFR) have also
been reported to mediate up-regulation of β1 integrin function and breast cancer progression
(Koistinen, P. et al., 2000).
Our results suggest that genetic alterations associated with the top 20 pathways and the
central pathway for our study may contribute to breast cancer susceptibility. While, some
of these pathways are already known and targeted for breast cancer therapies, others may be
new, and harbouring genes that participate actively in biological processes involved in breast
cancer. These pathways can, in addition, reveal novel genes to target as potential candidates for
association studies aiming at understanding breast carcinogenesis. Ultimately, further studies
would definitively be needed to confirm these results, and explore further the genetic variations
underlying the association of these pathways with breast cancer.
Most targeted therapies that are currently being developed for breast cancer are used and
tested in combination with standard therapies. However, since cancer cells are often subject
to multiple signaling pathways, targeting multiple pathways for a combination of targeted
therapies might reduce the development of drug-resistant tumor cells, and help in designing




As stated in the introduction to this thesis, the primary purpose of the study was to explore
post Genome-wide Association Study approaches for genetic association studies with respect to
the combined effect of interacting loci, and the implementation of a new network-based method
to identify sub-networks of genes associated with complex disease in admixed heterogeneous
population, as well as in homogeneous populations. As the overview in the theoretical part of
this thesis showed, the need for complementary methods for current genome-wide association
study methods is imperative. On the other hand, although our knowledge on the human in-
teractome is far from complete, integrating network topological features with GWAS data can
provide experimentally verifiable insights into the understanding of complex traits.
In the first chapter of this thesis, I introduced the background and literature relevant to this
project. We discussed basic concepts on genetic association studies and genome-wide associa-
tion study, focusing on the case-control design in population association studies. The limita-
tions of current methods for genome-wide association study motivated us to look at alternative
approaches that can complement the single-marker-based approach of GWAS, further devel-
oped in chapter two. We also reviewed current methods for pathway-based analysis of GWAS
data, focusing on some technical differences between these pathway-based approaches, as well
some common challenges observed in these methods. I have also discussed some functional
information that is widely used in pathway-based methods for GWA study, the comprehension
of which was vital for the design and implementation of the new method, ancGWAS, in chapter
2. The main aim of chapter three was to propose a new method to identify sub-networks that
combined effects of multiple interacting loci based of the topological structure of the gene-
gene network that results from GWA study data, also incorporating the ancestral information
in the case of an admixed population. In the fourth chapter, we presented ancGWAS and
the implemented algorithm for a step-wise network-based analysis of GWA study data. We
also emphasized testing for genes and pathways specific for particular subpopulations by in-
tegrating ancestral information into the analysis. Besides, this method has the advantage of
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using the structure of the network generated using known human protein-protein interactions
from the genes from GWAS, and uses the correlation between these genes to investigate genes
playing important structural roles (which can also represent biological roles), to break down
the network into sub-networks, before scoring these sub-networks using GWA study signals.
Thus, ancGWAS sub-networks can not only discover novel disease pathways, but also reveal
disease genes that are currently not part of any pathways. Through simulations in chapter
four, we assessed how well ancGWAS performs in identifying disease associated pathways, and
demonstrated that ancGWAS performs better than an existing network-based method, dmG-
WAS, and holds promise for approximating disease associated pathways. We also tested for
differences in ancestry at gene and pathway levels, to investigate whether deviations from the
expected ancestry proportions in genes and generated sub-networks exist. Chapter five provides
an application of the proposed new method on a real data of case-control breast cancer study.
The majority of sub-networks identified by ancGWAS were highly enriched in known breast
cancer genes, and overlapping in genes with well known breast cancer pathways from public
pathway annotation databases. This suggests that the presence of many of the genes in these
sub-networks, which are not known breast cancer genes may be because of the incompleteness
of pathway databases and our incomplete knowledge of disease associated genes, since they are
connected with short paths to known breast cancer genes, and thus may be involved in the
disease pathogenesis.
Although ancGWAS has been demonstrated using a GWAS of breast cancer, it can be used
to interpret GWA studies of other traits and organisms too. By identifying disease associated
modules, the ancGWAS approach provides insights into the involvement in complex pheno-
types with multiple susceptibility loci with small effects. In this way, ancGWAS as well as
other network-based approaches may be of crucial use in gaining a thorough understanding of
biological function of crucial genetic components in order to dissect complex diseases in the
coming era of systems medicine.
Despite many challenges of pathways-based approaches for analysis of GWAS data, which
need to be addressed as discussed in chapter 1, there are also many opportunities ahead.
For instance, the integration of additional types of data to SNP genotypes, including copy
number variants, gene expression, epigenetic modifications and somatic mutations, among other
genomic data types, together into the same pathway analysis may be more powerful in revealing
novel biological insights. In addition to improvements in the searching algorithm, future work
will include integrating other types of genomic data, including the Gene Ontology (GO), and
integrating data sets from multiple GWA studies, as is done in meta-analysis, into one pathway-
based analysis tool to increase the power to reveal biological insights.
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Table A.1: Module genes of ancGWAS on a simulated disease in an admixed population.
(Subsection 3.2.2). Complete list of genes of modules using ancGWAS where each module in the main
text is represent by its hub.
Module hub Genes in module
TRAF3IP3 CCT8, FGFR1OP2, SIKE1, STK24, TRAF3IP3, CTTNBP2NL, FAM40A
CTTNBP2NL FGFR1OP2, SIKE1, STK24, STRN, TRAF3IP3, CTTNBP2NL, FAM40A
RPSA SI, SLC2A5, RPSA, CCL5
SLC2A5 SLC2A5, SI, RPSA, CCL5
SRSF10 MARK1, ZC3H11A, PI4KB, RORC, RPL31, SFN, RBM34, PKP3, SRSF10, YWHAB,
C1orf74, KIAA0101, POU5F1, GJA5
LEPR LEPROT, PTPN11, TIE1, LEPR
IPO13 HDAC1, HSPA6, IPO13, RPL7, CRX, RPL5, PSMD2, CBX5, RPS8, NEDD8, CRABP2,
HNRNPR, FBXO42, PPM1J, RAD21, LGALS3BP, HIST3H2BB, RPL11, RPL12, IPO7,
UBE2I, WDTC1, TP73, RPL10A, HSP90AA1, ACTB, YBX1
SNRPE HDAC1, UBE2I, ETV3, DDX20, CRABP2, SLX1A, NR0B2, HNRNPA1, PPM1J, TP73,
GEMIN5, LRRC41, DCUN1D1, STXBP3, RGSL1, PPARD, PEF1, SNRPE
CTSD PSMD4, PSMD2, ANP32E, PKP1, KRT8, DCLRE1B, S100A14, FLG, S100A16, FKBP8,
UBQLN4, ATG5, PSMC1, LYST, CUL2, CENPJ, PSMA5, CTSD, TXN2, BGLAP, USP14,
MGMT, UCHL5, CTSS, SLPI, SHFM1, PSMB4, GSTM2, GSTM3, PSMD10, PSAT1,
ATP6V0A1, WFS1
Continued on next page
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Table A.1 – continued from previous page
Module hub Genes in module
PSMA5 PSMD4, PSMD2, ANP32E, PKP1, KRT8, DCLRE1B, S100A14, FLG, S100A16, FKBP8,
UBQLN4, PSMA5, PSMC1, LYST, CUL2, ATG5, CTSD, TXN2, BGLAP, USP14, MGMT,
UCHL5, SHFM1, PSMB4, GSTM2, GSTM3, PSMD10, PSAT1, ATP6V0A1, WFS1
S100A14 PSMD4, PSMD2, ANP32E, PKP1, KRT8, DCLRE1B, S100A14, FLG, S100A16, FKBP8,
UBQLN4, PSMA5, PSMC1, LYST, CUL2, ATG5, CTSD, TXN2, BGLAP, USP14, MGMT,
UCHL5, SHFM1, PSMB4, GSTM2, GSTM3, PSMD10, PSAT1, ATP6V0A1, WFS1
PSMB4 PSMD4, PSMD2, ANP32E, PKP1, KRT8, DCLRE1B, S100A14, FLG, S100A16, FKBP8,
UBQLN4, PSMA5, PSMC1, LYST, CUL2, ATG5, CTSD, TXN2, BGLAP, USP14, MGMT,
UCHL5, SHFM1, PSMB4, GSTM2, GSTM3, PSMD10, PSAT1, ATP6V0A1, WFS1
RPL31 SNIP1, OLFML3, PPP1R8, SRSF10, S100A10, KIAA0101, CRABP2, RORC, PPM1J, RPL22,
RBM34, PRKRA, SETDB1, POU5F1, C1orf74, GIPC2, TMBIM4, TARDBP, UBE2I, HDGF,
ZC3H11A, TP73, RPL31, SFN, CDC42
CGN EXOSC10, TJP1, STAT3, RBM8A, DIRAS3, CGN, GJA8, RRAS2, ARHGEF2, YWHAH,
ISG15, PPP6R3, STMN1, IL22RA1, USP21, IL23R
STXBP3 HDAC1, UBE2I, ETV3, DDX20, CRABP2, SLX1A, NR0B2, HNRNPA1, PPM1J, TP73,
GEMIN5, DCUN1D1, STXBP3, PPARD, PEF1, SNRPE
NID1 FCGR3A, LAX1, LACRT, ADAM15, ZC3H12A, SHC1, PTPN22, TANK, CRABP2, PPM1J,
NID1, PTPRD, CD48, KHDRBS1, MUC1, SH2D2A, CSF3R, LAMC1, UBE2I, TP73, PTPRF,
STAT5A, CD247, HSP90AA1, LCK, CDC42
RPAP2 HSPA6, RPL7, HSPA8, PABPC4, KHDRBS3, PSMD2, TP73, PITX2, RPS8, NEDD8,
CRABP2, HNRNPR, PPM1J, JAK1, EIF2C4, RPL5, INTS7, INTS6, FBXO42, GBP2,
CREB1, LGALS3BP, EIF2C3, RPL12, UBE2I, RPS6KA1, WDTC1, RPL35, RPAP2, TUBB,
MYCBP, RPL10A, HSP90AA1, ACTB, YBX1
SFN ZC3H11A, PI4KB, EXO1, RORC, RPL31, SFN, RBM34, PKP3, MARK1, YWHAB, C1orf74,
KIAA0101, RIMS3, SRSF10, TESK2, GJA5
LAMC1 UBE2I, TANK, CRABP2, PPM1J, TP73, PTPRF, NID1, LACRT, ZC3H12A, LAMC1, LCK,
PTPRD
APOA2 APOA1BP, APOD, APOA2
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Table A.2: 129 previously confirmed breast cancer susceptibility genes.
Gene Chr Journal Reference Gene Chr Journal Reference
GSTM1 1 Helzlsouer, K.J. et al . 1998. PMID:9539246 GSTP1 11 Nordgard, S. H. et al . 2007. PMID:17301692
GSTM3 1 Mitrunen, K. et al . 2001. PMID:11303592 HRAS 11 Nefedov MD et al . 1990. PMID:2086347
Intergenic 1 Thomas et al . 2009. PMID:19330030 LSP1 11 Easton et al . 2007. PMID:17529967
LEPR 1 Gallicchio, L. et al . 2007. PMID:17428620 MMP1 11 Przybylowska, K. et al . 2004. PMID:15149160
MTHFR 1 Martha, J. S. et al . 2005. PMID:15868433 PGR 11 Pooley, K. A. et al . 2006. PMID:16614108
MYCL1 1 Champeme MH et al . 1992. PMID:1345822 SIPA1 11 Crawford, N. P. et al . 2006. PMID:16563182
PTGS2 1 Langsenlehner, U. et al . 2006. PMID:16489098 CDKN1B 12 Ma, H. et al . 2006. PMID:16804901
TNFRSF1B 1 Mestiri, S. et al . 2005. PMID:15863392 IFNG 12 Kamali-Sarvestani, E. et al . 2005. PMID:15890243
TP73 1 Li, H. et al . 2006. PMID:16950799 IGF1 12 Al-Zahrani, A. et al . 2006. PMID:16306136
BARD1 2 Huo, X. et al . 2006. PMID:17028982 Intergenic 12 Murabito et al . 2007. PMID:17903305
CASP8 2 Cox, A. et al et al . 2007. PMID:17293864 LRP1 12 Benes, P. et al . 2003. PMID:12793904
CTLA4 2 Ghaderi, A. et al . 2004. PMID:15218356 MDM2 12 Wasielewski, M. et al . 2006. PMID:17080308
CYP1B1 2 Matyjasik, J. et al . 2007. PMID:17458695 VDR 12 Lundin AC et al . 1999. PMID:10344739
Intergenic 2 Stacey et al . 2007. PMID:17529974 ABCC4 13 Murabito et al . 2007. PMID:17903305
LHCGR 2 Powell, B. L. et al . 2003. PMID:12679452 BRCA2 13 Golshan, M. et al . 2006. PMID:16769276
SRD5A2 2 Yang, C. et al . 2002. PMID:12100746 LIG4 13 Bau, D. T. et al . 2004. PMID:15256476
UGT1A1 2 Mol Biol (Mosk). 2006. 40(2). 263-70. PMID:16637266 RB1 13 Berns EM et al . 1995. PMID:7615356
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ALDH1L1 3 Stevens, V. L. et al . 2007. PMID:17548676 ESR2 14 Gallicchio, L. et al . 2006. PMID:16808847
GPX1 3 Cox, D. G. et al . 2006. PMID:16945136 MTHFD1 14 Stevens, V. L. et al . 2007. PMID:17548676
PIK3CA 3 Breast cancer research and treatment. 2005. PMID:16317585 RAD51L1 14 Thomas et al . 2009. PMID:19330030
RASSF1 3 Schagdarsurengin, U. et al . 2005. PMID:15942659 XRCC3 14 Bewick, M. A. et al . 2006. PMID:17116943
PPARGC1A 4 Wirtenberger, M. et al . 2006. PMID:16704985 AKAP13 15 Wirtenberger, M. et al . 2005. PMID:16234258
SULT1E1 4 Choi, J. Y. et al . 2005. PMID:15894657 CYP11A1 15 Zheng, W. et al . 2004. PMID:15159300
ADRB2 5 Huang XE et al . 2001. PMID:11434877 CYP19A1 15 Miyoshi Y et al . 2000. PMID:10956405
FGFR4 5 Thussbas, C. et al . 2006. PMID:16822847 CYP1A1 15 Long, J. R. et al . 2007. PMID:17429315
Intergenic 5 Easton et al . 2007. PMID:17529967 CYP1A2 15 Kotsopoulos, J. et al . 2007. PMID:17507615
MAP3K1 5 Easton et al . 2007. PMID:17529967 FBN1 15 Murabito et al . 2007. PMID:17903305
PPARGC1B 5 Wirtenberger, M. et al . 2006. PMID:16704985 RAD51 15 Jakubowska, A. et al . 2003. PMID:12750242
PRLR 5 Vaclavicek, A. et al . 2006. PMID:16434456 ERCC4 16 Smith, T. R. et al . 2003. PMID:14652281
XRCC4 5 Allen-Brady, K. et al . 2006. PMID:16835328 GLG1 16 Kibriya et al . 2008. PMID:18463975
C6orf97 6 Zheng et al . 2009. PMID:19219042 MMP2 16 Zhou Y 2004. PMID:14604886
CDKN1A 6 Staalesen, V. et al . 2006. PMID:17062672 NQO1 16 Menzel, H. J. et al . 2004. PMID:15138483
ECHDC1 6 Gold et al . 2008. PMID:18326623 SULT1A1 16 Mol Biol (Mosk). 2006. 40(2). 263-70. PMID:16637266
ESR1 6 Gallicchio, L. et al . 2006. PMID:16808847 TOX3 16 Thomas et al . 2009. PMID:19330030
GSTA1 6 Sweeney, C. et al . 2003. PMID:12516103 CASC16 16 Easton et al . 2007. PMID:17529967
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HLA-DQB1 6 Chaudhuri, S. et al . 2000. PMID:11027344 TNRC9 16 Stacey et al . 2007. PMID:17529974
HLA-DRB1 6 Chaudhuri, S. et al . 2000. PMID:11027344 ACACA 17 Sinilnikova, O. M. et al . 2004. PMID:15333468
PRL 6 Vaclavicek, A. et al . 2006. PMID:16434456 AKAP10 17 Wirtenberger, M. et al . 2006. PMID:16956908
RNF146 6 Gold et al . 2008. PMID:18326623 BRCA1 17 Fu, X. et al . 2007. PMID:17557253
SOD2 6 Yao S et al . 2010. PMID:20309628 COL1A1 17 Murabito et al . 2007. PMID:17903305
VEGFA 6 Krippl, P. et al . 2003. PMID:12845639 ERBB2 17 Tommasi, S. et al . 2007. PMID:17452776
ABCB1 7 Zubor, P. et al . 2007. PMID:17549370 GH1 17 Endocrine-related cancer. 2005 Dec:12(4):917-28.
PMID:16322331
AHR 7 Pharmacogenet Genomics. 2006. 16(4). 237-43.
PMID:16538170
HER2 17 Ameyaw MM et al . 2002. PMID:12166652
CYP3A5 7 Tucker, A. N. et al . 2005. PMID:15596297 HSD17B1 17 Wu AH 2003. PMID:12584742
IGFBP3 7 Al-Zahrani, A. et al . 2006. PMID:16306136 ITGB3 17 Wang-Gohrke, S. et al . 2004. PMID:15609125
IL6 7 Snoussi, K. et al . 2005. PMID:16464738 MPO 17 Ahn, J. et al . 2004. PMID:15492293
Intergenic 7 Murabito et al . 2007. PMID:17903305 SHBG 17 Cui, Y. et al . 2005. PMID:15894658
NOS3 7 Lee, K. M. et al . 2007. PMID:17262178 TIMP2 17 Zhou Y 2004. PMID:14604886
PON1 7 Gallicchio, L. et al . 2007. PMID:17428620 TP53 17 Thangarajan Rajkumar et al . 2008. PMID:18058229
POR 7 Haiman, C. A. et al . 2007. PMID:17440066 Intergenic 18 Murabito et al . 2007. PMID:17903305
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SERPINE1 7 Lei, H. et al . 2007. PMID:17616807 GPX4 19 Nasim Mavaddat , et al . Cancer epidemiology, biomarkers
&amp; prevention 2009 18(1):255-9. PMID:19124506
XRCC2 7 Kuschel, B. et al . 2002. PMID:12023982 KLK3 19 Yang, Q. et al . 2002. PMID:12168876
Intergenic 8 Easton et al . 2007. PMID:17529967 TGFB1 19 Thangarajan Rajkumar et al . 2008. PMID:18058229
MYC 8 Wirtenberger, M. et al . 2005. PMID:15929079 UQCRFS1 19 Ohashi Y 2004. PMID:15047214
NAT1 8 Pfau W 1998. PMID:9829711 XRCC1 19 Bewick, M. A. et al . 2006. PMID:17116943
NAT2 8 Christine B Ambrosone et al . 2008. PMID:18187392 AURKA 20 Lo, Y. L. et al . 2005. PMID:15688402
NBN 8 Lu, J. et al . 2006. PMID:16714331 GNAS 20 Otterbach, F. et al . 2006. PMID:17186357
POLB 8 Sliwinski, T. et al . 2006. PMID:17131038 MMP9 20 Grieu, F. et al . 2004. PMID:15609121
TNFRSF10A 8 Frank, B. et al. 2005. PMID:15975957 CBS 21 Stevens, V. L. et al. 2007. PMID:17548676
PTCH 9 Chang-Claude J et al . 2003. PMID:12516098 COL18A1 21 Balasubramanian, S. P. et al . 2007. PMID:17587451
CYP17 10 Wu AH 2003. PMID:12584742 CHEK2 22 Meyer, A. et al . 2007. PMID:17250914
CYP17A1 10 Piller, R. et al . 2006. PMID:16702327 COMT 22 Song, C. G. et al . 2006. PMID:17217814
CYP2C19 10 Werner Schroth et al . 2007. PMID:18024866 CYP2D6 22 Werner Schroth et al. 2007. PMID:18024866
FGFR2 10 Hunter et al . 2007. PMID:17529973 EP300 22 Wirtenberger, M. et al . 2006. PMID:16704985
MGMT 10 Han, J. et al . 2006. PMID:16788379 GSTT1 22 Mitrunen, K. et al . 2001. PMID:11303592
ATM 11 Sommer, S. S. et al . 2002. PMID:11996792 AR X Yu H et al . 2000. PMID:10817350
Table A.3: Top 20 sub-networks, and related pathway enrichment results from dmGWAS. Modules are
ranked by their z-score, ZM , from dmGWAS. For each pathway, the z-score (ZP) is reported representing the
level of its similarity with the related module, which is also a function of the size of the module. Different
scores of overlaps between the module, the pathway and the set of known genes are also reported.
Hub ZM MS Pathway ZP MOG MKG PKG
COPS6 10.54 8 PI3K/AKT activation 147.7851 1 1 0
BCAR3 10.52 7 Proteoglycan syndecan-mediated
signaling events
1.8236 2 1 2
SPTLC1 10.44 8 Proteoglycan syndecan-mediated
signaling events
1.2892 1 1 2
ETS1 10.30 7 Proteoglycan syndecan-mediated
signaling events
3.9929 2 1 2
DMWD 10.21 7 Proteoglycan syndecan-mediated
signaling events
2.683 2 1 2
GALK1 10.18 8 Proteoglycan syndecan-mediated
signaling events
3.7358 3 1 2
CBL 10.14 5 Proteoglycan syndecan-mediated
signaling events
1.8236 2 1 2
ATP6V1E1 10.13 8 Hemostasis 35.3949 3 1 0
MLH1 10.12 6 Proteoglycan syndecan-mediated
signaling events
2.8943 3 1 2
RPS14 10.08 7 TRAIL signaling pathway 2.7755 2 1 2
RORA 10.06 6 LKB1 signaling events 4.024 4 1 2
MDM2 10.04 6 Proteoglycan syndecan-mediated
signaling events
2.683 2 1 2
DSG1 10.04 8 Signaling events mediated by VEGFR1
and VEGFR2
3.123 3 1 2
RPS27A 10.03 7 Cell Cycle, Mitotic 9.8726 1 1 1
PTN 9.99 5 FAS (CD95) signaling pathway 42.752 2 1 1
ATXN7 9.97 6 Metabolism of proteins 28.0057 2 1 0
UBB 9.93 6 Proteoglycan syndecan-mediated
signaling events
4.8908 3 1 2
LRP2 9.92 6 Hemostasis 27.0515 2 1 0
PIAS2 9.90 7 Proteoglycan syndecan-mediated
signaling events
2.2339 3 1 2
HNF4A 9.86 7 Proteoglycan syndecan-mediated
signaling events
1.2892 1 1 2
Abbreviation. P : P -value; AdjP : Adjusted p-value; MS: Module size; ZP: Pathway z-score; MOG: Gene overlapping
between the module and the pathway; MKG: Number of genes overlapping between the module and the set of arbitrarily
chosen genes as known disease genes; PKG: Number of genes overlapping between the pathway and the set of arbitrarily
chosen genes as known disease genes;
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Table A.4: Module genes of ancGWAS on a case-control breast cancer data set (Hunter,
D. J. et al., 2007), from the CGEMS project. (Section 4.2). Complete list of genes from
modules using ancGWAS, where each module in the main text is represented by its hub.
Module hub Genes in module
MAP3K12 LHCGR , MBIP, SH3RF1, CXCL9, RPL18A, MFAP5, FBN1, CHST9, SPRY2, MAP3K12,
MAPK6, RGS1, RABEPK, RHOB, GNAI2, CANX, PF4
CDKN1A TTLL5, MYCL1, CDC5L, C1orf123, TXN, MAX, CCND2, GCKR, MKRN1, GADD45G,
TNIP2, POLD2, RABEPK, TK1, CDC45, BAD, CIZ1, RPL18, CCDC85B, NR1H2, HPD
UNC93B1 SEL1L, CCDC47, PIGN, SPNS1, GOLT1B, NPC1, TM9SF3, TM9SF2, UNC93B1, STT3B,
STT3A, YIPF5, HM13
EIF2B1 IL6, FBN1, ZBTB16, CXCL9, DCD, PDIA4, ARHGDIA, EIF2B3, IL6R, DCC, SPRY2,
MFAP5, PF4, MRPL4, Adra2a, RHOB, ADRA2C, EIF2S2
SMC3 MYCL1, RPLP1, FBXO2, ANP32E, KIFAP3, MXD3, EIF3H, WFDC5, SMC3, TRAF3IP1,
ANXA1, BECN1, STAG2, STAG3, RABEPK, SLC25A4, MCM3, USP19, WRAP73, SYCP3,
H2BFM, CCNB1, MAX, FEZ2, REC8, PHB
LNX2 RIPK1, HIP1, CRADD, OTUD7B, PEA15, BID, CFLAR, NOD1, RNF138, RLIM, MALT1,
PRKCI, LNX2, SHISA2, PARP2, PLEC, NUMB, CD8A, DEDD, NOL3, BCAP31, CASP10,
UBE2Z, MAP3K14, APAF1, MAPT, FASLG
ITGA5 LHCGR, AUP1, RABIF, ITGA5, CHST9, ANGPTL3, L1CAM, GIPC1, FLT4, GNAI2, CANX
ATF7IP ZBTB6, CSPG4, SLC12A4, SENP3, PKD1, SVEP1, MCAM, ATF7IP, GLG1, COL4A2,
RRBP1, NFKB2, SPTBN1, CADM1
GRIN2B CTLA4, DLG3, DLG2, FGF2, CDH2, AP1M1, FYN, RABEPK, PRKCG, PARK2, GRIN2B,
STAT5B, CAMK2N1, FGF8, FGF7, FGF6, FGFR4, CD86, FGF3, LYN
RTN4 IL6, COL4A3BP, ACTG1, TRAF6, WWP1, RTN4, LSP1, ATL1, IL6R, CNTNAP1,
RAD51AP1, PALB2, MAPKAPK2, ZBTB16
PRKCG PDLIM5, GJA3, IGSF21, ANXA7, EXOC5, EEF1A1, PARD6A, PARD6B, PRKCG, GRIN2B,
SULT1E1, GRM5, GRIA4, RGS2, UNC119, NOXA1, GABRA4, PTPN1, STXBP1
MAPKAP1 RPTOR, PECAM1, PDGFRA, CAAP1, GZMB, GULP1, CDC42EP1, PTK2B, CD36,
PTPRZ1, RPS6, ECI1, CIB1, SETMAR, EPS8, DAB2, ABCC4, FBLN2, XRCC4
PACSIN3 YWHAZ, TGM2, ASAP1, PACSIN3, SPDYA, PON1, SUMO4, RABEPK, WIPF1, HSPA1A,
DNM1, WASL, UBAC1, TRPV4, SYNJ1, ADAM12, PACSIN1, RHOA, HIST1H1B, FBL
Continued on next page
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Module hub Genes in module
LEF1 EEF1A1, MYCL1, CYP11A1, DPYSL2, FHIT, CTLA4, CDX1, MAX, NOTCH1, SMAD2,
CD86, LYN, STAT5B, IGSF21, UNC119, PITX2, CYP11B2, LEF1, ALX4, SULT1E1, KPNA1
ACVR1 PLEKHB1, TGFBR1, ACVR1, ZBTB16, ENG, PLEKHJ1, NUAK2, RRAS2, NRAS, IGSF1,
NEK8, IL6R, IL6, USP39, CHN1, DCAF6, GDF5, RHOJ, PLEK, DUSP13, RASD2
PCBD2 GTF2E1, ZZZ3, PCBD2, HES4, PALB2, RAD51AP1, MED7, WFDC1, ASCC2, PBXIP1,
SSX3
WAS PACSIN1, RHOQ, FYN, RBBP5, ARPC4, ARHGAP1, KDM4A, PTPRB, KDM6B, WAS,
ENAH, BTK, CDC42
BSG RFXANK, CAND1, SULT1E1, EEF1A1, PON1, SLC16A4, PPP2R1B, SUMO4, VHL, USP50,
IGSF21, UNC119, ATXN10, HGS, RANBP3
ARL4D DNAJA1, UBR1, NEK3, PRLR, ARL6IP1, PRKCSH, SNRPN, EML4, CSH1;, ARL4D,
TMEM230, ZAP70
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